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Abstract 
Gene addition strategies to correct inherited diseases are showing promise for treatment 
in the clinic, but an improved approach to treat both dominant and recessive genetic 
disorders would be to repair the mutant gene by homologous recombination-mediated 
gene targeting. Recently, gene targeting frequencies have dramatically increased 
through the development of (i) improved designer nucleases, including zinc finger 
nucleases (ZFN), able to introduce specific double-strand breaks at their target locus; 
and (ii) efficient DNA delivery tools, including integration-deficient lentiviral vectors 
(IDLVs). Even when using these state-of-the-art systems, gene repair frequencies in 
stem cells are moderate. To obtain proof-of-principle of phenotypic rescue in the 
haematopoietic system, a model in which corrected cells had selective advantage would 
be optimum. An ex vivo strategy to correct the classical scid mouse, a model of human 
DNA-dependent protein kinase catalytic subunit (DNA-PKcs, PRKDC) deficiency, is 
hereby presented. Donor templates to correct the scid point mutation and a ZFN were 
produced, optimised and incorporated into IDLVs. Specific ZFN activity in mouse scid 
fibroblasts and haematopoietic progenitors was demonstrated by Cel-I assay (which 
detects modifications introduced at the target site upon repair by non-homologous end-
joining) and by deep sequencing. ZFN- and template-mediated gene repair of the scid 
mutation was demonstrated via the incorporation of a selection cassette and/or a 
diagnostic restriction site from the donor template into the targeted locus. In scid 
fibroblasts, gene repair led to DNA-PKcs activity rescue and increased resistance to 
DNA damage. In scid haematopoietic progenitors, gene correction was demonstrated 
only when the ZFN genes were delivered by integrating lentiviral vectors. Following an 
optimised ex vivo protocol, transplantation of potentially corrected scid haematopoietic 
progenitors into irradiated scid recipients has been carried out. Preliminary results of the 
ex vivo gene repair and transplantation experiment have indicated potential rescue of the 
T-cell compartment in a fraction of the scid transplant recipients. The results presented 
in this work highlight the potential of gene repair for future therapy in the 
haematopoietic system. 
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Abbreviations 
AAV Adeno-associated virus 
Ad Adenoviral vectors 
bp Base pair(s) 
BSA Bovine serum albumin 
CAR Coxsackie and adenovirus receptor 
CD  Cluster of differentiation 
CFU Colony forming unit 
CHO cells  Chinese hamster ovary cells  
CMV Cytomegalovirus 
CNS Central nervous system 
Cre Recombinase enzyme (causes recombination) 
DMEM Dulbecco’s modified Eagle’s medium 
DMSO Dimethyl sulfoxide  
DNA Deoxyribonucleic acid 
DNA-PK DNA-dependent protein kinase  
DNA-PKcs DNA-dependent protein kinase catalytic subunit 
ds Double stranded 
DSB Double stranded breaks 
Env Envelope 
EtBr Ethidium Bromide 
FCS Foetal calf serum 
FLP Flippase recombination enzyme 
Flt-3 Fms-related tyrosine kinase 3 ligand 
Gag Group Specific antigen  
GFAP Glial fibrillary acidic protein 
GFP Green fluorescent protein 
HEK-293T 
Human embryonic kidney cell line, containing SV40 large T-
antigen 
HeLa Cervical cancer cell line derived from Henrietta Lacks 
HIV Human immunodeficiency virus 
HR Homologous recombination 
HSC Haematopoietic stem cell 
HSCT Hematopoietic stem cell transplantation 
IDLV Integration-deficient lentiviral vector 
InDel Insertion/deletion  
IPLV Integration-proficient lentiviral vector 
ITR Inverted terminal repeat 
Kb Kilobase(s) 
LAM-PCR Linear amplification-mediated polymerase chain reaction 
LTR Long terminal repeat 
MA Matrix protein 
MFI Mean fluorescence intensity 
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MOI  Multiplicity of infection 
mTert Mouse telomerase reverse transcriptase (immortalised fibroblasts) 
MTT Dimethylthiazol diphenyltetrazolium bromide 
NHEJ Non-homologous end joining 
Pac Puromycin resistance gene 
PAGE Polyacrylamide gel electrophoresis 
PBMCs  Peripheral blood mononuclear cells 
PBS Phosphate buffered saline 
pbs Primer binding site 
PCR Polymerase chain reaction 
PFA Paraformaldehyde 
PGK Phosphoglycerate kinase  
PIC Pre-integration complex 
PID Primary immunodeficiency 
Poly A Polyadenylation 
PPT Polypurine tract 
qRT-PCR Quantitative real-time polymerase chain reaction 
RBS Rep-binding site 
RCV Replication-competent vectors 
RE Restriction enzyme 
RNA Ribonucleic acid 
RRE Rev responsive element 
RSV Rous Sarcoma virus 
RT Room temperature 
S/MAR Scaffold/Matrix attachment region 
SCF Stem cell factor 
SCID Severe combined immunodeficiency 
SELEX Systematic evolution of ligands by exponential enrichment 
SFFV  spleen focus-forming virus 
SIN Self-inactivating  
SSB Single stranded breaks 
SSC Saline sodium citrate buffer 
SV40 Simian virus 40 
TALENs Transcription activator-like effector nucleases 
TAR tat response element 
TU Transducing unit 
V(D)J Variable, Diverse, and Joining 
VSV-g Vesicular stomatitis virus glycoprotein G 
WPRE Woodchuck hepatitis virus post-transcriptional element 
Wt Wild-type 
ZFN Zinc finger nuclease 
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1 Literature review  
1.1 Introduction to gene therapy  
Gene therapy is an advanced form of molecular medicine that promises new treatments 
for the majority of inherited diseases (Verma and Weitzman, 2005). It can be defined as 
a deliberate alteration of the nucleic acid content of a patient’s cells with aim to cure  a 
disease or at least to arrest the development of a disease such as inherited and acquired 
diseases, in which a defective mutant gene is corrected via using a functional one 
(Hendrie and Russell, 2005; Verma and Weitzman, 2005). Gene therapy has the 
potential to revolutionise the approach of medical treatment; a single round of treatment 
might provide a lasting cure to what may otherwise need permanent treatment (Kohn, 
2001). Thus, the main goal for gene therapy is to provide a lifelong treatment by either 
prevention of expression of unwanted genes or expression of a transgene, the gene of 
interest, at levels high enough to cure the disease or to at least to improve the patient 
clinically. As of August 2012, there were a total of 1843 gene therapy trails worldwide 
(http://www.wiley.co.uk/genetherapy/clinical, accessed on 16/08/2012 ). Currently, 
gene therapy is explored widely as a possible treatment for many serious disorders, like 
cancer, genetically inherited diseases, like haemophilia, cystic fibrosis, and severe 
combined immunodeficiency, and acquired diseases such as Parkinson’s and 
Alzheimer’s diseases.  
A point of major concern related to the practical application of this approach is that of 
using an efficient delivery system capable of efficient gene transfer into a target cell 
without any problematic effects (Verma and Weitzman, 2005). In general, the target 
cells for the gene therapy are limited to two types; proliferative stem cells and highly 
differentiated long-lived cells. Undoubtedly the features of the targeted cells will 
significantly direct the choice of the delivery system. For example, it is important 
sometimes to ensure sustained expression of the transgene, a process that can be 
achieved by using delivery vectors that can integrate in the genome efficiently. While in 
other cases and especially when non-dividing cells are targeted, it is preferable to 
choose non-integrated vectors (Vink et al., 2009). In this regard, the introduction of 
genetic material into targeted cells is based on two concepts: the first is ex vivo gene 
introduction which involves taking away of the desired cells outside the body to achieve 
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in vitro cellular modification, by transduction for example, followed by re-
administration of the modified cells back into the body. The second is in vivo gene 
introduction which involves direct introduction, local or systemic, of genetic material 
into target cells and tissues of the body (Mulligan, 1993; Wolff and Lederberg, 1994) 
Two main strategies have been developed to achieve the ambitious aims of gene 
therapy. First “gene addition” involves complementing a faulty gene with a therapeutic 
one, using vectors that typically contain a functional expression cassette allowing 
persistence via an extrachromosomal episome or integration at non-homologous 
chromosomal sites (Hendrie and Russell, 2005); though the faulty gene remains intact 
(Nakayama, 2010). The second approach known as gene repair, site-specific repair, or 
gene targeting can be defined as a correction of the defective gene by introduction of 
specific genetic change using homologous vector sequence (Delenda, 2004). The first 
gene repair study was carried out in 1989 to correct mutated HPRT in murine animal 
model (Thompson et al., 1989).  
Gene repair approach offers many advantages over gene addition, including: 
• the defect in the target locus of interest can be corrected more precisely by gene 
repair.  
• the proper copy number of the gene is preserved. 
• gene repair, unlike gene addition, reduces the possibility of creating risky insertional 
mutations and oncogene activation which may be caused by random integration.  
• gene repair requires the delivery of only the nonfunctional sequence of the faulty 
gene; therefore it is not related to the full size of the faulty gene whereas in gene 
addition the whole functional region needs to be delivered which occasionally will 
be inapplicable for large size genes.  
• the corrected gene will be expressed under the control of its own normal regulatory 
endogenous chromosomal elements, resulting in precise correction of the defective 
gene that will repair the genetic disorder lastingly by re-establishing the normal 
function for the gene; leading to reduced possibility of non-physiological gene 
expression and long-term gene inactivation problems which normally accompany 
gene addition and, 
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• the ability of gene repair to correct both dominant and recessive mutations, whilst 
gene addition is limited to recessive defects only (Ellis et al., 2012; Levine et al., 
2006; Yanez and Porter, 1998).  
 
To date two main delivery systems have been used in gene therapy studies: viral and 
non-viral vectors. The non-viral vectors include for instance: direct microinjection, gene 
gun, liposome formulations, and synthetic peptides. In general, viral vectors represent 
the most successful gene delivery systems (Moldt et al., 2008). RNA viruses, 
retroviruses and lentiviruses, are exploited for integrative gene manipulations, whereas 
DNA viruses provided non integrative manipulations (Verma and Weitzman, 2005). 
Increasingly lentiviral vectors have become very useful tools in genetic manipulation, 
because of their unique ability to insert genetic cargo in both dividing and non-dividing 
cells (Moldt et al., 2008). Despite many successful applications that use viral vectors as 
efficient gene delivery systems, there are a number of drawbacks accompanying this 
approach. These issues include: maintaining and regulating of transgene expression 
(Cornu and Cathomen, 2007; Vigna and Naldini, 2000), random integration which may 
lead to insertional mutagenesis (Modlich et al., 2009; Philpott and Thrasher, 2007)), and 
relatively limited genetic packaging capacity (Philippe et al., 2006). 
1.2 Viral Vectors  
Viral vectors are either RNA or DNA viruses, they could be found as both integrating 
into the host DNA and non-integrating as an episomal element. Their use in gene 
therapy is based on harnessing their ability to deliver genetic material into transduced 
cells, thus some viral pathogens could be recruited as delivery vectors by removing their 
elements causing disease and employing their components needed for infection and 
replication. The nature of viral life cycle generally determines the protocols of 
production. As an example, adenovirus and adeno-associated virus (AAV) vectors are 
harvested by lysis of infected cells to release the viral particles because they are 
produced from transfections. One of the important features that typical viral vectors 
should possess is to be produced in a highly concentrated form to ensure stable and 
sustained gene expression. Additionally, viral vectors should be able to target the most 
suitable cell type for the disease. And most importantly, produced viral vectors should 
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have no pathogenic or unfavourable effects relevant to their transduction and finally 
have no or lower immunogenicity (Tomanin and Scarpa, 2004; Warnock et al., 2011). 
The murine leukemia virus (MLV) from family retroviridae was the first virus to be 
used in gene therapy applications as viral delivery systems (Fischer and Cavazzana-
Calvo, 2005). Interestingly they have remained useful in gene therapy because of their 
long-term expression since the genes they transduce are integrated into the genome of 
the target cells. Conversely, their use is restricted in in vivo gene transfer of non-
proliferating cells, such as hepatocytes, myofibers, and neurons because of their nature 
to transduce proliferating cells only (Naldini et al., 1996). Currently, the introduction of 
lentiviral vectors into the gene therapy applications has limited the use of MLVs as the 
former vectors can transduce both proliferating and non proliferating cells.  
 
1.2.1 Adenoviral vectors  
 
Adenoviruses (Ads) are nonenveloped, icosahedron -shaped protein capsid (70-100 nm 
in diameter) that surrounded inner nucleic acid containing core (Raus et al., 2011). They 
were first isolated from human adipose tissue in 1953 (Warnock et al., 2011) and since 
then, Ads were isolated from other species. Ads are usually associated with mild 
respiratory symptoms, keratoconjunctivitis and gasteroenteritis (Khare et al., 2011). 
These viruses differ from retroviruses and lentiviruses in that they do not integrate into 
the host genome (Nakayama, 2010). This will lead to reduced risk of insertional 
mutagenesis; yet their use in gene therapy is restricted to non dividing cells as cell 
division will result in loss of the transgene (Stephen et al., 2010). Ads can efficiently 
transduce their target cells in vivo and are the most commonly used vectors in gene 
therapy (Shirakawa, 2008). The Ads-based vectors have been used in many gene 
modification trials like: retinal diseases and ocular malignancies such as retinoblastoma 
(Ildefonso et al., 2012); peritoneal fibrosis (Li et al., 2012b); cystic fibrosis (Hida et al., 
2011); and cardiovascular diseases (Kawase et al., 2011).  
 
Ad genomes are linear, double stranded DNA of about 36-40 kb; and as vectors they 
possess the ability to incorporate large therapeutic transgenes. Their DNA is organised 
into nucleosome-like structure and known to have inverted terminal repeats (ITR) on the 
DNA two ends (Figure  1.1) (Khare et al., 2011). These viruses are naturally transducing 
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their target cells via binding to cellular receptor “Coxsackie and adenovirus receptor” 
(CAR) which is mainly expressed by epithelial cells. The CAR receptors mainly 
mediate viral interaction with most of target cell types. So far, there are about 57 
different human Ad serotypes have been isolated, which are divided into subgroups A to 
G. (Wong et al., 2012). However the serotypes 2 and 5 represent the most widely used 
Ads (Douglas, 2004). 
 
Ad genes are organized into two main transcription regions: the early and late, and 
minor delayed region (Iva2) based on the time course of their expression before and 
after DNA viral replication, respectively (Warnock et al., 2011). Ads, like other DNA 
viruses, need to deliver their genome into nucleus to trigger viral replication. As a 
defence mechanism, cells can recognise spontaneous replication or foreign nucleic acids 
initiating DNA damage response and leading to cell cycle arrest and/or apoptosis. 
Therefore, DNA viruses have developed ‘early’ viral genes to block cellular antiviral 
machinery (Schreiner et al., 2012). These early genes are: E1A which necessary to 
stimulate early phase transcription enhancing the S phase of the target cell; E1B which 
required to prevent apoptosis allowing viral replication; E2 encodes viral proteins 
required for replication; E3 encodes proteins that inhibit cellular responses to viral 
infection; and finally E4 encodes different proteins required for viral DNA transcription 
(Warnock et al., 2011).   
 
Figure 1.1: Schematic representation of adenovirus genome organisation. The 
inverted terminal repeats (ITR) are located on the DNA ends and in between them are 
the early genes (E1A, E1B, E2, E3 and E4), delayed gene (IVa2) and late genes (L1, L2, 
L3, L4 and L5). Ψ: RNA packaging signal. Diagram adapted from Verma and 
Weitzman, 2005.  
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The initial interaction between Ads and their host cells is facilitated by a high affinity 
attachment of the viral fiber knob domain with a CAR cell receptor. This is followed by 
beginning of endocytic uptake and viral internalisation via clathrin-mediated 
endocytosis through the penton base interaction with so-called alpha V integrins. Next, 
an early endosome containing virion will be formed and the viral compartments begin to 
dissociate in the low pH endosome environment. Then the viral particles will be 
released out of the endosomes into the cytoplasm via endosomal membrane 
endosomolysis by the action of viral specific proteins. The viral DNA will be moved by 
microtubules reaching the nuclear pore complex. Finally, the viral DNA will enter the 
nucleus by transportation through the nuclear pore (Nemerow et al., 2009). 
 
The genetic modification of adenoviral genome and capsid has led to safe recombinant 
Ad-based vectors (Shirakawa, 2008). The Ad vectors have many advantages over other 
viral vectors such as: the relative ease of production and high functional vector titers 
achievable; their ability to infect non-dividing cells with broad target cell tropism; 
delivering of their double-stranded DNA genome into the nucleus in a form that is 
naturally episomal at high efficiency; and absence of mutagenic effect. Nevertheless, 
the most potential advantage of adenovirus vectors is their ability to package large 
capacity for DNA insertion (Hendrie and Russell, 2005; Li et al., 2012b; Verma and 
Weitzman, 2005). In contrast, their ability to stimulate strong immune and 
inflammatory reactions, and their promiscuity related to transduction of other different 
cells in addition to targeted cells, has limited their use (Kawase et al., 2011). 
Ads are known to have lytic life cycle inside their host cells; therefore Ad-based vectors 
were developed by removing those viral genes that cause this undesirable effect. In this 
regard, Ad first generation vectors designed to be replication-deficient by the deletion of 
El early genes, which is essential for expression of E2 genes and other genes necessary 
for DNA synthesis and replication. The combined deletion of E1 and some of E3 genes 
that are not necessary for viral replication in vitro and involved in stimulation of viral 
immunogenicity, has led to development of Ad second generation vectors. These two 
deletions in E1 and E3 regions provide about 8 kb in the Ad vector genome to be used 
for insertion of DNA of interest, ensuring sustained expression of transgenes in Ad 
vector transduced-mammalian cells. Additional subsequent deletion of some E4 genes 
has introduced Ad third generation (Campos and Barry, 2007; Vorburger and Hunt, 
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2002). On the other hand, gutted (also called gutless or helper-dependent) adenoviral 
vectors are reported to be considerably safer compared to early generation adenoviral 
vectors. Unlike first- and second generation adenoviral vectors which still include some 
of the adenoviral coding sequences, gutted adenoviral vectors are devoid of all viral 
coding sequences. They can induce sustain transgene expression and possess 
significantly less inflammatory potential than early-generation Ad vectors (Ehrhardt and 
Kay, 2005; Toietta et al., 2005). 
 
Human embryonic kidney (HEK) 293T cells were previously transduced with modified 
Ad5 genomic DNA establishing HEK 293T cell line which stably expressing Ad E1 
genes. Hence E1-deficient Ad vectors can be produced and amplified in these 293T cell 
lines via trans-complementation (Graham et al., 1977). Currently Ads vectors are 
produced in 293T cell line at efficient titres, and purified using CsCl density gradient 
centrifugation. 
 
1.2.2 Retroviral vectors 
Retroviruses are enveloped viruses with ~ 100 nm in diameter; their genomes consist of 
two identical copies of RNA of varied sizes ~ 8-11 kb surrounded by a conical-shaped 
core (Goff, 2001). These viruses are considered the only truly diploid viruses and they 
are the only RNA viruses whose genome is produced without any participation of viral 
encoded polymerase depending only on cellular transcriptional machinery (Coffin et al., 
1997). Retroviruses have the ability to efficiently integrate their genetic material into 
host chromosomes (Hendrie and Russell, 2005). They are known for their ability to 
promote reversal of genetic transcription from RNA to DNA using reverse transcriptase 
upon to transduction of host cell genome. Some retroviruses can cause various fatal 
human diseases, including acquired immunodeficiency syndrome (AIDS), inflammatory 
diseases and multiple types of cancer. 
These viruses are subdivided into two categories, simple and complex, according to the 
organisation of their genome. Simple retrovirus carries only essential major genes, gag, 
pol, and env; while complex retrovirus encodes additional regulatory genes that play 
important roles in their replication and pathogenesis. In fact, all retroviruses possess the 
basic genome structure of centrally located main genes (gag, pol, and env) flanked by 
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long terminal repeats (LTR) at either ends of genome. The basic organisation of 
retroviral genome is showed in Figure  1.2. The role of LTRs is important for regulating 
transcription of the viral genes and integrating of viral DNA and initiating its synthesis 
(Shida, 2012). Retroviruses are further subdivided into seven genera; five are the alpha- 
to epsilon-retroviruses that are characterised by oncogenic abilities, and two other 
genera, the spumaviruses and lentiviruses (Lim, 2012). In general simple retroviruses, 
like gammaretroviruses and alpharetroviruses, transduce non dividing cells at reduced 
efficiencies; though lentiviruses show approximately no difference between dividing 
and non-dividing cells. So, some retroviruses are almost completely dependent on cell 
cycle progression, others show an intermediate dependence, and lentiviruses have nearly 
no dependence on cell proliferation (Yamashita and Emerman, 2006).  
 
Figure 1.2: Schematic representation of retroviral genome organisation. The long 
terminal repeats (LTR) located on the DNA either ends and in between them structural 
genes (gag, pol and env), Ψ: RNA packaging signal. Diagram adapted from Delenda, 
2004.  
The gag region encodes genes for the matrix, capsid proteins, and nucleocapsid which 
are produced by proteolytic cleavage of the gag precursor protein; the pol region 
encodes genes for reverse transcriptase, protease, and integrase viral enzymes which are 
generated from the gag-pol precursor, and the env region encodes genes for the 
envelope glycoproteins and proteins needed for receptor recognition, which facilitate 
virus entry. The life cycle of retroviruses starts with binding of viral surface 
glycoproteins incorporated in the viral envelope to its receptor on the surface of the host 
cell. Any modifications in these glycoproteins will affect viral tropism, hence they 
mediate the viral tropism and they were exploited for vector pseudotyping. Then the 
entry of viral capsid containing the RNA genome into the cell will be mediated by 
endocytosis. Subsequently, the retroviral RNA genome will be transcribed into a 
double-stranded proviral DNA by the viral enzyme reverse transcriptase. The reverse 
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transcribed proviral DNA, reverse transcriptase, integrase, nucleocapsid, and other viral 
proteins will be combined together to form a preintegration complex (PIC). Then the 
PIC will be translocated into the nucleus, and viral DNA enters the nucleus as a part of 
the PIC. The integrase enzymes catalyse the integration of the provirus into the host 
chromatin. Next, the cellular machinery of transcription will be initiated by viral LTR 
and the proviral DNA will be transcribed into mRNA and genomic retroviral RNA. The 
viral mRNA then will be translated into glycoproteins and nucleocapsid proteins and 
viral compartments will be formed at the plasma membrane. Finally, the cell membrane 
of host cell buds out and new progeny virions will be released (Sundquist and 
Krausslich, 2012; Verma and Weitzman, 2005; Vile, 1992). 
Retroviral-based vectors are designed for safety reasons by removal of those genes 
essential for viral replication and their genomes were additionally modified to encode 
therapeutic transgenes between the two LTRs. Retroviral replication-defective vectors 
were mainly recruited to create genetic modifications in stem cells for treatment of 
various human diseases, including blood disorders, diabetes, and neurological disorders 
(Lim, 2012). However, retroviral related insertional mutagenesis has emerged as 
potential side effects after retroviral gene therapy. In this regard, the previous 
assumption of random retroviral integration has recently changed; it is believed now 
retroviral integration does not occur randomly. Retroviruses posses the tendency to 
integrate close to transcription start sites of active genes inducing activation of a proto-
oncogene or disruption of a regulatory gene (Fischer and Cavazzana-Calvo, 2005). As a 
result when retroviral integration occurs near oncogenes, normal cells can be 
transformed into cancerous cells, as demonstrated by the incidence of leukaemia in 
earlier gene therapy trials (Fischer and Cavazzana-Calvo, 2005; Fischer et al., 2012; 
Qasim et al., 2009). 
 
1.2.3 Lentiviral vectors  
Lentiviruses (LVs) are complex retroviruses, known with their abilities to transduce 
both dividing and non-dividing cells and maintain long-term transgene expression 
(Lesch et al., 2011). LV genomes, like other retroviruses, comprise the structural three 
genes of gag, pol, and env; however they additionally code for a set of accessory genes 
that required to ensure efficient viral transduction/ replication in the host cells. In 
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Human Immunodeficiency Virus Type -1 (HIV-1), the common member of lentiviruses, 
these genes includes two regulatory genes vital for viral replication: rev encodes 
regulator viral protein and tat encodes transactivator of transcription, and four accessory 
genes essential for in vivo rep viral replication and pathogenesis and not critical for 
virus growth in vitro; vif encodes viral infectivity factor, vpr encodes viral protein R, 
vpu encodes viral protein U and nef encodes negative factor  (Matsuda et al., 2009). 
Additionally, LVs possess nuclear localization signals (NLS) which facilitate entry of 
PIC into nuclei of non dividing cells enabling LVs to transduce non dividing cells like 
neurons (Li et al., 2010). A schematic representation of the HIV-1 structure is 
illustrated in Figure  1.3 and diagrammatical representation of the HIV-1 genome 
organisation is shown in Figure  1.4 A. 
 
Figure 1.3: Schematic representation of the HIV-1 structure. General diagram of 
wild type HIV-1 structure showing a viral conical-shaped core including matrix, capsid 
and nucleocapsid surrounded by viral bilayer lipid envelope. Viral core also comprises 
viral essential enzymes: reverse transcriptase, integrase and protease. The envelope 
contains surface and trans-membrane glycoproteins essential for attachment entry to 
host cell. Adapted from Buchschacher and Wong-Staal, 2000. 
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Figure 1.4: Diagrammatical representation of developing of HIV-1 based lentiviral 
vector packaging constructs. Panel A, gene organisation of typical HIV-1- provirus, 
panel B, C and D are first-, second- and third-generation types of packaging constructs 
comprise derived features of the HIV-1, respectively. The cytomegalovirus (CMV) 
promoter and polyadenylation signal (polyA) replaced viral 5’ and 3’ LTRs, 
respectively. The envelope was deleted and some of accessory proteins were mutated in 
first generation packaging construct keeping structural and most of accessory genes 
intact. Yet, all the accessory genes have been removed in second generation packaging 
construct. While subsequent modification in third generation packaging construct has 
led to remove Rev and Tat genes and to express the Rev gene under Rous Sarcoma 
Virus (RSV) promoter and a polyA from separated and non-overlapping construct. SA: 
splice acceptor, SD: splice donor site. The figure is not to scale and is adapted from 
Vigna and Naldini 2000, and Zufferey et al. 1998.  
 
The lentiviral LTRs of the viral RNA comprise two sequence elements: the 5’LTR 
includes the repeated R and unique 5’ (U5) region whereas the 3’LTR contains the 
unique 3’ (U3) region in addition to a second copy of the 5’R region. During the reverse 
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transcription, portions of both LTRs will be duplicated and the reverse transcribed DNA 
will possess U3, R and U5 sequences at either ends. Upon integration of reverse 
transcribed DNA into host cell genome, the proviral DNA will act as a template for host 
transcription machinery during replication and formation of new viral particles 
(Buchschacher and Wong-Staal, 2000). 
 
The basic structure of HIV-1 genome additionally includes cis-acting nucleic acid 
sequence. These non- translated elements are essential for viral packaging and reverse 
transcription and are mainly located in the highly structured region of 5’ end. They 
contain: the gag leader sequence region located between 5’ LTR and gag region which 
comprise the encapsidation signal (ψ), the main splice donor (SD) site and primer 
binding site (PBS) which is needed to initiate the reverse transcription process; central 
polypurine tract (PPT) located in the central region of the genome and in the 3’ region 
which is required for DNA synthesis; and Rev-responsive element (RRE) which is 
located near the 3’ end and is essential for RNA transport (Buchschacher and Wong-
Staal, 2000). 
 
1.2.3.1 Development of lentiviral vectors for gene therapy  
 
Lentivectors are LV based vectors modified for gene therapy applications by harnessing 
LVs natural abilities in transduction of both dividing and non-dividing cells. Continuous 
vector development has always focused on the production of efficient and safe vectors 
relying on minimising the chances of replication-competent vectors (RCVs) arising, 
insertional mutagenesis and oncogenesis, and ensuring at the same time efficient viral 
expression. The aim is to design a viral modified genome encoding a therapeutic gene 
cassette to replace the viral original genome. Accordingly, this development produces a 
non-pathogenic, non-replicative and abortive viral transduction, which introduces 
transgenes into the target cells and ultimately generates efficient expression from the 
recombinant vectors. 
 
The main strategy used for developing lentiviral vectors was to eliminate genes 
responsible for pathogenesis. For example, in third generation lentiviral vectors this 
strategy has result in splitting the viral genome to be expressed from separated plasmids 
leading to separate structural and regulatory genes. In that case the viral structural genes 
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encode essential enzymes and proteins are expressed from trans acting elements in the 
packaging plasmids, whereas regulatory genes encode viral gene expression and 
packaging of vector genome are expressed from cis acting elements in the transfer 
plasmids. Then these two systems (trans / cis) are brought together by co-introduction 
into the producer cells. The principle of this approach aimed at increasing the 
recombination events needed for production of (RCVs) and eventually reduces the 
possibility of generating of virulent viruses (Kay et al., 2001).  
In this connection, first generation lentiviral vectors were generated by separation of the 
packaging, envelope and vector cassettes and express them in trans from 3 separated 
plasmids. The Env was removed, some of accessory genes of packaging plasmid were 
mutated and most of other HIV-1 provirus features were maintained (Figure  1.4 B), 
keeping minimal cis-acting elements essential for packaging. The lentiviral vectors were 
pseudotyped with vesicular stomatitis virus glycoprotein G (VSV-G) which is carried 
by separated plasmid (Naldini et al., 1996). This approach intended to reduce the 
opportunities of RCVs generation by homologous recombination and the same time 
lentiviral vectors were produced inside producer cells upon cotransfection.  
Along with trans / cis system, another strategy was applied to improve viral biosafety 
based on the deletion of non-essential viral genes leading to design of the second 
generation lentiviral vectors. The accessory genes vif, vpr, vpu, and nef encode 
important proteins to HIV-1 infection but not essential for viral replication and 
packaging. However, rev was considered vital for gene expression, not only in wild type 
viruses but in LV based vectors as well, while tat was considered essential only for 
those vectors based on transfer plasmids with HIV LTR, like pHR’ family. Importantly, 
Zufferey et al showed that deletions of HIV accessory genes vif ,vpr, vpu and nef from 
the packaging plasmid, for safety reasons, did not result in reduction of vector 
production (Zufferey et al., 1997). Hence, of the nine genes in the original HIV 
pathogen, only four – pol, gag, rev and tat were considered crucial for vector production 
(Figure  1.4 C).  
A further lentiviral system that became known as the third generation lentiviral vectors 
(Figure  1.4 D) was early developed by removing tat expression from the packaging 
construct. Additionally, the gag/pol and rev genes were segregated and expressed from 
two distinct constructs. Moreover, as from first generation lentiviral vectors the CMV, 
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as a constitutive promoter, replaced the viral 5’ LTR, while the polyA signal replaced 
viral 3’ LTR (Dull et al., 1998).  
Additional improvements of lentiviral vectors safety have exploited the viral replication 
mechanism to generate self-inactivating (SIN) vectors. The HIV RNA contains 
promoter / enhancer sequences at LTR of both the 5’ and 3’ ends. During the reverse 
transcription the tRNA primer binds to the PBS and LTR start to extend firstly at the 5’ 
end of the viral RNA, then transferring to the 3’ end allowing reverse transcriptase to 
complete transcription in the 3’ to 5’ direction. Hence, this process ‘copies’ the 5’ end 
of the LTR to the 3’ end of the growing DNA strand and vice versa. This process has 
been exploited by introducing a deletion via removal of 400 base pairs from the U3 
region comprising the TATA box in the 3’ LTR, which after reverse transcription in the 
host target cell is flipped into the U3 region of the 5’LTR of the proviral DNA. As a 
result this deletion essentially eliminates the promoter function of the LTR and 
consequently prevents the expression of full-length vector RNA. Thereby the generated 
lentiviral vectors will be only capable of producing a single copy of double stranded 
DNA for each RNA molecule resulting in further improving of vector safety aspects. 
The lentiviral vectors produced by this strategy are called SIN vectors as their transgene 
expression will be available from only the internal promoter in the transfer construct 
and have even weaken abilities to produce RCVs. The significance of the deletion in the 
enhancer region of the 3’ U3 of the LTR gene has made SIN vectors safer because it 
results in a transcriptionally inactive vector that can not be converted into a full length 
RNA and reduces likelihood of RCV regeneration. Eventually this will lead to reduce 
risk of tumorigenesis via promoter insertion (Logan et al., 2004; Miyoshi et al., 1998; 
Qasim et al., 2009; Zufferey et al., 1998). 
The woodchuck hepatitis virus post-transcriptional regulatory elements (WPREs) are 
found to enhance transgene expression and transduction efficiency of lentiviral vectors. 
The placement of WPREs near the 3’ untranslated region downstream of the transgene 
has been assumed to improve mRNA nuclear export and genomic transcription 
(Zufferey et al., 1999). This element act at post-transcriptional level, most possible to 
enhance the efficiency of polyadenylation of newly transcribed RNA leading to increase 
it is amount in the cells (Vigna and Naldini, 2000). It has been reported that 
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incorporation of WPREs in transgene construct could result in overall transgene 
expression by more than fivefold (Werner et al., 2004). 
Pseudotyping of lentiviral based vectors with a variety of envelope proteins, commonly 
the VSV-G glycoprotein, has led to: widening viral tropism considerably to infect 
different species both in vitro and in vivo; enhancement of viral production techniques 
by stabilisation of vectors particles from shearing forces during ultracentrifugation 
leading to achieve high titres; and, in LVs particularly, facilitating the viral entry into 
host cells by endocytic pathway reducing the viral dependency on accessory proteins. 
Moreover, retroviral based vectors incorporation of combined synthetic and tissue-
specific promoters has evoked sustained and regulate gene expression in vector host 
cells (Cockrell and Kafri, 2007; Mikkola et al., 2000). 
The LV natural features together with improvements mentioned above have resulted in 
making the lentivectors attractive tools in gene therapy because: 
• Their relative large packaging capacity (up to 8 Kb), which is a key feature in 
packaging large expression cassettes of tissue-specific promoters and transgenes, 
• Their ability to transduce effectively both dividing an non-dividing cells, 
• Their ability to integrate genes into targeted chromosomal DNA and subsequently 
lead to stable and sustained gene expression, and  
• Their reduced immunogenicity compared to other vectors, making them possible 
considerable systemic delivery routes and reducing the likelihood of anti-vector 
antibody formation (Verma and Weitzman, 2005; Wanisch and Yanez-Munoz, 
2009).  
Lentiviral vectors are commonly produced by transient cotransfection of HEK 293T 
cells using recombinant constructs encoding transgenes, packaging elements, rev gene 
and sequences encoding Env glycoproteins (Figure  1.5), and harvesting lentiviral-
containing supernatant. The Env VSV-G is used widely to replace HIV-1 envelope 
protein, providing highly stable capsid vectors; although a wide range of alternative 
glycoproteins have the ability to attach to lentivectors’s membrane. It has been 
suggested that VSV-G attach to phosphatidylserine on host cell membrane (Burns et al., 
1993; Kutner et al., 2009).  
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Figure 1.5: Diagrammatical representation of recombinant constructs used for 
lentiviral vector production. Different constructs used to produce lentiviral vectors 
based on third generation system. The figure is not to scale.  
1.2.3.2 Integration-deficient lentiviral vectors 
Integration of viral DNA copy into the host cell genome is an essential step of the life 
cycle of retroviruses as it is ensures long-term expression of the retroviral genes 
allowing a productive viral propagation. Retroviral integration has been confirmed to be 
non-random and at virus-specific locations (Ciuffi, 2008). As an example, gamma-
retroviral vectors are known by their ability to integrate close to the LMO2 proto-
oncogene, resulting in triggering and then overexpression of this gene leading 
eventually to oncogenesis. Lentiviruses have the tendency to integrate their genomes 
near or within transcriptionally active host cell genes, having, unfortunately, a risk of 
insertional mutagenesis and subsequent oncogenesis. In general lentiviruses have 
strongly attenuated, but not abrogated, oncogenic potential (Montini et al., 2006). From 
safety point of view, this could cause a major problem for gene therapy approach as 
reported earlier (Qasim et al., 2009). In order to circumvent possible related insertional 
mutagenesis and to reduce its risk, the integrase-deficient lentiviral vectors (IDLVs) are 
introduced. The development of IDLVs is considered a further improvement to boost 
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HIV-1 derived vectors biosafety, as they still keep the earlier characteristics of 
integrating proficient lentiviral vectors (IPLV) (Philippe et al., 2006). 
The viral enzyme integrase plays a critical role in viral integration, reverse transcription 
and nuclear import. Upon virus entry into the host cell, integrase will combine with 
other elements to form PIC which will mediate nuclear entry, and eventually the 
integrase will mediate proviral DNA integration into the chromosomal DNA genome 
(Arhel et al., 2007). Integrase catalyses the hydrolysis of two terminal nucleotides from 
each end of HIV-1 DNA leaving a 5’ dinucleotide overhang and 3’ hydroxyl exposed 
group, this process called “3′ processing”. Consequently, the integrase employ ed the 
exposed 3’ hydroxyl group to cut opposite strands of chromosomal DNA facilitating the 
connection of the viral exposed DNA 3′ ends to the generated 5′ overhangs  via 
phosphodiester bond. In the end, the gaps in the single-strand discontinuities are 
repaired by host cell enzymes (Engelman and Cherepanov, 2008; Engelman et al., 1991; 
Pauza, 1990).  
Integration into chromosomal DNA is not the only destiny for viral DNA; as those viral 
DNAs that fail to integrate into the host genome can persist in the nucleus as episomal 
DNA, so called ‘episomes’. Two types of episomes could persist as intermediate or by-
product of viral integration: double or single LTR circles (see Figure  1.6). Double LTR 
circles are the result of either end to end joining, LTR to LTR, by non-homologous end 
joining (NHEJ), while single LTR circles  the result of homologous recombination (HR) 
of one LTR to another creating an episome with only one LTR (Nakajima et al., 2001; 
Philpott and Thrasher, 2007). There is also the possibility of tandem joining of two 
episomes in auto-integration, which is non-functional (Farnet and Haseltine, 1991). The 
episomes are unable to replicate and they will be diluted with time in proliferating cells 
or degraded by cellular nucleases (Butler et al., 2002). Nevertheless, they are detected 
in the nucleus of transduced cells and are transcriptionally active (Banasik and McCray, 
2009). Hence, if a therapeutic gene was present in the nucleus of a proliferating cell as 
an episome, it would not have long-term effect. Furthermore, the incorporation of a 
gene segment of a Scaffold/Matrix Attachment Region (S/MAR) from the human β-
interferon gene, into vector transcription units to enhance transgene expression was 
achieved (Nielsen et al., 2009). However, this had only limited effects on the 
establishment of stable transgene in lentiviral vectors  in contrast to, for instance SV40-
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based vectors which has shown that controlled episomal replication could be stably 
maintained for over 100 generations (Piechaczek et al., 1999). 
 
Figure 1.6: HIV-1 based vector transcription model transcription. Upon viral entry 
into the target cell, the viral RNA genome will be reverse transcribed in the cytoplasm 
into double stranded linear DNA. Subsequent nuclear entry will be facilitated by PIC 
leading to proviral DNA entry into the nucleus. Three possibilities could occur: 
integration of the proviral genome into chromosomal DNA, forming of 2 LTRs circle 
episomes via non-homologous end joining (NHEJ) or forming of 1 LTR circle episomes 
via homologous recombination (HR). Model adapted from Philpott and Thrasher 2007. 
  
The natural tendency of LVs to form episome could be enhanced by impairing the 
virus’s ability to integrate into chromosomal DNA avoiding all the related possibilities 
of mutagenesis and / or oncogenesis. This can be achieved by mutating the viral 
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integrase; accordingly there are two types of integrase mutations: class I and II 
mutations. Integrase class I mutations result from individual changes (point mutations) 
of specific amino acids leading to impaired viral integration and at the same time 
maintain the function of reverse transcription and nuclear import. On the contrary, class 
II mutations are usually occur in integrase active site leading to alteration of several 
functions of integrase which in turn will affect the integration step resulting in 
production of reduced amounts of viral DNA. Thus, this mutation related to complete 
integrase absence and faulty reverse transcription, nuclear localisation, nuclear entry 
and most importantly viral integration (Engelman, 1999; Lu et al., 2004). 
The integrase active site encompasses three vital residues: aspartic acid at position 64 
and 116 and a glutamic acid at position 152 (Leavitt et al., 1993). The so-called “D64V 
mutation” represent most common class I mutation. In this mutation the aspartic acid 
residue at position 64 is replaced by valine residue leading to generating integrase only 
faulty to catalyses viral integration while keeping its other functions (Engelman et al., 
1995; Leavitt et al., 1996). It is noteworthy to mention that IDLVs possess, in general, 
lower expression levels than IPLVs in many cells types, while in other cells, like retinal 
pigment epithelium and neurons, there was no difference (Bayer et al., 2008; Yanez-
Munoz et al., 2006). Because of their episomal nature, IDLVs will be diluted out in 
dividing cells as they are unable to replicate leading to limit their use into non-dividing 
cells (Wanisch and Yanez-Munoz, 2009).  
1.3 Gene repair and DNA double-strand breaks 
DNA repair mechanisms are essential for any living cell to maintain the structural 
integrity of the genome, which requires repair of any DNA damage with high fidelity. 
There are two types of DNA breaks: single-strand breaks (SSBs) and double-strand 
breaks (DSBs). The most hazardous DNA damages that cells could face are DNA 
DSBs, which can be caused by endogenous factors like collapsed replication forks or 
reactive oxygen species generated as a by-product of normal metabolic processes, and 
exogenous effects like exposure to ionizing radiation and certain chemicals (Mauro et 
al., 2012). Unrepaired DSBs may lead to very serious effects to the cells, like 
mutagenesis, tumorigenesis, genomic instability and cell death (Kirchgessner et al., 
1995). In human cells, as an example, thousands of SSBs and DSBs events occur 
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naturally per day without necessarily leading to harmful consequences (Holmquist, 
1998). Even so; a single DSB could potentially lead to cell death or oncogenic 
mutations in theory. Two main mechanisms are available for the cells to repair DSBs: 
homologous recombination (HR) which relying on recruiting an intact homologous 
segment of DNA, naturally from the sister-chromatid, as a template from which to copy 
the information across the DSB (Figure  1.7). An alternative pathway of DSB repair is 
non-homologous end joining (NHEJ), which non-specifically rejoins ends without 
homology and often results in short insertion or deletion (InDel) mutations at the site of 
break (McKinnon and Caldecott, 2007; San Filippo et al., 2008), or leading to 
chromosomal translocation (Brunet et al., 2009).  
HR represents the major DSBs repair mechanism in bacteria and yeast but it is 
infrequent in the majority of higher eukaryotes (Johnson and Jasin, 2001). In contrast, it 
is believed that NHEJ mechanism play a dominant role in DSBs repair in higher 
animals (Iiizumi et al., 2008; Pruett-Miller et al., 2008). An emerging approach “gene 
repair” is introduced to gene therapy by harnessing the natural mechanism of HR to 
repair faulty genes at their endogenous loci maintaining genes integrity and regulation. 
Consequently, gene therapy strategies favor HR to modify the mutated gene rather than 
deliver a supplementary correct copy of the gene because HR mediates a genetic 
manipulation which ultimately restores a normal copy of damaged gene and guarantee 
permanent genetic alterations. Hence, an ideal correction would be achieved as the 
correct copy accurately replaces mutated sequences. Nevertheless, the low spontaneous 
frequency of HR in somatic mammalian cells has limited the therapeutic (and even 
experimental) gene modification strategies. In somatic mammalian cells (including 
human and murine cells) the expected spontaneous HR rate is (~ 1 in 106 cells), while 
the rate of NHEJ is about (~ 1 in 103 cells) (Gellhaus et al., 2010; Porteus and 
Baltimore, 2003; Pruett-Miller et al., 2008). For instance, in mouse embryonic stem 
cells the HR rate is about 1% of total random integration events (Osakabe et al., 2010). 
Thus, HR natural spontaneous frequency is too low to be used clinically for gene 
therapy studies; however this rate could be raised up to 20% when DSBs are introduced 
by nuclease-inducing DSBs like ZFNs in different cell types (Cornu et al., 2008). 
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Figure 1.7: Sschematic diagram of DSBs repair mechanisms. Two main strategies 
are available in living cells to repair DSBs; the first is non homologous end-joining 
(NHEJ) which is considered as a dominant pathway in mammals and could be available 
during G1, S and G2 phases of cell cycle. During NHEJ, the broken strands of DNA are 
re-joined directly and non-specifically generating frequent mutations and eventually 
error prone repair. The DNA end-binding protein Ku 70 and Ku 80, recruits the DNA-
dependent protein kinase (DNA-PK), XRCC 4, and DNA ligase IV for re-joining.  
While the second is homologous recombination (HR) mediated repair which is 
considered as a dominant pathway in lower organisms and could be available during G2 
phase of cell cycle. BRCA co-localizes with RAD 51, which is implicated in DSB 
repair through its ability to bind single-stranded DNA and facilitate DNA strand 
exchange. Then, Rad 52 binds to the resected ends, and Rad 51 forms a ﬁlamen t that 
facilitates DNA strand invasion. The resected 3’end invades a homologous DNA duplex 
and is extended by DNA polymerase. HR naturally uses a sister chromatid homologous 
template or any other supplied extrachromosomal homology generating a perfect repair. 
The diagram was amalgamated from San Filippo et al. 2008, and Weberpals et al. 2008.  
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1.3.1.1 The role of HR in gene repair  
In 1978, the concept of homologous gene targeting was first described in yeast by 
Hinnen et al. (Hinnen et al., 1978), then it is successfully transferred to mammalian 
cells by Mario Capecchi, Martin Evans and Oliver Smithies. For that, 
Capecchi, Evans and Smithies have jointly awarded the Nobel Prize in physiology or 
medicine for 2007 for their discoveries of "principles for introducing specific gene 
modifications in mice by the use of embryonic stem cells" 
(http://www.nobelprize.org/nobel_prizes/medicine/laureates/2007/press.html, accessed 
on 4/7/2012). They opened the door for gene repair approach by their recognisable 
achievement of demonstration of that mammal genes could be targeted by HR in 
cultured cells and changes transferred into the mouse germ line using embryonic stem 
cells. Their pioneering research has highlighted the importance of therapeutic gene 
repair because it has made the cell genetically wild type, restored the function of faulty 
gene permanently and avoided the insertional mutagenesis.  
During the process of DSBs repair by HR, a second homologous copy to the mutated 
sequence must be available to act as a template.  The cell usually prefers to use the sister 
chromatid as a donor-template for DNA polymerase to extend and repair the DSBs. 
Thus, cell cycle phase could be the major determinant for the genomic DSB to be 
repaired by NHEJ or HR (Olsen et al., 2010). As a result HR is most active at late S and 
G2 phases of the cell cycle, while NHEJ can be active at all the phases (Kotnis et al., 
2009), but it is most essential in G1 and G0 phases (Wiegant et al., 2010). As an 
example for this preference Saccharomyces cerevisiae prefers to use the sister 
chromatid by 2-3 orders of magnitude over a homologous or heterologous chromosome 
(Johnson and Jasin, 2001).  
 
Interestingly, the cellular machinery controlling HR could be exploited for gene repair 
by providing an extrachromosomal homologous sequence to act as a template to replace 
precisely the mutant one but this exogenous DNA contains mismatches or intervening 
sequences. Of note, HR machinery can be stimulated by 2 to 3 orders of magnitude 
when homology is provided either from extrachromosomal  DNA in gene repair  
experiments or from a repeated chromosomal sequence (Elliott et al., 1998). The two 
DNA ends resulted from DSB (the broken ends) will be under the influence of 
exonuclease action, generating single stranded 3’ ends in both sequences. These single 
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stranded 3’ ends invades the donor DNA template (whether a sister chromatid or 
extrachromosomal DNA) at the homologous region, producing DNA duplexes with a 
donor template. Later on the DNA polymerase extends the 3’ ends using the donor 
DNA as a template (Wong and Chiu, 2011). At the end, HR will mediate integration of 
the new sequence into a small fraction of the targeted cell genome; and if selector genes 
are included in the donor sequence (to be removed eventually), the genetically modified 
cells can be isolated (Capecchi, 2001). Furthermore, it has been confirmed recently that 
arresting the targeted cells at the late S and G2 phases of the cell cycle would increase 
the HR rate by up to 5 fold (Connelly et al., 2010; Olsen et al., 2010), simultaneously 
that will not have any influence on the activity of NHEJ repair pathway (Guirouilh-
Barbat et al., 2008). 
There are two conserved class of enzymes, so called recombinases, control the HR 
function (San Filippo et al., 2008). Those recombinases include the RAD51 group 
(containing RAD50, RAD51, RAD52, and RAD54) and Dmc1 group (containing RPA, 
XRCC2, XRCC3, and BRCA) (Johnson and Jasin, 2001). Both recombinases mediate 
the formation of DNA joints that link homologous DNA molecules, but they are active 
at different conditions. The Rad51 enzyme is active in somatic and meiotic cells, while 
the second recombinase, Dmc1, is active only in meiosis and acts in concert with 
Rad51(San Filippo et al., 2008). The proteins controlling the NHEJ activity will be 
discussed below (section 1.8.2). It has been suggested that there is competition between 
NHEJ and HR mechanisms upon the DSBs repair (Iiizumi et al., 2008; Ramirez et al., 
2012). However; the selection is more probably to be decided by the functional proteins 
that initially recognize and process the DNA ends at the DSBs locus (Yun and Hiom, 
2009).  
The efficiency of HR mediated gene repair depends on different factors: 
• delivering of intact homologous template into the nucleus of targeted cells. 
• the efficiency of transfection or transduction efficiency of targeted cells.  
• the nature and type of cell ; it is essential to understand and modify the balance of 
HR and NHEJ mechanisms.  
• the type of genetic mutation to be repaired; it would be ideal therapy if the repaired 
cells possess a selective advantage as for instance in some SCID disorders. 
37 
 
• the induction of genome site specific DSBs to stimulate HR (Ellis et al., 2012; 
Urnov et al., 2010).   
 
It has been reported that HR-mediated manipulation could be possible at least in 
hematopoietic stem cell (HSC) progenitors (Hatada et al., 2000) because of many 
reasons: the repaired cells would possess a selective repopulation advantage, the 
suitability of HSCs to many viral vectors including (lentivirus based vector) and the 
ease of ex vivo gene therapy (Cartier et al., 2012; Langford-Smith et al., 2012). On the 
other hand, this approach is hindered by two main problems: the low abundance of these 
cells and the low achieved HR frequency. However; several procedures can be adapted 
to improve the HR frequency such as: 
• increasing the length of the homologous template, for example it has been found 
that doubling the length will lead to a 10 fold increase in the gene repair frequency 
(Deng and Capecchi, 1992),  
• pretreatment of the HSCs with appropriate cytokines will lead to 10 times increase 
in their repopulating abilities (Glimm et al., 2000),and  
•  it has been recently shown that introduction of a DSB at a specific genomic target 
locus can increase targeting frequencies (Carroll, 2008). 
1.4 Induction of DSBs 
As mentioned above, HR is inefficient in mammalian cell gene repair therapies because 
of: the low spontaneous frequency and the vectors integrate randomly into the host 
genome sites via NHEJ at least 3000 times more (Iiizumi et al., 2008). However; there 
are several ways to improve the efficiency of gene repair including: the use of 
recombinant AAVs (Pruett-Miller et al., 2008), and gene repair stimulation by inducing 
of  DSBs at the target sites. It has long been confirmed that the induction of site-specific 
DSBs in the target sequence raises the HR rates by up to 3000 fold (Olsen et al., 2010). 
Additionally, the presence of genomic DSB inducers not only enhance the DNA 
damage response signalling pathways  but also changes  the activity of many central 
cellular proteins, affect the cell cycle and impinge on cell death (Harper and Elledge, 
2007). Furthermore, it has been reported that induction of DSBs will not only enhance 
the repair efficiency but also the range of possible types of corrections resulting for 
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instance to large insertions of 8 kb (Moehle et al., 2007). Thus, the new emerging 
approach of “genome surgery” has revolutionized gene repair research using custom-
designed enzymes directed to introduce genome site-specific DSBs. These designer 
nucleases include: ZFNs, meganucleases, and transcription activator-like effector 
nucleases (TALENs).  
 
1.4.1 ZFNs 
1.4.1.1 ZFN structure and function 
ZFNs are engineered chimeric proteins that link wild-type Fok I endonuclease domains 
to zinc finger DNA binding domains (Kandavelou et al., 2005; Porteus and Carroll, 
2005).  These proteins are custom designed to induce DSBs at very specific DNA 
sequences (Urnov et al., 2005). Each ZFN protein consists of two monomers and 
typically every monomer incorporates a non-specific cleavage domain of the Fok I type 
II restriction enzyme (a restriction endonuclease from Flavobacterium okeanokoites) 
(Liu et al., 2010)  fused to about 3-4 zinc finger domains (Durai et al., 2005; Liu et al., 
2010). Each zinc finger domain is particularly designed to recognize 3-4 base pairs (bp) 
of double stranded DNA. Normally,  three (Kandavelou et al., 2005) or four (Urnov et 
al., 2005) zinc domains are linked together in tandem to generate a zinc finger protein 
(ZFP) that recognizes and binds to a 9 bp (Kandavelou et al., 2005) or 12 bp (Urnov et 
al., 2005) respectively, depending on the basic design for the ZFN. This 9 or 12 bp of 
the DNA sequence which can be recognized by one ZFP is known as the ZFN (or 
monomer) binding site, with one binding site for each monomer (see Figure  1.8).  
 
Historically, the zinc finger domains were first discovered in Xenopus laevis (Durai et 
al., 2005), later it became known that they are naturally present in the genomes of 
different organisms including human (Klug, 2005). There is a high degree of conserved 
residues within the fingers; however there are some differences in few residues allowing 
them to bind specifically to distinct DNA sequences. Multiple fingers are assembled in 
a modular tandem fashion to recognize a specific DNA sequence (Cathomen and 
Weitzman, 2005). The three dimensional structure of the zinc finger has been shown to 
be composed of two β-sheets in an antiparallel configuration, which forms a loop 
produced by the two cysteines and an α-helix including two histidines loop (see Figure 
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 1.9 a). The two structural entities are stabilized together by the zinc ion and for this 
reason this structure is called as ββα motif (Klug, 2005). 
 
 
Figure 1.8: Schematic representation of ZFN structure targeted against mouse 
Prkdc. ZFNs are dimeric proteins with 5 zinc-finger domains forming the right ZFN 
monomer binding site or 4 zinc-finger domains forming the left monomer. Zinc-finger 
domains are fused to the endonuclease domain of Fok I; each finger recognizes 3 base 
pairs of double stranded DNA via a single α -helix. The binding sites for the monomers 
are separated by a nucleotide spacer where DSB takes place.  
 
The two ZFN binding sites are separated by approximately a 5-7 bp spacer, where the 
DSB occurs (Townsend et al., 2009). Altogether, the two ZFN binding sites (18 or 24 
bp, in addition to the nucleotide spacer in between) represent the full ZFN recognition 
site (Dolan, 2006). So, the ZFN full site is long enough to be a unique locus within 
mammalian genomes (Kandavelou et al., 2009).  The Fok I domain is able to dimerize, 
inducing a sequence specific DSBs whenever the two ZFPs bind their equivalent DNA 
target sequence in the opposite orientation (Zou et al., 2009). Hence in order for the 
ZFNs to create the cutting at the desired sequence, two Fok I must be dimerized. In fact, 
the actual DSBs of the targeted DNA sequence is initiated by the Fok I domain, a fact 
that confirmed by Pruett-Miller et al when HEK 293 cells were transfected with 
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designed ZFNs lacking the Fok I domain; there were on detected cytotoxicity (Pruett-
Miller et al., 2009). It is not essential for the two monomer recognition sites to possess 
the same length to provoke specific targeted DSBs. By modification of the zinc 
domains, ZFNs can be precisely directed to induce DSBs at any region within the 
genome  using the zinc finger targeter (ZiFiT) software that predicts possible genomic 
ZFN binding sites for engineered ZFPs (Osakabe et al., 2010; Sander et al., 2010).  
 
 
Figure 1.9: The basic structure of zinc finger domain. Panel (A) antiparallel β-sheets 
of two cysteines and an α-helix of two histidines forming the ββα structure, which is 
stabilized by zinc atom. Panel (B) is showing the primary attachments between α-helical 
amino acids at the positions 1, 3 & 6 (green, red & yellow arrows respectively) and the 
cognate DNA triplet (letters A). C: cysteine, H: histidine, F: phenylalanine, Y: tyrosine, 
L: Lucien, Zn: zinc atom, triple A: recognized DNA sequence by single zinc finger 
domain. Amalgamated from Dolan 2006, and Klug 2005. 
 
The basic structure of a zinc finger consists of 30 amino acids within the ββα structure 
(Dolan, 2006).  Predominantly, there are two cysteine and two histidine residues in 
every single zinc finger, in addition to other three dominant amino acids, tyrosine, 
leucine and phenylalanine; therefore this domain is also known as the C2H2 domain.  It 
has been suggested that these seven amino acids probably form a hydrophobic structural 
centre in the zinc fingers; as well as providing a vital role in determining the tertiary 
folding configuration of the zinc fingers; see Figure  1.9. The primary interactions 
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between the zinc fingers and the DNA bases are produced by the α-helix. The α-helical 
amino acids at positions 1, 3 and 6 contact the three (triplet) consecutive DNA sequence 
bases by binding in DNA major groove via particular hydrogen-bond interactions 
(Dolan, 2006). Apparently, the mechanism of zinc finger recognition to the DNA target 
sequence is a one-to-one contact between particular α-helical amino acid to particular 
DNA nucleotide base (Figure  1.9 b). This mode of interaction differs from other DNA- 
binding proteins, where one amino acid contacts two nucleotides or vice versa (Klug, 
2005). 
Klug has reviewed a basic technique to produce target site-specific ZFN domains. The 
ZFN protein domains are cloned as fusions to the minor coat protein (pIII) of 
bacteriophage fd, which in turn, initiates their expression on the tip of the viral capsid. 
Phage showing the peptides of interest can be affinity purified by binding to the target 
and then amplified in bacteria for use in further rounds of selection and for DNA 
sequencing of the cloned genes (Klug, 2005).  
ZFN’s mode of action is adapting the recombinogenic repair mechanism of DSBs in the 
target DNA sequence of the living cells (Shukla et al., 2009). When site specific DSBs 
are induced by the use of ZFNs, the cellular DNA damage response will be stimulated 
leading to repair these DSBs by either NHEJ or HR. Importantly, it has been suggested 
that ZFN cutting could take place mainly during S phase of the cell cycle, when all 
genomic DNA initialise for replication (Carroll, 2011). Consequently, by harnessing the 
cell’s individual DSBs repair mechanism, specific gene alterations can be generated.  As 
a result, ZFNs have been developed to induce precise genetic modifications in many 
different types of living cells. This implies that, hypothetically at least, it is possible to 
target any gene in the genome, through the manipulation and recombination of ZFPs 
with varying specificities (Porteus, 2009). Recently, the ZFNs technique has been 
extensively utilized for genome modifications at endogenous loci in eukaryotic systems; 
since the zinc-finger domain can be designed to recognize unique DNA sequences 
(Shukla et al., 2009). It has became clear that using ZFNs will induce site specific DSBs 
enhancing gene targeting at precise loci in human cells (Hockemeyer et al., 2009; Zou 
et al., 2009), plant models (Shukla et al., 2009; Townsend et al., 2009) and animal 
model (Li et al., 2011a). 
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1.4.1.2 ZFN applications 
ZFN technology has been successfully used; so far, for: 
• repression of gene expression; for example in a mouse cell line by selective 
targeting for genetic alterations in pathogens or transformed cells and in HIV 
replication (Reynolds et al., 2003), 
• regulation of promoter specific activation by switching on/ off gene expression; for 
example in herpes simplex virus (Papworth et al., 2003),  
• gene knocking out by sequence-specific ZFN mediated NHEJ (Geurts et al., 2009a; 
Malphettes et al., 2010),and 
• gene repair by sequence-specific ZFN mediated HR (Olsen et al., 2009).  
From practical point of view, it has been shown that site specific ZFNs can significantly 
increase the gene targeting frequency several orders of magnitude. For example, 
Kandavelou et al has pointed out that gene correction using ZFN was about 200 fold 
more efficient in albino mouse melanocytes (Kandavelou et al., 2009). Moreover, Zou 
et al (Zou et al., 2009), has demonstrated that the use of site specific ZFN improved the 
HR frequency 2400 fold in human embryonic stem cells. Impressively, Townsend et al 
confirmed that gene targeting frequency exceeded 2% in plant cells (Townsend et al., 
2009). While using ZFNs in HEK 293T or human chronic myelogenous leukemia K-
562 cells frequencies ranged between 2 and 20% (highest in cells temporarily arrested at 
G2/M boundary and targeting the endogenous IL2RG gene rather than a chimeric eGFP 
target locus); importantly, biallelic correction was detected in up to 6.6% of cells. Gene 
targeting of IL2RG in primary CD4+ T cells occurred in 5.3% of cells (Urnov et al., 
2005). Alternatively, gene disruption can also be obtained at high frequency (13%) in 
human stem cell lines by NHEJ repair of a ZFN-induced DSB (Lombardo et al., 2007). 
This CCR5 knockout strategy is paradigmatic for the generation of CD4+ T cells 
resistant to HIV-1 infection (Perez et al., 2008). These impressive results and other (de 
Pater et al., 2009; Perez et al., 2008) indicate that the specificity of the designer ZFNs 
majorly improves the efficacy and the efficiency of the gene targeting rates. 
Increasingly, ZFN technology has been exploited in gene targeting to provide DSBs at 
specific DNA sequences, a process that many researchers (Carroll, 2008; Kandavelou et 
al., 2005; Lombardo et al., 2007; Porteus and Carroll, 2005) have adapted to enhance 
43 
 
the HR mechanism in gene repair. The impressive results, higher modification 
frequencies and precision of ZFN-driven HR could revolutionise the field of gene 
therapy for mammalian somatic cell genetics and the study of gene function. This study 
will adapt the same strategy to enhance gene repair by HR using especially designed 
ZFNs. This new designed ZFN has been recently engineered, particularly for repairing 
the mutant Prkdc gene, by Sangamo BioScience Inc., Dr Yáñez’s collaborators in 
somatic gene therapy.  
1.4.1.3 ZFN-related toxicity  
In spite of successful ZFN applications; ZFNs exhibit no perfect action. A major 
limitation affecting the application of ZFN technology is the related cytotoxicity; which 
has been reported in human cells, zebrafish and Drosophila (Zhang et al., 2010b). 
Related toxicity can be attributed to either the high expression of the ZFNs leading to 
induce more DSBs (de Pater et al., 2009), or the off-target DNA induced DSBs at 
related sequences somewhere else in the genome because of the non-specific binding. 
These unwanted DSBs may possibly result in non-anticipated genotoxic effects. Some 
of these genotoxic problems could be seriously adverse to the cell, generating 
chromosomal abnormalities as the unpredictable DSBs could result in chromosomal 
translocations or NHEJ (Dolan, 2006); and eventually to cell death and elimination of 
targeted cells. Other genotoxic effects may cause minor alterations and induce less 
harmful changes to the cells such as small deletion and addition mutations that could be 
continued in the existing population (Pruett-Miller et al., 2009; Zou et al., 2009). 
Additionally, NHEJ mediated repair could lead to introduce undesirable alterations at 
other off-target genomic sites; it has been reported recently that ZFNs introduce a wider 
range of off-target DSBs (and as a result NHEJ-mediated mutations) than previously 
expected (Gabriel et al., 2011; Pattanayak et al., 2011). 
One possibility to minimize the genotoxic effects is to improve the specificity of the 
recognition of the designer ZFNs for their target locus; this can be achieved by 
engineering more than 3 zinc finger domains per monomer. Accordingly, the length of 
the targeted DNA will be increased, thus exponentially maximising the level of 
uniqueness. A good example for this successful strategy was reported by Hockemeyer et 
al, when ZFNs were designed to contain 4-6 zinc finger domains which collectively 
bind to DNA stretch of 24-36 bp to guarantee a high degree of rarity within the targeted 
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sequence (Hockemeyer et al., 2009; Porteus, 2009). In another study, ZFNs with 5-6 
zinc fingers recognizing 30-36 bp of the DNA sequence have been engineered to 
maximize the specificity and elongate ZFN recognition site (Geurts et al., 2009a). More 
recently, ZFNs with 5 zinc domains in one monomer and 6 domains in the other, have 
been designed to recognise 38 bp of the targeted locus (Malphettes et al., 2010).  
The second promising strategy to reduce the ZFN off-target cleavage is to re-engineer 
the Fok I domains in a way that preventing, or at least minimising, the 
homodimerization of ZFNs. As mentioned above, a pair of Fok I domains must 
dimerize to activate the ZFN mechanism, which eventually will induce site specific 
DSBs. It seems that Fok I domains are naturally able, even if they are not bound to any 
DNA sequence, to create homodimers although feebly (Mani et al., 2005). In addition to 
that, normal dimerization of Fok I domains is quite weak (Miller et al., 2007). It has 
been shown that the Fok I domains could be altered such that only heterodimeric ZFNs 
could form upon binding to DNA leading to significantly reduced ZFN-associated 
cytotoxicity (Sollu et al., 2010). Therefore, the engineering of obligatory heterodimers 
of the Fok I domains is vital to avoid or at least to significantly decrease the levels of 
genotoxicity in human cells (Kandavelou et al., 2009). As a result, this will ensure that 
both left and right monomers are situated at their proper target recognition sites on the 
DNA sequence.  
It has been reported that longer term of ZFN expression could afford extra time for off-
target DNA cleavages leading to further alterations and cytotoxic effects (Remy et al., 
2009). Consequently, an alternative strategy to reduce the cytotoxicity of the ZFNs has 
been applied by limiting ZFNs expression. There are several approaches have been 
reported here:  
• attenuation of ZFNs toxicity through regulation of protein levels, which in turn 
creates ZFNs with shortened half-lives. This is achieved by engineering small 
molecules which destabilise ZFNs leading to regulate protein levels, this approach 
blends both high rates of ZFN-mediated gene targeting while reducing ZFN toxicity 
(Pruett-Miller et al., 2009).  
• direct injection of ZFNs as RNA molecules into the targeted cell (Mashimo et al., 
2010). This may be additionally favourable because of: (i) apparently, RNA has 
shortened half-lives; therefore the ZFNs will be present for only limited duration 
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(Beumer et al., 2008; Zhang et al., 2010b),  (ii) remarkably, there will be an 
acceleration of the expression rate, and (iii) reduced possibility of ZFN insertional 
mutagenesis, as RNA cannot integrate into genomic DNA.  
• transient DNA delivery (Zhang et al., 2010b). 
• inducible expression systems (Zhang et al., 2010b). 
Another possible strategy to improve ZFN efficiency and reduce off-target cuttings has 
been tested recently by using mild hypothermia (cold shock by incubation of the ZFN 
transfected cells at 30⁰C) leading to several fold increase in ZFN activity.  ZFN-
hypothermia has generated a proficient and constant genome editing in different cells 
which can be attributed to the extensive reduction in mRNA and protein turnover, 
initiation of molecular chaperones, or viability enhancement and delayed apoptosis 
(Doyon et al., 2010).  
For current study, two important improvements in ZFN technology will be adapted to 
minimize possible genotoxicity. The first will be the use of reengineered ZFN Fok I 
domains to avoid homodimerization by using of obligatory heterodimers Fok I domains. 
This step has been done by our collaborator; Sangamo BioScience Inc (California, 
USA). The second improvement will be via controlling ZFN delivery system. The ZFNs 
genes will be delivered by incorporation them into IPLVs and IDLVs. For clinical 
application it is hoped that IDLVs could be efficient to deliver ZFNs at levels enough to 
induce DSBs, as the use of IDLVs will decrease the amount of vector integration 
considerably. Despite the fact that the use of IDLVs will not eliminate such integration 
events absolutely; this approach will rely on their short term expression to avoid 
permanent integration because of their episomal nature. Hence, this approach will not 
allow additional time for ZFNs to create unpredictable off-target cleavages. 
 
1.4.2 Meganucleases: the homing endonucleases 
Another technology to introduce site specific DSBs and maybe exploited in HR leading 
to gene repair, is the use of meganucleases. Meganucleases are a varied group of highly 
specific endonucleases, which recognize a large stretch (12-45 bp) of DNA sequence 
(Epinat et al., 2003; Moure et al., 2002). These nuclease could be found inserted in 
different genomes in eukaryotes, prokaryotes and viruses (Moure et al., 2002). In 
nature, meganucleases are embodied by “homing endonucleases”; a large family of 
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DNA endonucleases. Meganucleases are generally encoded within introns or inteins 
(segments of proteins that are able remove themselves and rejoin the remaining 
portions) although some exceptions are also present (Grabher and Wittbrodt, 2007). 
They called “homing” because they mediate the gene mobility event of their hosting 
genes (Moure et al., 2003), resulting in DSBs at the targeted sequences which do not 
include these mobile elements (Moure et al., 2002). Site-specific DSBs induced by 
meganucleases in living mammalian cells increased gene repair rates by a number of 
orders of magnitude (Epinat et al., 2003). 
Homing endonucleases are divided into five families based on sequence and structure 
motifs: LAGLIDADG, GIY-YIG, HNH, His-Cys box and PD-(D/E)XK (Orlowski et 
al., 2007; Zhao et al., 2007). The largest one is LAGLIDADG family and hold either 
one or two sets of the LAGLIDADG sequence motif. Endonucleases with one motif act 
as homodimers like I-CeuI or I-CreI; while those enzymes with two LAGLIDADG 
motifs act as monomers like I-SceI, PI-SceI and I-DmoI (Duan et al., 1997; Heath et al., 
1997). In all members of LAGLIDADG family, the LAGLIDADG motif generates two 
full α-helices where a 2-fold symmetry axis separates two monomers or apparent 
domains. On both sides of the LAGLIDADG α-helices, there are a four-stranded β-sheet 
offering a DNA recognition part which mediates the binding between endonucleases 
and a half sequence of the recognition site of the target DNA locus, see Figure  1.10 
(Epinat et al., 2003). 
Usually, meganucleases are acting as movable DNA elements and they are able to bind 
to DNA sequences which match to intron-free or intein-free genes, where DSBs will be 
introduced. Those DSBs will be repaired ultimately by cellular repair machinery leading 
to insertion of the intron or intein where the DSBs induced (Epinat et al., 2003). 
Therefore, organisms encoding homing endonucleases are not affected by their own 
endonucleases as they located on either intron or intein which splice them from the host 
mRNA or protein, respectively (Moure et al., 2002). 
Homing endonucleases are similar to restriction enzymes in their ability to induce DNA 
DSBs precisely in the presence of divalent cations; however there are several 
differences between them: (i) the recognition site of the restriction enzymes is shorter 
(3-8 bp) than homing endonucleases one; (ii) the restriction enzymes are extremely 
sensitive to any single nucleotide alteration in their recognition site, whereas homing 
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endonucleases are more rather tolerant of single nucleotide alteration; (iii) homing 
endonucleases mostly fall within one of four families, while restriction enzymes do not 
subdivided into identifiable families; and (iv) they differ in their genomic location 
(Belfort and Roberts, 1997).  
Figure 1.10: Schematic representation of monomeric structure of homing 
endonuclease.  In monomeric enzyme, each monomer has two copies of LAGLIDADG 
motif forming four α-helices in total (blue) and four β-sheets (purple). The induced 
DSBs will happen at the centre of DNA recognition site. Reprinted from 
http://www.cellectis.com/genome-engineering/meganucleases/engineered-meganuclease 
/meganuclease-technologies/. Accessed on 20/06/2012. 
 
Homing endonucleases bind their DNA targets within the recognition site via many 
direct phosphate and base-specific contacts, which are equally distributed between the 
two domains, in addition to hydrophilic interactions which represent a good indicator of 
the high specificity of these enzymes (Moure et al., 2003). However, they might 
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introduce random DSBs in their target DNA due to off-target cutting (Moure et al., 
2002). As a result, the specificity of DSBs at defined sites expanded the use of 
meganucleases in gene repair strategies in different fungal, plant and mammalian 
applications (Belfort and Roberts, 1997). The use of majority of natural meganucleases 
in gene repair studies relies upon the presence of enzymes whose recognition sites are 
previously encoded in the target sequence. However, this occurrence is very rare since 
the usual collection of homing endonucleases, at present, is restricted to about 300 
enzymes, the majority of them still uncharacterized or theoretical. Currently, 
meganucleases have become more attractive because of continued engineering efforts 
that generated custom designed meganucleases targeting several genomic sequences. 
These modified proteins are based, for example, on subunit inter-changeability by 
fusing both similar and different α / β domains, and some mutations in specific residues 
(Silva et al., 2011). 
I-SceI, from Saccharomyces cerevisiae, was the first discovered homing endonucleases 
(Moure et al., 2003). This enzyme belongs to the LAGLIDADG family and it is an 
intron-encoded endonucleases. The I-SceI endonucleases acts as a monomeric form of 
235 amino acids, including two conserved motifs (the two LAGLIDADG motifs) and it 
is catalysed by either magnesium or manganese (Grabher and Wittbrodt, 2007). DSBs 
result from I-SceI action will have a 4 bp overhang presenting a 3’-hydroxyl terminus 
(Moure et al., 2003). The recognition site of the I-SceI endonuclease is 18 bp long 
(TAGGGATAACAGGGTAAT), which is very rare in genomic DNA because of its 
theoretically low frequency ,only one time in 7x1010 bp of random sequence (Choulika 
et al., 1995a; Thermes et al., 2002), or once per 20 human genomes 
(http://www.cellectis.com/genome-engineering/meganucleases/engineered-
meganucleases/meganuclease-technologies/, accessed on 20/06/2012). Additionally, 
pre-engineered I-SceI sites can tolerate quite a few nucleotide alterations, making this 
endonuclease the enzyme of interest to induce site specific DSBs at selected genes in 
yeast, plants, insects, fish, and mammalian applications (Moure et al., 2003). Finally, 
vertebrate genomes examined so far are free from I-SceI sites, eliminating the risk for 
genome fractionation by the action of meganucleas (Grabher and Wittbrodt, 2007). 
It is worth mentioning that designing of meganuclease novel DNA binding without 
disrupting their catalytic activity it is confirmed to be quite challenging as their DNA 
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recognition and cleavage domains are not structurally independent as they are for ZFNs 
and TALENs (Ramirez et al., 2012). Two research groups had reported that co-
transfecting a plasmid expressing I-SceI together with the targeting construct in cell 
lines led to up to 4-log increases in gene repair frequencies (Choulika et al., 1995b, a; 
Smih et al., 1995). Additionally, I-SceI vector dose-dependent and cell type-dependent 
targeting frequencies were noticed, being about 5-fold higher in U-2 OS 
(human osteosarcoma) and HEK 293T cells than in HT1080 (fibrosarcoma) cells 
(Cornu and Cathomen, 2007). Moreover, high-efficiency gene conversion has been 
demonstrated with chimeric meganucleases at chromosomal target loci. Frequencies 
approached 0.2% with a designer meganuclease in Chinese hamster ovary (CHO) cells 
(Arnould et al., 2007). Also, it has been reported that engineered meganucleases have 
successfully cleaved two different human genes, XPC and RAG1 (Arnould et al., 2007; 
Smith et al., 2006). 
 
1.4.3 TALENs  
Genome surgery can also be achieved by harnessing the transcription activator-like 
effector (TALEs) nucleases to introduce site specific DSBs. The TALE modules a 
family of proteins used in the infection process by plant pathogenic bacteria 
Xanthomonas oryzae, (Boch, 2011; Sugio et al., 2007). TALE nucleases (TALENs) are 
DNA recognition repeats of native or synthesized transcription activator-like fused to 
DNA cleavage domains of Fok I. These customized proteins are synthesized using a 
modular assembly method (Li et al., 2012a). Their DNA binding domain are composed 
of so- called TALE repeats, which they are ~34-35 multiple amino acids arranging in 
tandem. The basic structure for the TALEN is showed in Figure  1.11. 
The structural features and domains of each TALE are composed of: an N-terminal 
translocation region, a central repeat region which recognises target DNA sequence, a 
C-terminal region which comprises NLS and an acidic activation domain. These 
nuclease are differ generally in the number and order of their TALE repeats in the DNA 
recognition domain (Mussolino et al., 2011). The TALE repeats sequence is almost 
identical apart from two highly variable amino acids in positions 12 and 13 of each 
repeat comprising a repeat variable di-residue (RVD). The RVD of each domain 
represents the base of recognition site for each unit to recognize one nucleotide in the 
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target DNA sequence, thus each individual domain can recognise one DNA base pair in 
the TALE recognition sequence (Boch et al., 2009; Hockemeyer et al., 2011; Moscou 
and Bogdanove, 2009). TALENs are recently used to induce site-specific genomic 
modifications in plant cells (Mahfouz et al., 2011), animal (Sander et al., 2011), and 
even in human pluripotent cells (Hockemeyer et al., 2011). 
 
 
Figure 1.11: Schematic diagram of TALEN structure and recognition site. The 
basic TALE element includes: an N-terminal translocation domain (TD), the central 
repeat units (0–17.5) composed of ~34-35 multiple amino acids that recognises DNA 
target site, a C-terminal region comprising NLS, and a transcriptional activation domain 
(AD). The central TALE repeat units can be linked to a nuclease domain to produce a 
site-specific TALEN. The amino acids in positions 4 and 24 show some variability, 
while DNA specificity of the repeat unit is determined by the highly variable residues in 
positions 12 and 13 (repeat variable di-residue, RVD). Reprinted from Mussolino and 
Cathomen 2012.  
1.5 Genome surgery by oligonucleotides  
Alternatively, site-specific genome alterations at relative rates could be achieved in 
selected cell lines by designing short single stranded oligonucleotides (ssODN), 
chimeric RNA/DNA oligonucleotides and triple helix forming oligonucleotides 
(Igoucheva et al., 2004; Radecke et al., 2006). The ssODNs are able to introduce site 
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specific alterations and modify the target sequence at high frequencies (Olsen et al., 
2009), hence, they represent an attractive option for gene repair. Some cell lines, like 
CHO and HEK 293T have shown site specific genetic alteration frequencies after 
transfection with ssODNs at about 0.03-0.5%, whereas primary mammalian cells 
demonstrated a very low frequency.  Importantly, it has been shown that in mammalian 
cells the ssODNs achieve higher repair frequencies than double stranded DNA and the 
most favourable size for the ssODNs is between 20-80 bases (Olsen et al., 2005). The 
ssODNs basic design is a complementary sequence to the target locus which carries a 
central mismatch to the locus to be targeted. Despite the fact that the actual mechanism 
controlling the ssODNs action is not currently well understood, it has been shown the 
ssODNs integrate to the targeted locus during replication (Olsen et al., 2009).   
1.6 Primary immunodeficiency   
Primary immunodeficiencies (PID), also called inherited immune system disorders, are 
rare inherited disorders of the innate and acquired immune system. They result from 
more than 130 inherited mutations in genes required for production, differentiation and 
survival of specialised leukocytes like T or B lymphocytes, natural killer (NK) cells, 
neutrophils or antigen presenting cells (Aiuti and Roncarolo, 2009; Kohn, 2010; 
Notarangelo, 2010). Currently, more than 300 human genetic disorders are diagnosed as 
PIDs. Patients regulerly presented with a higher vulnerability to opportunistic infections 
or infection with uncommon organisms and may also develop autoimmunity or 
autoinflammatory disease and lymphoreticular malignancies (Rivat et al., 2012). PIDs 
are called "primary" because they are resulted from an inherited gene defect that affects 
the immune system. Secondary immune deficiencies are caused by acquired factors, 
such as chemotherapy or infection. PIDs, in general, are monogenic disorders following 
simple Mendelian inheritance while quite a few PIDs are polygenic. Monogenic 
diseases are those inherited disease that controlled by a single gene, while polygenic 
ones are more than one gene are involved. All the PIDs are rare (except the IgA 
deficiency) with incidence rate of approximately 1:10000 live births (Notarangelo, 
2010). Usually, leukocytes are produced from the multipotent HSCs in bone marrow; so 
allogeneic hematopoietic stem cell transplantation (HSCT) is the preferred treatment for 
many PIDs (including SCID) (Kohn, 2010).  
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In spite of recent improvements in the allogeneic HSCT treatment, some patients are 
still suffering from lasting complications, and using of alternative donors is still 
associated with many difficulties. Alternatively, gene therapy approaches based on ex 
vivo HSCT by transferring functional genes into autologous HSCs using viral vectors, 
are emerged (Aiuti and Roncarolo, 2009). The first gene therapy treatment for PID was 
performed in 1991 for adenosine deaminase (ADA) SCID patient.  Between 1991 and 
2009, more than 90 patients have received gene therapy treatment for different PIDs 
(Aiuti and Roncarolo, 2009).  
 
There are many possible advantages that make gene therapy treatment more attractive 
treatment: 
•  Reduction of graft-versus-host disease (GVHD) and minimising the related 
complications as gene therapy treatment based on gene correction and re-
transplantation of the patient's own HSCs leading to the same clinical benefits as 
allogeneic HSCT, but without the immunologic complications (Kohn, 2010). 
• Rapid access to treatment. 
• HSCs abilities in renewal and proliferation could provide an important survival 
advantage for the gene-corrected cells leading to immunological repopulation and 
ultimately restoration of immune system (Qasim et al., 2009).  
• HSCT can be easily manipulated ex vivo, and the in vivo vectors administration 
related problems can be bypassed (Qasim et al., 2009). 
 
1.7 Hematopoietic Stem Cells (HSCs) 
HSCs are rare cells of heterogeneous population capable of differentiating into blood 
lineages (Aguila et al., 2011). They are characterized by their capabilities in self-
renewal, multi-lineage differentiation into different blood cells, and lifelong 
repopulation of haematopoiesis in lethally irradiated recipients (Trobridge and Kiem, 
2010; Wognum et al., 2003).  Thus, they are attracting a lot of interest for gene therapy 
applications and studies. Many life–threatening PIDs and acquired immune diseases can 
be treated successfully via gene transfer into HSCs by gene therapy (Mikkola et al., 
2000). In healthy adults, different mature hematopoietic cells are normally substituted 
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by the proliferation and differentiation of multipotent HSCs mainly present in the bone 
marrow. It has been suggested that HSCs may also be found in other non-hematopoietic 
tissues like muscle, liver, vasculature and skin. Those HSCs to be used for gene therapy 
applications can be from different clinical sources, such as bone marrow, mobilized 
peripheral blood and umbilical cord blood (Kohn, 2010; van Hennik et al., 1998; 
Wagemaker et al., 1998). The relative ease of HSCs gene modification protocols in 
terms of simply harvesting of donor cells, transducing them with therapeutic vectors ex 
vivo and re-infusing them intravenously into an irradiated recipient; has made the 
hematopoietic gene therapy more applicable. This contrasts with gene therapy of solid 
organs which is more complex because of the in vivo or ex vivo trials to deliver genes 
with maximum transduction efficiency to large number of varied cell types within a 
complex tissue composition is very difficult (Trobridge and Kiem, 2010). 
The features of human HSCs (like their cell-cycle characteristics, proliferative needs, 
purification techniques, engraftment kinetics, cytokines responsiveness, radiation 
sensitivity and homing abilities) are approximately similar to those of other higher 
mammals (Trobridge and Kiem, 2010; Wognum et al., 2003). Consequently, mouse 
HSCs are widely used as an attractive tools for hematopoietic studies establishing a 
solid knowledge  of HSCs biology (Ema et al., 2006) . However; mouse HSCs are not 
useful for long-term engraftment assessment as they are short-lived animal model, and 
the variation between mouse and human HSC cluster of differentiation (CD) markers 
result in overestimation of gene therapy efficiency in mouse model (Trobridge and 
Kiem, 2010). The main differences between human and mouse HSCs can be 
summarised below: 
• Division rate in vivo: mouse HSCs divide every 2.5 weeks; whereas human HSCs 
every 45 weeks (Shepherd et al., 2007), this is crucial when deciding the proper 
vectors that can transduce even the quiescent cells. 
• Cell Cycle: about 75% of mouse HSCs are outside G0 (Cheshier et al., 1999) 
whereas human HSCs cannot be subjected to cell cycle analysis because of the 
failure to obtain homogeneous cells (Trobridge and Kiem, 2010).  
• Transduction efficiency: mouse HSCs can be transduced more easily than human 
ones (Trobridge and Kiem, 2010). 
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• Surface markers: there are different HSC CD markers; generally CD34+ markers are 
used for human HSCs whereas lineage-,Sca-1+ and c-kit+ are used for mice ones 
(Mikkola et al., 2000). 
Theoretically, a single HSC can proliferate and expand to substitute the whole 
hematopoietic cells. However this concept is very difficult to be proved in practice 
mainly because a single HSC is not enough to re-generate the required quantities of 
hematopoietic cells to restore the entire haematopoietic system in patients or lethally 
irradiated animals. It has been reported that host (recipient) and donor HSCs can 
compete with each other in proliferation, engraftment and expansion in process known 
as “competitive repopulation”(Micklem et al., 1972). In mice, ex vivo HSCs protocols 
prefer to inject donor HSCs intravenously into the tail vain or subcutaneously. The 
process of migration, repopulation and localisation of these injected donor HSCs to the 
bone marrow is called “seeding efficiency” (Benveniste et al., 2003; Matsuzaki et al., 
2004).  
Importantly the HSCs and progenitors are not separate as there is a continuous 
proliferation in a hierarchy (Rosendaal et al., 1979). In vivo, adult HSCs are mostly 
quiescent and they possess very slow dividing kinetics, it is possible that maintenance 
of HSC quiescence and slow cell-cycle progression could be critically involved in 
sustaining a self-renewing HSC compartment for life (Qian et al., 2007). The quiescent 
nature of human HSCs has restricted gene transfer, since they are rather poor targets for 
common oncoretrovirus vectors which necessitate divided cells for integration 
(BouHamdan et al., 1999). This obstacle has been bypassed by using lentivirus vectors 
as their NLS elements enable the nuclear entry of PIC leading to transduce even the 
non-dividing cells (Engelman and Cherepanov, 2008); therefore lentivectors are 
recruited to transduce different HSC populations (Mikkola et al., 2000). The transduced 
vectors must not hinder HSCs features in renewal, differentiation or expansion; on the 
other hand vectors genome must be successfully sustained and transferred into HSCs 
progeny (Trobridge and Kiem, 2010).  
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1.8 SCID disorder 
1.8.1 SCID description   
Severe combined immunodeficiency (SCID) disorders, commonly called “bubble boy 
disease” (Kandavelou et al., 2005), are inherited fatal monogenic primary 
immunodeficiencies (Aiuti et al., 2007). SCID can be defined immunologically as a 
severe lack of specific immune response and clinically as a lethal disease in infants 
because of high susceptibility to opportunistic infections (Niehues et al., 2010). So far, 
there are at least 15 different genetic mutations causing different SCID disorders 
(Wiegant et al., 2010). Thus, SCID patients are a varied group of rare disorders 
characterized altogether by a severe decrease or lack of functional T cells (Alexander et 
al., 2007). Occasionally, there is a direct or indirect B cell dysfunction, and in some 
other cases NK cells will be affected as well. About 20% of SCID patients suffer from 
partial or complete lack of B and T lymphocytes. SCID disorders are classified into two 
categories according to the immunological phenotype, first is SCID with absence of T 
cells but presence of B cells (T-B+ SCID) and second with absence of both T and B cells 
(T-B- SCID), (Notarangelo, 2010). The estimated general incidence rate is ranged 
between 1:50,000 and 1:100,000 live births; whilst the actual rate may be increased 
slightly if the early deaths are already counted.  
Noteworthy, different features have been used to diagnose at least 11 diverse SCID 
conditions (Cavazzana-Calvo and Fischer, 2007). The most frequent SCID condition is 
the X-linked form (SCID-X1), which represent about 40-50% of all cases. SCID-X1 can 
be attributed to the defect in the gene encoding the interleukin-2 receptor γ chain 
(IL2RG). This molecule is a major subunit of the cytokine receptor complex for IL-2, 
IL-4, IL-7, IL-9, IL-15, and IL-21 and is termed the common cytokine receptor γ chain 
(γc) (Gaspar et al., 2011a). SCID-X1 patients suffer from profound absence of cellular 
and humoral immunity, specifically lack T and NK cells with normal or high B cells 
numbers that are incapable of undergoing immunoglobulin maturation and antibody 
generation (Ginn et al., 2010). Because of profound growth of native HSCs and 
selective survival advantage that could be presented in corrected cells, SCID-X1 is a 
predominantly attractive target for gene therapy (Gaspar et al., 2011a). 
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The other common SCID disorder is ADA deficiency (ADA SCID) which represents 
about 10%-15% of all SCID forms. The absence of ADA enzyme leads to accumulation 
of high intracellular levels of toxic phosphorylate metabolites of adenosine and 
deoxyadenosine (ADA)  substrates enhancing apoptosis of lymphoid precursors in the 
bone marrow and thymus (Notarangelo, 2010). As a result, abnormal T, B, and NK 
lymphocyte development and function is noticed in addition to other related systemic 
defects. Patients are routinely presented with severe opportunistic infections, failure to 
thrive, and a typical SCID profile. ADA-SCID could be treated by gene therapy as the 
regulation of ADA gene expression is relatively uncomplicated, and ADA-corrected 
cells have a survival advantage over mutated cells (Gaspar et al., 2011b).  
Importantly, the first human patient with mutant DNA PKcs has been identified recently 
(van der Burg et al., 2009a). This DNA-PKcs deficiency was considered the first human 
PRKDC SCID patient. Phenotypically the patient presented with T-B- SCID; and 
immunologically she had a severe lack in B and T cell numbers in peripheral blood and 
reduced numbers of B cell progenitors in the bone marrow. The patient cells lacked 
normal V(D)J recombination due to a deficient NHEJ repair mechanism (see section 
1.8.2 below), (van der Burg et al., 2009b). The human PRKDC SCID patient (DNA-
PKcs deficient) has two homozygous variations; the first is 3-nucleotide deletion 
causing the deletion of a glycine and the second is a missense mutation causing an 
amino acid substitution. The second mutation was confirmed to be the disease causing 
mutation (van der Burg et al., 2009b).  
 
In the vast majority of SCID patients clinical findings are characterized by severe 
opportunistic infections (regularly in the respiratory tract), chronic diarrhoea 
accompanied by opportunistic microbes such as Pneumocystis carinii and Aspergillus 
spp. and intracellular organisms such as Cytomegalovirus can  cause frequent infections 
and a failure to thrive. Unfortunately, without intensive medical care, death usually 
happens within the first year of the life (Cavazzana-Calvo and Fischer, 2007; van der 
Burg et al., 2009a). SCID is usually treated by bone marrow transplantation from 
human leukocyte antigen (HLA) matched sibling donor. Unfortunately, some patients 
do not have a proper donor leading to HLA mismatched transplant and eventually 
related with high risk of morbidity and mortality. Generally this treatment is associated 
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with insufficient immunological reconstitution, especially B cell function, and 
permanent requirement for immunoglobulin substitute therapy. Possible improved 
treatment has been provided by gene therapy promising a high survival rates and more 
comprehensive immunological reconstitution (Ginn et al., 2010). 
SCID disorder can be cured by allogeneic HSCT; the first successful attempt was 
reported in 1968. Thus; by using allogeneic HSCT, hundreds of SCID patients have 
restored their healthy immune system around the world with about at least 80% chance 
of success when HLA-matched sibling donor is available and 70% in the case of 
availability of HLA-matched unrelated donor. However; the success of this approach of 
SCID treatment is limited because of different factors:  
• It is highly dependable on the patient’s age, older recipients usually related to higher 
failure rate. 
• Immunological problems related to engraftment rejection 
• Slower and occasionally incomplete immunological reconstitution  
•  Long-term decline of functional T cells. 
Alternatively, gene therapy has emerged as a promising approach in SCID treatment 
exploiting the principle of genetic modification of autologous HSCT using retroviral 
vectors encoding for corrective genes. As of 2008, a total of 20 SCID-X 1 patients have 
been subjected to this treatment in London and Paris in two independent trails; 17 of 
them have effectively been cured. Out of these 17, 5 patients have developed leukaemia 
because of treatment-related insertional mutagenesis and unfortunately 1 of leukemic 
patiants has died (Cavazzana-Calvo and Fischer, 2007; Howe et al., 2008).    
 
1.8.2 PRKDC SCID and NHEJ machinery  
B and T cells can detect foreign antigens via the acquisition of specialised receptors, 
during lymphocyte maturation; these acquired receptors are immunoglobulin and T-cell 
receptors (TCR), respectively (Moshous et al., 2001). The profound immune disorder in 
SCID patients is a result of the failure to rearrange these receptors, which blocks 
lymphocyte maturation process causing lymphopenia and hypogammaglobulinemia 
(van der Burg et al., 2009a). In these receptors; the large diverse antigen-recognition 
areas are made of variable (V), diversity (D), and joining (J) gene segment, which 
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eventually go through rearrangement changes before their expression by a process 
called V(D)J recombination. V(D)J recombination is vital for both antigen recognition 
and development of lymphocytes (Niehues et al., 2010). Therefore; V(D)J 
recombination is considered a critical process for immune system maturation (Moshous 
et al., 2001). 
At the borders of each of V, D and J segments there are recombination signal sequences 
(RSSs), where the V(D)J recombination is initiated by introduction of DSBs (van der 
Burg et al., 2009a), by the action of lymphoid-specific recombination activating gene 
(RAG) endonucleases 1 and 2 ( RAG is referred to RAG 1 and RAG 2 together), 
(Rooney et al., 2002). RAG 1 and 2 are strongly related to each other and are situated 
on human chromosome 11p13, producing 1043 and 527 amino acids respectively 
(Niehues et al., 2010). RAG induces DSBs at RSSs of the segment V, D or J generating 
two intermediates; a hairpin-sealed DNA coding ends on the chromosome and blunt 
signal ends removed from the chromosome (Rivera-Munoz et al., 2009). The next step 
is recognition and repair of the generated DSBs by the general NHEJ machinery. The 
mammalian NHEJ repair machinery is composed of at least 7 known proteins: Ku70, 
Ku80, DNA-PKcs, Artemis (Art), XRCC4, Cernunnos/XLF, and DNA ligase IV (lig 4), 
(Rivera-Munoz et al., 2009; Rooney et al., 2002). DNA-PK is a complex protein, 
containing heterodimeric Ku protein (Ku70 and Ku80 subunits of 70 and 86 kDa, 
respectively) and DNA-PKcs (Beamish et al., 2000). The Ku70 and Ku80 subunits can 
bind to DNA DSB ends, nicks and DNA hairpins; whereas DNA-PKcs is completely 
dependent, for activity, on binding to DNA DSB including broken ends, nicks and 
single stranded gaps (Kirchgessner et al., 1995). Ku proteins can act as component of 
DNA-PKcs (Blunt et al., 1995).  
The earlier recognition of DSBs is achieved by Ku70/Ku80 heterodimers, where the 
DNA-PKcs is recruited producing DNA end synapsis, to guarantee protection from 
exonuclease activities (van der Burg et al., 2009a). The final step of V(D)J 
recombination is to re-ligate the DNA DSBs of the two broken ends of the chromosome 
by the other NHEJ proteins. Thus, any mutations in the genes coding for NHEJ proteins 
will result in different SCID disorders in humans. Obviously, in mammalian cells the 
NHEJ repair machinery acts as a key pathway in DSBs repair. For that reason SCID 
patient are hypersensitive to any DSBs inducer regents like ionizing radiations. 
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Likewise SCID mice suffer from severe dysfunction in B and T cells differentiation 
(Rivera-Munoz et al., 2009).  
 
1.8.3 Spontaneous mutations in mouse Prkdc gene 
The spontaneous mutations in the Prkdc gene were identified first in scid mice; 
nevertheless scid mice are not the only known scid animal; as these mutation are found 
in dogs (Trobridge and Kiem, 2010), horses of Arabian breed and very recently in 
human as well (van der Burg et al., 2009b). The scid mice, are lacking recombination 
process needed for both DSB repair and V(D)J recombination (Kirchgessner et al., 
1995). Phenotypically, they suffer from cellular hypersensitivity to ionizing radiation 
and severe deficiency in B and T cells. Murine scid disorder is attributed to a 
spontaneous point mutation in the Prkdc gene (Al-Wahiby et al., 2005), a gene coding 
for DNA-PKcs comprising of 86 exons extending across about 193 kb and is located on 
chromosome 16 (Gilley et al., 2001). It is worth mentioning that, the point mutation of 
the scid mouse was corrected previously using complementation of Prkdc gene. A full 
copy of the gene cDNA was cloned into the yeast artificial chromosome (YAC) and 
used to transfect immortalised mouse scid cell line leading to correct Prkdc and restore 
DNA-PKcs function (Priestley et al., 1998).   
The DNA-PKcs is a serine/ threonine protein kinase activity which belongs to the 
phosphoinositol 3-kinase family (Niedernhofer, 2008), and composed of ~465 kDa 
(Hande et al., 1999). In the scid mice, defective Prkdc gene switches the Tyr-4046 
codon into a stop codon resulting in truncation of 83 amino acids, losing the highly 
conserved C-terminal region (Al-Wahiby et al., 2005); scid mice have a profound 
impairment V(D)J recombination. The function of DNA-PKcs is initiated by the 
binding of Ku70/Ku80 heterodimers to the DNA ends of the DSB leading to form the 
DNA PK complex (Ku70, Ku80 & DNA-PKcs). This complex will acquire the activity 
to phosphorylate many proteins involved in NHEJ repair including itself. This self-
phosphorylation process is vital in NHEJ repair mechanism (van der Burg et al., 2009c). 
The scid mice first reported in 1983 by Bosma et al (Bosma et al., 1983) , are 
characterised by their severe lack of T and B cells but with functional NK cell 
encouraging many researchers to use scid mice as a model for different studies. 
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Interestingly, scid mice are also used to develop tissues and cell lines, which show 
similar features to their original scid mice in terms of hypersensitivity to gamma 
irradiation and a fault in the repair of DSBs. However, it has been reported that scid 
mice are not absolute mutants as many of them show low DNA-PKcs activity. Those 
“leaky” scid mice represent about 2-25% of young adult of the scid population and 
nearly all old scid mice. In the laboratories, scid mice can be housed under conventional 
facilities for only 5-6 months, as like their human patient counterparts, they fall victim 
to opportunistic infections. However, if they housed under pathogen-free environment 
these animals can survive for up to 2 years (Leblond et al., 1997).   
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1.9 Aims of the project 
 
HSCs are an attractive target for gene therapy, as they can both self-renew and 
differentiate into all blood lineages, and the possibility to manipulate them ex vivo. 
Gene transfer into HSCs can potentially provide a cure for many inherited and acquired 
diseases of the hematopoietic and immune systems. Thus, corrected HSCs could support 
hematopoiesis throughout the lifetime. So far, conventional retroviral vectors were used 
to treat the hematopoietic disorders by gene therapy and the success of these attempts 
has been limited by insertional mutagenesis mainly due to the natural tendency of these 
retroviruses to integrate into the host genome.  
This study could be considered as an attempt to improve the accuracy of gene therapy 
treatment. It will use gene repair to correct classical scid mouse which recently has 
become a model of human PRKDC SCID (DNA-PKcs deficiency). A combined 
technology of ZFNs and lentiviral vectors will be applied to correct scid mouse models 
by using HR mediating gene repair. The dysfunctional Prkdc gene in the HSCs will be 
targeted at a very close region to the scid mouse point mutation by ZFNs to induce site-
specific DSBs. This aim can be achieved by ex vivo transduction of these cells with 
lentiviral vectors carrying two different transgenes; the first is ZFN to induce site-
specific DSBs, which will provoke the HR repair machinery and the second is a 
functional homologous sequence of the wild type Prkdc gene, which will act as a 
corrective template for the HR machinery.  
A short time after the ex vivo transduction, scid HSCs will be transplanted back into the 
scid mouse recipients. When the corrective template replaces the faulty Prkdc sequence 
and expression restored in the transplanted cells, the corrected cells should display 
significant growth as they possess a selective survival advantage. In order to reach this 
aim and to generate even a sustained effect, the corrected HSC progenitors must have a 
self-renewal capacity and at the same time repopulate the T- and B-cells, i.e. keep their 
multipotency. In fact, the multipotency and selective advantage of corrected HSC 
progenitors are hypothesized to be the major factors counting for the success in this 
project. By transplantation of the corrected cells into recipient scid mice and by relying 
on their abilities to repopulate with a selective survival advantage, the scid mouse is 
hoped to be corrected perfectly.  
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The current project intends, for the first time, to show that gene repair could be 
considered as an efficient therapeutic strategy for the treatment of PIDs in 
haematopoietic animal model. Such therapeutic gene manipulation would be the ideal 
form of gene therapy for PIDs and many other genetic disorders because the repaired 
gene would be expressed under endogenous regulation, bypassing concerns about 
expression level, timing or stability.  
The feasibility of this system will be tested and optimised first in vitro using scid 
fibroblast cell line. Two corrective donor templates will be used both carrying 
homologous sequences of Prkdc around the scid point mutation. Additionally, the first 
codes for positive selective marker to be used for in vitro selection and the second 
encodes a unique site for the enzyme BsaWI to be used as a diagnostic site for ex vivo 
gene repair. The following steps will be used in this project to achieve the final aim: 
 
1. Immortalisation of murine scid fibroblasts to avoid the extensive senescence noticed 
in these cells. 
2. Incorporation of corrective templates into IDLVs. 
3. Incorporation of ZFN gene constructs into IPLVs and IDLVs. 
4. Testing and optimising the efficiency of ZFNs to induce site-specific DSBs in 
mouse scid fibroblasts.  
5. First gene repair attempt in vitro using immortalized scid fibroblasts cell line and 
corrective constructs carrying diagnostic markers.  
6. Analysis of ZFN cutting efficiency in mouse HSCs. 
7. Main gene repair experiment ex vivo using scid HSCs and corrective constructs 
carrying a silent diagnostic restriction site. 
8. Transplantation of repaired haematopoietic stem cells will be transplanted into scid 
mouse recipients. 
9.  Finally, engraftment and potential therapeutic effect in recipient mice will be 
analysed. 
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2 Materials and Methods  
2.1 Materials 
All solutions, buffers and media were prepared with double deionised water (ddH2O). 
Stock solutions were sterilised by autoclaving or passing through a 0.22 µm filter and 
then stored at room temperature (RT), unless otherwise stated. 
 
2.1.1 Common Materials 
Materials/reagents common to more than one protocol are listed below in alphabetical 
order:  
2.1.1.1 General Laboratory Chemicals  
Items Supplier 
2-mercaptoethanol Sigma-Aldrich, UK 
AccuGel acrylamide solution (40 % w/v) 
National diagnostic, 
USA 
Acrylamide solution (30 %) Merck, Germany 
Agar, Noble Sigma-Aldrich, UK 
Agarose molecular grade  Bioline, UK 
Albumin, from bovine serum Sigma-Aldrich, UK 
Alkaline protease Promega, USA 
Ammonium acetate Sigma-Aldrich, UK 
Ammonium persulfate  Sigma-Aldrich, UK 
Ampicillin  Sigma-Aldrich, UK 
Bacto-Trytone/Peptone DIFCO, USA 
Barium chloride Sigma-Aldrich, UK 
Boric acid Sigma-Aldrich, UK 
Bromophenol blue Sigma-Aldrich, UK 
Calcium chloride anhydrous  Sigma-Aldrich, UK 
Crystal violet Sigma-Aldrich, UK 
DAPI Sigma-Aldrich, UK 
dN6 Sigma-Aldrich, UK 
Dried skimmed milk powder Merck, Germany 
DTT Sigma-Aldrich, UK 
EDTA  Sigma-Aldrich, UK 
Ethanol  
British Drug House 
(BDH) 
Ethidium bromide Invitrogen, USA 
Ficoll type 400  Sigma-Aldrich, UK 
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Formaldehyde  Sigma-Aldrich, UK 
G418 Sigma-Aldrich, UK 
Gelatine Sigma-Aldrich, UK 
GeneScreen Plus membrane Perkin Elmer, USA 
Glacial acetic acid  Sigma-Aldrich, UK 
Glycerol Sigma-Aldrich, UK 
Glycine Sigma-Aldrich, UK 
HEPES Sigma-Aldrich, UK 
Hybond™ ECL™ Nitrocellulose membrane  Amersham Biosciences 
Hydrochloric acid BDH, UK 
IGEPAL  Sigma-Aldrich, UK 
Kanamycin  Sigma-Aldrich, UK 
Kodak Biomax light film Kodak, USA 
LB broth medium  Sigma-Aldrich, UK 
Magnesium acetate Sigma-Aldrich, UK 
Magnesium chloride Sigma-Aldrich, UK 
Magnesium sulphate  Sigma-Aldrich, UK 
Manganese chloride Sigma-Aldrich, UK 
Microspin S-300 column  GH Healthcare 
MOPS Sigma-Aldrich, UK 
N2 supplement  Invitrogen, USA 
Orange G Sigma-Aldrich, UK 
Paraformaldehyde  Sigma-Aldrich, UK 
Phenol Fisher Scientific  
Phosphoric acid BDH, UK 
Polybrene Sigma-Aldrich, UK 
Potassium acetate Sigma-Aldrich, UK 
Potassium chloride  Sigma-Aldrich, UK 
Potassium hydroxide. Sigma-Aldrich, UK 
Puromycin  Sigma-Aldrich, UK 
Rubidium chloride Sigma-Aldrich, UK 
Sodium acetate  Sigma-Aldrich, UK 
Sodium azide Sigma-Aldrich, UK 
Sodium bicarbonate Sigma-Aldrich, UK 
Sodium chloride Sigma-Aldrich, UK 
Sodium deoxycholate Sigma-Aldrich, UK 
Sodium dodecyl sulphate (SDS) BDH, UK 
Sodium fluoride  Sigma-Aldrich, UK 
Sodium hydroxide  Sigma-Aldrich, UK 
Sucrose Sigma-Aldrich, UK 
TEMED Sigma-Aldrich, UK 
Tris base Sigma-Aldrich, UK 
Tris hydrochloride  Sigma-Aldrich, UK 
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Trisodium citrate dihydrate Sigma-Aldrich, UK 
Triton X-100  Sigma-Aldrich, UK 
Tween 20 Sigma-Aldrich, UK 
  
2.1.1.2 Biological Kits 
Kit Supplier 
Accuprime™ Taq DNA high fidelity 
polymerase kit Invitrogen, USA 
Bradford method for protein detection Bio-Rad, USA 
Complete mini tablets protease inhibitor 
cocktail  Roche, Germany 
CopmbeadsTM anti-mouse Ig, k/negative control 
(FBS) compensation particles set  BD Biosciences, USA 
DNA endonuclease Surveyor® mutation 
detection kit  Transgenomic, USA 
DNeasy® extraction kit Qiagen, Germany  
ECLTM Western blotting detection reagents  Amersham Pharmacia, UK 
Endotoxin-free Maxiprep kit , tip-500 Qiagen, Germany  
Endotoxin-free Megaprep kit, tip-2500 Qiagen, Germany  
Endotoxin-free Miniprep kit, spin columns Qiagen, Germany  
Lineage cell depletion kit  Miltenyi MACS, Germany 
Qiagen PCR purification kit  Qiagen, Germany  
Qiaquick® gel extraction kit  Qiagen, Germany  
RBC lysis buffer  Biolegend, USA 
SignaTECT® DNA-dependent protein kinase  Promega, USA 
 
2.1.1.3 Markers and Restriction Enzymes 
Item Supplier 
1 Kb ladder Promega, USA or 
 
New England Biolabs (NEB), UK 
DNA modifying enzymes NEB, UK 
HyperLadder™ I Bioline, UK 
HyperLadder™ V Bioline, UK 
Loading DNA Buffer (6 X) NEB, UK 
Novex® Sharp Pre-stained Protein Standard Life Technologies, UK 
Restriction enzymes and buffers NEB, UK 
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2.1.1.4 PCR and Southern blotting reagents 
Item Supplier 
[α-32P] dATP Perkin Elmer, USA 
[γ-32P] ATP Perkin Elmer, USA 
ABI universal master mix  Bioline, UK 
GoTaq DNA polymerase  Promega, USA 
Longamp Taq DNA polymerase  NEB, UK 
SYBR green  Bioline, UK 
Taqman master mix  Roch, Germany 
β-actin probe   Applied Biosystems, USA 
 
2.1.1.5 Tissue culture  
Item Supplier 
0.22 µm-pore-size filter Nalgene, USA 
30 μm nylon mesh filters Millipore, USA  
DMSO Sigma-Aldrich, UK 
Dulbecco’s modified Eagle medium DMEM  PAA, Austria 
Dulbecco's phosphate buffer saline (PBS) PAA, Austria 
Foetal bovine serum (FBS) PAA, Austria 
High-speed polyallomer centrifuge tube Beckman Coulter, USA 
Human IL-6 PeproTech, USA 
Melphalan Sigma-Aldrich, UK 
MTT Sigma-Aldrich, UK 
Murine Flt-3 PeproTech, USA 
Murine stem cell factor (SCF) PeproTech, USA 
Penicillin / streptomycin PAA, Austria 
StemSpan® medium  Stemcell Technologies, Canada 
Trypsin/EDTA PAA, Austria 
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2.1.1.6 Antibodies 
Item Supplier 
Alexa fluor 680Goat anti-rabbit  secondary antibody (cat ≠A-
21076) Invirogen, USA  
Anti-Human/Mouse CD45R (B220) PE (cat ≠12-0452-81) eBioscience, USA 
Anti-Mouse CD11b APC (cat ≠17-0112) eBioscience, USA 
Anti-Mouse CD3e PerCP-Cy5.5 (cat ≠45-0031-82) eBioscience, USA 
Anti-Mouse CD4 PE (cat ≠12-0041) eBioscience, USA 
Anti-Mouse CD8a APC (cat ≠17-0081) eBioscience, USA 
Armenian Hamster IgG Isotype Control PerCP-Cy5.5 (cat ≠45-
4888) eBioscience, USA 
HRP-conjugated polyclonal goat anti-mouse secondary antibody 
(cat ≠P044701-2) Dako, UK  
IRDye 800CWgoat anti-mouse  secondary antibody (cat ≠926-
32210) 
Li-cor 
GmbH,Germany 
Mouse anti-FLAG M2 monoclonal primary antibody (cat 
≠200472) Stratagene, UK 
Mouse monoclonal anti α-tubulin primary antibody (cat ≠T9026)  Sigma Aldrich,UK 
Rabbit polyclonal to α-tubulin primary antibody (cat ≠ab18251)  Abcam, UK 
Rat IgG2a K Isotype Control PE (cat ≠12 -4321) eBioscience, USA 
Rat IgG2b K Isotype Control APC (cat ≠17-4031) eBioscience, USA 
 
2.1.2 Buffers for agarose gel electrophoresis 
TAE (50 X stock) buffer was prepared by dissolving 242 g of Tris base (2-amino-2-
hydroxymethyl-propane-1, 3-diol), 57.1 ml of glacial acetic acid and 100 ml of 0.5 M 
EDTA (pH 8.0) in 600 ml of ddH2O. The pH was adjusted to 7.6, and then the final 
volume was made up to 1000 ml. A working solution was prepared by diluting to 1 X 
with ddH2O. TBE (10 X stock) buffer was prepared by dissolving 108 g Tris base, 55 g 
of boric acid, and 40 ml of 0.5 M EDTA (pH 8.0) in 600 ml of ddH2O. The pH was 
adjusted to 8.3, and then the final volume was made up to 1000 ml. A working solution 
was prepared by diluting to 1 X with ddH2O. 
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2.2 Methods 
2.2.1 Bacterial Manipulation 
2.2.1.1 Growth and Maintenance of E. coli 
Escherichia coli (E. coli), Top 10 strain, were grown in Luria-Bertani (LB) (Gellhaus et 
al., 2010) broth medium at 37 ºC with agitation at 250 rpm or streaked out on solid LB 
plates containing 1.5 % bacto agar. Depending on the antibiotic resistance conferred by 
transforming plasmids, both LB broth and agar media were supplemented with either 
ampicillin (100 µg/ml) or kanamycin (50 µg/ml) as final concentrations. Stock solutions 
of ampicillin (100 mg/ml) and kanamycin (10 mg/ml) were made up using sterile 
ddH2O, filtered, aliquoted and stored at -20 ºC. LB agar media were sterilised by 
autoclaving, then left to cool down to ~45 ºC before addition of antibiotic and pouring 
of plates. 
For liquid cultures individual E. coli colonies were retrieved from fresh culture plates 
using a sterile inoculation loop and dispersed in 1-2 ml of LB broth. For plated cultures 
an inoculation loop was used to streak out bacteria across the surface of the agar plate.  
Culture plates were then incubated at 37°C for 16- 18 h. Plates were then sealed by 
wrapping in parafilm and stored at 4 °C. 
2.2.1.2 Glycerol stocks  
For long-term storage at - 80 °C, bacterial cultures were supplemented with glycerol to 
15 %. 
2.2.1.3 Transformation of E. coli 
2.2.1.3.1 Preparation of chemically competent E. coli 
Chemically competent E. coli were prepared by streaking out LB agar plates with loops 
inoculated with E. coli from glycerol stocks and incubating overnight at 37 °C. Then, a 
mini-culture was prepared by picking up a single colony to inoculate 5 ml of LB broth 
and overnight incubation with agitation. The 5 ml mini-culture was mixed with 10 ml 
LB broth and incubated at 37 °C with agitation for ~ 1.5 h until the culture reached an 
optical density of ~0.5 at 600 nm wavelength. The cells were collected by centrifugation 
at 1000 X g for 5 min at 4 °C. The pellets were then resuspended in 15 ml of cold TFB1 
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buffer (see below for recipe) and incubated on ice for 15 min. Afterwards, the mixture 
was centrifuged at 1000 X g for 5 min at 4 °C. The pellets were then resuspended in 5 
ml of ice cold TFB2 buffer (see below for recipe) and incubated 15 min on ice. Finally, 
100 µl aliquots in microfuge tubes were placed in liquid nitrogen for a few seconds and 
then stored at -80 °C. 
Buffer TFB1 was: 100 mM Rubidium chloride, 50 mM manganese chloride, 30 mM 
potassium acetate, 10 mM Calcium chloride, 15 % (v/v) glycerol, pH adjusted to 5.8 
with potassium hydroxide. TFB2 buffer was: 10 mM MOPS (3-N-morpholino-
propanesulfonic acid), 10 mM Rubidium chloride, 75 mM Calcium chloride, 15 % (v/v) 
glycerol, and pH adjusted to 6.8 with potassium hydroxide. Both TFB1 and 2 solutions 
were sterilised by filtration through 0.2 µm filters. 
2.2.1.3.2 Heat-shock bacterial transformation 
Heat-shock mediated plasmid DNA transformation was performed by initially thawing 
chemically competent E. coli on ice. Plasmid ligation mixture was added to 100 µl of 
competent cell suspension and incubated on ice for 30 min. The cells were then heat-
shocked at 42 °C for 45 s in a water bath and then immediately placed back on ice for 
10 min. The cells were then diluted with 1 ml of plain LB medium and incubated at 37 
°C for 60 min at 250 rpm using a thermo-block shaker, prior to spreading onto agar 
plates containing an appropriate selective antibiotic. 
2.2.1.3.3 Screening of bacterial transformants 
About 100-200 µl of transformed bacterial suspension was spread onto LB agar plates, 
supplemented with the selective antibiotic matching the antibiotic resistance of the 
corresponding plasmid backbone. Colonies were allowed to grow overnight at 37 °C. 
An individual, isolated colony was picked from the plate using a sterile pipette tip, and 
used to inoculate 5 ml of LB/antibiotic media. The culture was then incubated overnight 
at 37 °C. DNA was subsequently isolated from 1.5 ml of culture using a Qiagen 
Miniprep kit, and characterised by restriction analysis followed by gel electrophoresis. 
For cloning purposes, batches of 20 colonies were typically tested. Clones displaying 
appropriate restriction maps were inoculated to larger culture volumes of LB/antibiotic 
for overnight culture at 37 °C with agitation. Subsequently Endotoxin-free Maxiprep or 
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Megaprep-scale plasmid purification was carried out according to the kit manufacturer’s 
instructions (see section  2.1.1.2).  
2.2.1.4 Plasmid DNA preparation 
2.2.1.4.1 Small-scale purification of plasmid DNA 
Small-scale plasmid DNA purification was achieved by alkaline lysis using Qiagen 
Miniprep kits as per manufacturer’s instructions from 5 ml of overnight culture. 
2.2.1.4.2 Large-scale purification of plasmid DNA 
For large-scale plasmid DNA preparation, alkaline lyses were done using Endotoxin 
free Maxi- and Megaprep kits (Qiagen) according to manufacturer’s instructions. A 10 
ml LB/antibiotic starter culture was set up from residual cultures previously checked by 
Miniprep purification and restriction analysis. Starter cultures were grown at 37 °C for 8 
h. These were then diluted 1:1000 in LB/antibiotic.  Maxi-cultures were prepared in 100 
ml, and mega-cultures in 500 ml of LB media. Briefly, the preparation was conducted 
by binding of DNA to the anion-exchange resin columns under low-salt and pH 
conditions with an integrated endotoxin removal step. A medium-salt wash used to 
remove protein and other low molecular weight impurities. Finally, plasmid DNA was 
eluted from the column using high-salt buffer, and was subsequently desalted and 
concentrated by precipitation with isopropanol. The DNA was allowed to dissolve in 
0.5-1 ml sterile ddH2O or TE buffer at room temperature and then stored at -20 °C.  
2.2.1.4.3 Measurement of DNA concentration 
Plasmid DNA concentration was calculated by measuring the absorbance of light with a 
wavelength of 260 nm (A 260) using a NanoDrop ND-1000 spectrophotometer with a 
0.2 mm path length. At this wavelength 50 µg/ml of double-stranded DNA has an 
absorbance of 1. Samples were run on an agarose gel against DNA molecular weight 
markers to double-check the concentration and DNA integrity. 
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2.2.2 Gel electrophoresis  
2.2.2.1 Agarose gel electrophoresis  
Mixtures of digested DNA/loading buffer were loaded into the wells of an agarose gel 
prepared in TAE buffer (see section  2.1.2 above). An appropriate DNA molecular 
weight marker and undigested samples of plasmid DNA were run alongside the digested 
samples. All samples were then electrophoresed in 1 X TAE electrophoresis buffer. 
Ethidium bromide (EtBr) was added to the gel at a final concentration of 0.5 μg/ml prior 
to casting, in order to facilitate visualisation of the DNA fragments under UV light. Gel 
images were captured electronically using a Bio-Rad Gel Doc 2000 system. 
Two types of electrophoresis gels were used: analytical gels (0.7 % agarose gel, run at 
50-60 V) to check the presence and concentration of digested DNA bands, and 
preparative gels (0.8-1.5% agarose gel, run at ~32 V) to separate required DNA 
fragments during the process of cloning. Prior to ligation reactions, comparison of 
visualised DNA bands with bands of known concentration within HyperLadder® 
molecular weight controls was used to estimate the relative amounts of vector and insert 
fragments.  
2.2.2.2 Polyacrylamide gel electrophoresis (PAGE) 
PAGE was used to analyse DNA fragments of less than 1000 bp in size. For double 
stranded DNA fragments of 50-300 bp, a 10 % acrylamide gel was prepared using a 
Minigel™ apparatus (Bio-Rad, UK). 2.5 ml of AccuaGel® 29:1 (National Diagnostic, 
USA), 7.4 ml of TBE 1 X, 100 µl of freshly prepared 10 % w/v ammonium persulfate 
(APS), and 5 µl Tetramethylethylenediamine (TEMED) were mixed and used for 
casting of vertical gels. The loading buffer was prepared with 15 % (w/v) Ficoll type 
400 (Sigma Aldrich) and 0.25 % (w/v) orange G (Sigma Aldrich) kept frozen at -20 °C. 
Usually, the gels were run at 100 V, and then they were stained with 5 µl EtBr of 10 
mg/ml in 100 ml 1 X TBE buffer for 10 min and then quickly washed several times with 
ddH2O. Images were captured with UV illumination using a Bio-Rad Gel Doc 2000 
system. 
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2.2.3 Molecular cloning methods 
2.2.3.1 Digestion of DNA by restriction endonuclease  
Restriction enzyme digestion was used to produce compatible DNA ends for subcloning 
to plasmid vectors and to verify the resulting DNA vectors. For production of plasmids 
and inserts for subcloning, 1-10 µg of plasmid DNA was digested with appropriate 
restriction enzyme and fragments were isolated by agarose gel electrophoresis (see 
section 2.2.2.1 above) and purified from gel by purification with an appropriate kit 
(Qiaquick, Qiagen, Germany). To verify the quality of DNA plasmid preparations, 
approximately (~0.5 μg) of plasmid DNA was digested. 
DNA was either linearised with a restriction enzyme corresponding to a unique site in 
the construct, or subjected to multiple enzymatic digestion. In the latter case, if the 
enzymes had compatible reaction conditions they were added to the same reaction; 
otherwise the digestions were performed separately for each enzyme with a purification 
(PCR purification kit, Qiagen-Germany) step in between. Digests were carried out using 
the endonuclease manufacturer’s (NEB or Promega) recommended conditions and 
buffers in a 15 μl total reaction volume. Prior to electrophoresis, a sample of digested 
plasmid DNA (~200ng) was diluted with H2O and mixed with the appropriate volume 
of 6x loading buffer. Vector NTI software (Invitrogen, UK) was routinely used to 
predict restriction patterns. 
2.2.3.2 118BAlkaline phosphatase treatment 
Following restriction enzyme digestion, to minimise the possibility of vector self-
ligation, the 5’phosphate residue groups were removed from both termini of the linear, 
double-stranded recipient plasmid vector DNA. This was achieved using Antarctic™ 
phosphatase enzyme (NEB, UK), which catalyzes the removal of 5´ phosphate groups 
from DNA. As phosphatase-treated fragments lack the 5´ phosphoryl termini required 
by ligase, they cannot self-ligate. 1 µl of Antarctic™ phosphatase was added to 20-50 µl 
of digested DNA and the mixture was incubated at 37 °C for 15 min and then stopped 
by heat inactivation at 65 °C for 5 min. Later, phosphatase-treated fragments were 
electrophoresed onto preparative agarose gel and the DNA was purified using Qiaquick 
gel extraction kit, Qiagen-Germany.  
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2.2.3.3  5’ overhang removal 
To convert 5’ overhangs to blunt-end termini, Klenow treatment was used. Digested 
DNA was generally purified (Qiagen, Germany), adjusted to DNA polymerase buffer 
and 40 µM dNTPs, and 1 unit of Klenow polymerase (NEB, UK) was added per 1 µg of 
DNA. Alternatively, whenever the restriction digest buffer was compatible with the 
function of the Klenow polymerase, the enzyme and dNTPs were added directly to the 
restriction digest mixture. The reaction mixture was incubated at RT for 15 min and 
then stopped by heat inactivation at 75 °C for 20 min.  
 
2.2.3.4 3’ overhang treatment  
Those DNA fragments with 3’overhangs were treated with T4 DNA polymerase for 
end-filling. A1 µl of T4 DNA polymerase (NEB, UK) together with 40 µM of dNTPs 
was added to the DNA mixture and incubated at 12 °C for 15 min and then stopped by 
heat inactivation at 75 °C for 20 min.  
 
2.2.3.5 Ligation-related preparation of cohesive and blunt termini 
DNAs were digested with the appropriate restriction enzyme(s) to produce compatible 
ends for cloning. DNA inserts can be re-joined by ligase enzyme to a cohesive terminus 
of a linear vector DNA fragment previously cut with a compatible restriction enzyme or 
to a blunt-ended plasmid DNA fragment, frequently resulting from Klenow treatment. 
The products of the ligation reaction are introduced to competent E coli via 
transformation. The number of "correct" clones can be maximised by using insert/ 
vector molar ratios of 3:1 for cohesive termini, and 5:1 for blunt termini ligation. The 
ligation reactions were usually set up by using 100 ng of the vector DNA as a 
benchmark. 
 
2.2.3.6 DNA retrieval from gels 
The plasmid fragments (vector/insert) were electrophoresed in EtBr-containing gels of 
appropriate density for the purpose of band size fractionation. Larger fragments (> 1000 
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bp) were electrophoresed into less dense 0.8 % (w/v) agarose gels, while for smaller 
fragments 1-1.5 % agarose gels were used. After electrophoresis, agarose bands 
containing the fragments of choice were retrieved by excision from the gel under UV 
radiation (EtBr-visualisation) using a sterile scalpel blade. DNA purification was done 
typically using a Qiaquick gel extraction kit (Qiagen, Germany). Finally the fragments 
were routinely dissolved in 30 μl of sterile TE and kept frozen at -20 °C. 
2.2.3.7 DNA ligation 
T4 DNA ligase catalyzes the formation of a phosphodiester bond between a 5' 
phosphate group and a 3’ hydroxyl terminus in duplex DNA. Purified DNA insert 
fragments were ligated into linearised/dephosphorylated vector fragments in a 10 µl 
reaction volume using bacteriophage T4 DNA ligase (NEB, UK) in 1 X T4 ligation 
buffer at 16 °C for 16 h. The ligation reactions were set up using 100 ng of the vector 
DNA as a benchmark .The molar ratio of (insert: vector) fragments was 3:1 for 
cohesive-end ligations; whereas for blunt-end ligations it was 5:1. For conversion of 
molar ratios to mass ratios, the calculations were done by using the formula: 
Molar ratio insert/vector = [Vector (ng) x insert size (kb)] / [insert (ng) x vector size 
(kb)] 
 
2.2.4 Tissue culture methods  
2.2.4.1 Cell lines  
 
Human and murine derived cell lines used for the purposes of this thesis are listed 
below. Further details of the features of the cell lines can be found at the European 
Collection of Animal Cell Cultures (ECACC, http://www.ecacc.org.uk) and the 
American Type Culture Collection (ATCC, http://www.lgcstandards-atcc.com). 
  
HEK-293T: an adherent epithelial human embryonic kidney cell line, characterised by  
the presence of integrated copy of the human adenovirus serotype 5, E1a gene and 
constitutive expression of SV40 large T antigen (Graham et al., 1977). HEK 293T cells 
were used in this work to produce lentiviral and retroviral vectors. 
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HeLa: an adherent cervical epithelial cell line derived from a human adenocarcinoma, 
first described by Scherer (Scherer, 1954). Its morphological aspects are described in 
(Macville et al., 1999). HeLa cells were used for titration of lentiviral vectors. 
 
BALB/c 3T3 fibroblast: 3T3 cells come from a cell line established by Todaro and 
Green in 1962. The 3T3 cell line was originated from primary Swiss mouse embryonic 
fibroblasts. The '3T3' nomenclature refers to growth condition of "3-day transfer, 
inoculum 3 x 105 cells" which is required to maintain the cells continuously. The 
spontaneously immortalized cells with stable growth rate were established after 20-30 
generations in culture, and then named '3T3' cells (Todaro and Green, 1963). 3T3 cells  
are adherent murine embryonic fibroblasts and they possess the ability to divide 
indefinitely, but are highly sensitive to the post-confluence inhibition of cell division. 
The cells grow in a monolayer, ceasing division when they cover the dish surface 
(Aaronson and Todaro, 1968). They were kindly provided by John Thacker (Medical 
Research Council, Radiation & Genome Stability Unit, Oxon- UK). 
 
BALB/c 3T3 scid fibroblast cell line: Adherent murine embryonic fibroblasts 
established from scid BALB/c mouse whole embryo cultures with similar 
characteristics to murine BALB/c 3T3 fibroblasts. These cells were also provided by 
John Thacker (Medical Research Council, Radiation & Genome Stability Unit, Oxon- 
UK). 
 
BALB/c 3T3 scid mTert fibroblast cell line: Adherent murine embryonic fibroblasts 
established from murine BALB/c 3T3 scid fibroblast cell line by immortalisation 
(please see section 2.2.8 below). 
 
Murine hematopoietic stem cells (wt and scid): non- adherent primary cell culture, 
prepared as described in section  2.2.4.2 below. 
2.2.4.2 125BCell line maintenance in culture 
HEK-293T and HeLa cell lines were normally maintained in Dulbecco’s modified 
Eagle medium (DMEM) with stable glutamine and 4.5 g/l glucose (PAA, Austria) 
supplemented with 10 % (v/v) heat-inactivated foetal bovine serum FBS (PAA, Austria) 
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and containing 100 U/ml penicillin / streptomycin (PAA, Austria). This basic culture 
medium will be referred to as complete DMEM in later sections. Cells were grown in 
25, 75 or 175 cm2 tissue culture flasks or in 10 or 15 cm tissue culture dishes in 37 ºC 
incubators and 5 % CO2 atmosphere. In order to maintain a normal growth of these 
cells, they were kept sub-confluent at all times by passaging them routinely when they 
were 80-90% confluent. To do so monolayers were first washed with Dulbecco’s PBS 
and then treated with 0.1 % trypsin (diluted in PBS/ EDTA) at 37 ºC for 5 min. Once 
cells were detached from the culture surface, they were subsequently collected in 
complete DMEM, spun (350 X g, for 5 min) and diluted 1:10 in fresh complete DMEM 
and transferred to new tissue culture flasks. 
Murine BALB/c 3T3 wt and scid fibroblast cell lines were maintained in complete 
DMEM, but they were passaged every 3 days and 3 X 105 cells were transferred to a 
new flask for each passage (Tordaro and Green, 1964). mTert murine BALB/c 3T3 scid 
3T3 fibroblasts were maintained likewise but in the presence of 3 µg/ml puromycin.  
wt and scid hematopoietic stem cells were grown without passaging in serum free 
StemSpan® medium (Stemcell Technologies, Canada) containing 100 ng/ml murine 
stem cell factor (SCF), 100 ng/ml murine Fms-related tyrosine kinase 3 (Flt-3), 20 
ng/ml human interleukin-6 (IL-6) and 100 U/ml penicillin / streptomycin. Cells were 
grown in 24-well non tissue culture treated plates at 37 ºC incubators and 5 % CO2 
atmosphere. 
2.2.4.3 Long-term cell storage  
For long term storage of cell lines a 90 % confluent monolayer from 75 cm2 tissue 
culture flask or 2-5 X 106 cells were pelleted by centrifugation at 350 X g for 5 min, 
resuspended in 1 ml of freezing medium (50 % FCS, 40 % DMEM and 10 % Dimethyl 
sulfoxide (DMSO)) and transferred to a cryovial. Cells were frozen slowly overnight to 
-80 °C in an isopropanol freezing box and then transferred into liquid nitrogen.  
To retriever frozen cells, aliquots were thawed rapidly in a 37 °C waterbath, transferred 
to 9 ml complete DMEM medium, spun at 350 X g for 5 min to remove the DMSO and 
finally resuspended in complete medium and cultured normally. 
 
78 
 
2.2.5 Plasmids transfection  
In this thesis, the plasmids were transfected using the calcium phosphate coprecipitation 
method. In 10-cm tissue culture plates, 1 X 106 BALB/c 3T3 scid mTert fibroblasts 
were seeded and allowed 4 h to attach to the tissue culture surface. 
10 µg of plasmid DNA (or a maximum of 30 µg, in cases where more than one plasmid 
was used) was placed in a 50 ml conical tube. Next, the DNA was mixed with 50 µl of 
2.5 M CaCl2, vortexed and then incubated for 5 min at RT.  To each tube, 500 µl of 2 X 
HBS-buffered saline [281 mM NaCl, 100 mM HEPES, 1.5 mM Na2HPO4 (pH 7.12)] 
was added drop-wise while vortexing at speed, and then immediately added to the 
plated cells and mixed. At about 14-16 h post-transfection, the medium was replaced 
after cells were twice washed with PBS. Cells and/or supernatants were harvested on 
days 2-3 post-transfection. 
 
2.2.6  Western Blotting  
2.2.6.1  Total protein isolation  
Total protein was isolated from cells transfected with plasmid DNA (section  2.2.5 
above) or transduced with lentiviral vectors (Aiuti et al., 2007). Three days later, 5 X 
105 cells were washed twice in pre-cooled Dulbecco's phosphate buffer saline (PBS) 
(PAA, UK), then they were lysed in 200 µl of ice-cold protein lysis buffer, which 
consist of Radio Immuno-Precipitation Assay (RIPA) buffer (de Campos-Nebel et al., 
2008) and freshly added protease inhibitor cocktail (Roche, UK). RIPA buffer was 
prepared using 150 mM NaCl, 1 % Triton X-100, 1 % sodium deoxycholate, 100 mM 
NaF, 0.1 % sodium dodecyl sulphate (SDS) and 50 mM Tris-HCl [pH 8.0]. Protease 
inhibitor cocktail tablets (containing serine, threonine, cysteine, aspartate and glutamic 
acid protease inhibitors) were prepared by dissolving 1 tablet in 1 ml of RIPA buffer to 
make 7 X protease inhibitor stock and then 1 X solution was made by diluting in RIPA 
buffer. Cells were harvested by detaching with a cell scraper, transferred into a 1.5 ml 
microfuge tube and centrifuged at 14000 X g at 4 °C to remove large debris, and finally 
samples were kept at -20 °C.  
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2.2.6.2  Protein quantitation 
Total protein extracted from cultured cells was quantified using Bio-Rad DC protein 
assay (Bio-Rad, USA) according to the manufacturer’s instructions. The protein 
concentration was calculated from a standard curve, using a series of known Bovine 
serum albumin (BSA) standards concentrations.  
2.2.6.3 SDS-PAGE Gel casting  
Discontinuous acrylamide gels of 12 % for lower (resolving) and 5 % for upper 
(stacking) gels, were prepared. The lower gel was prepared using 4 ml acrylamide (30 
%) (Merck, Germany), 2.5 ml lower gel buffer [1.5 M Tris-HCl and 0.4 % w/v SDS, 
(pH 8.8)], 100 µl 10 % w/v APS, 5 µl TEMED, and made up to 10 ml with ddH2O. The 
upper gel was prepared using 0.67 ml acrylamide (30 %), 2.5 ml upper gel buffer [1 M 
Tris-HCl and 0.8 % w/v SDS, (pH 6.8)], 100 µl 10 % w/v APS, 5 µl TEMED, and made 
up to 4 ml with ddH2O.  
A Minigel™ apparatus (Bio-Rad, USA) was assembled and the lower gel was cast first, 
leaving 1 cm distance at the top for the stacking gel. 15 min later the upper gel was 
poured into this 1cm space and ddH2O was added to the top of the gel to remove 
bubbles and level the top of the gel. 
2.2.6.4 Gel Running 
Proteins were denatured by heating in a thermo-block at 95 °C for 10 min. Wells were 
flushed thoroughly with RIPA buffer before loading samples. Next, between 2–25 µg 
protein in 1 X RIPA buffer per sample was prepared and bromophenol blue was added 
to samples to 0.05 %. Pre-stained Novex® sharp protein standard (Life Technologies, 
UK) was loaded alongside the samples. Then, the tank was filled with 1 X migration 
buffer [25 mM Tris-HCl, 0.1 % w/v SDS and 192 mM glycine, (pH 8.3)] and the gel 
was electrophoresed at 200 V until the bromophenol blue run out of the gel. 
2.2.6.5 Electrotransfer  
The glass plates were dismantled and the stacking upper gel cut off and discarded; then 
the separating gel was equilibrated for 10 min in cold (1 X) transfer buffer [4.8 mM 
Tris, 3.9 mM Glycine and 0.375 % SDS, (pH 8.3) with methanol freshly added at 20 % 
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(v/v)]. Proteins were blotted onto Hybond™ ECL™ nitrocellulose membrane 
(Amersham Biosciences/GE Healthcare, USA) using a BIO-RAD electrotransfer 
apparatus with (1 X) transfer buffer/methanol at 150 mA for 1.5 h. Later the membrane 
was washed with Tris buffered Saline plus Tween (TBS-T) [50 mM Tris-HCl, 150 mM 
NaCl and 0.05 % (v/v) Tween-20 (pH 7.5)]. Non-specific binding was blocked in TBS-
T containing 5 % (w/v) non-fat milk powder for 2 h at RT or overnight at 4 °C with 
gentle agitation. Finally, the membrane was washed several times with TBS-T. 
2.2.6.6 Membrane hybridisation  
I used two protocols to visualise protein bands blotted onto nitrocellulose membrane: 
enhanced chemiluminescence (ECL) and infrared imaging (Odyssey system). 
2.2.6.6.1 ECL development  
All antibody solutions were made in blocking solution (5 % milk powder, 0. 1 % tween-
20). The nitrocellulose blots were hybridised overnight at 4 °C with mouse anti-FLAG 
M2 monoclonal primary antibody (Stratagene, UK) at 1:1000 dilution. Subsequently, 
the membranes were washed 5 min X 3-4 times with TBS-T, and incubated with HRP-
conjugated secondary antibody polyclonal goat anti-mouse immunoglobulin (Dako, 
UK) at 1:2000 dilution in blocking solution for 2 h at RT with gentle agitation. Then, 
the membranes were washed and treated with ECL reagent as directed (Thermo 
scientific, UK) for 1 min. Finally, membranes were exposed to film (Kodak Biomax 
light film, USA) and this was developed. 
2.2.6.6.1.1 Membrane stripping  
For the purpose of re-probing with alternative antibody, the nitrocellulose membrane 
was stripped after ECL development. The membrane was washed first with TBS-T to 
remove any traces of ECL reagents. Then, the membrane was placed in stripping buffer 
[100 mM 2-mercaptoethanol, 2 % SDS and 62.5 mM Tris] at 80 °C with gentle 
agitation for 30 min. The blot was rinsed with ddH2O then TBS-T, twice each, to ensure 
removal of any traces of stripping buffer. Then the membrane was blocked in TBS-T 5 
% milk powder for 1 hour. To normalise for gel loading blots were re-probed with a 
mouse monoclonal anti α-tubulin antibody (Sigma Aldrich) at dilution of 1:2000 for 2 
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hour at RT with agitation, incubated with HRP secondary antibody and then developed 
as described above.  
2.2.6.6.2 Odyssey development  
This protocol used an Odyssey infrared imaging system (Li-cor Bioscience, Germany). 
The same anti-FLAG primary antibody was used (section  2.2.6.6.1 above), and the 
secondary antibody was IRDye® 800CW goat anti-mouse (Li-cor GmbH, Germany) at 
1:2000 dilution for 2 h. The blots were then washed 5 min X 3-4 times with TBS-T. To 
normalise for gel loading, the blots were hybridised with rabbit polyclonal anti α-tubulin 
primary antibody (Abcam, UK) at 1:2000 dilution then Alexa Fluor® 680 Goat anti-
rabbit secondary antibody (Invitrogen, USA) at 1:5000 dilution. Then the blots were 
scanned at 700 and 800 nm channels for α-tubulin and anti-FLAG, respectively.  
 
2.2.7 Preparation of lentiviral vectors 
2.2.7.1 Lentiviral vector production 
Lentiviral plasmids were kindly donated by Prof. Luigi Naldini (Milano, Italy). Second- 
and third-generation human immunodeficiency virus-1 (HIV-1)-based vectors were 
produced by transient transfection of HEK-293T cells using the calcium phosphate 
coprecipitation method (Yanez-Munoz et al., 2006). 3 X 106 cells were seeded in 15-cm 
plates in 25 ml complete DMEM, 72 h prior transfection. When the cell confluence 
reached ~80 % (~3 X 107 cells), cells were ready for transfection and the medium was 
replaced with 20 ml fresh complete DMEM, 2 h prior transfection. 
For preparation of third-generation vectors, HEK-293T were co-transfected with four 
plasmids in molar ratio of 1:1:1:2 (packaging: REV: envelope: transfer). To 50 ml tube, 
12.5 µg of integration-proficient packaging plasmid (pMDLg/pRRE) or pMDLg/pRRE-
intD64V (integration-deficient through a point mutation leading to D64V change, which 
inactivates the catalytic site of integrase), 7 µg of VSV-G pseudotyping plasmid 
(pMD2.VSV-G), 6.25 µg of REV plasmid (pRSV-rev) and 32 µg of transfer plasmid of 
choice, were added. The DNA was mixed with 125 µl of 2.5 M CaCl2 [14.3 g of 97 % 
pure CaCl2 in 50 ml ddH2O], vortexed and then incubated for 5 min at RT. To each tube 
1,250 µl of 2 X HBS-buffered saline [281 mM NaCl, 100 mM HEPES, 1.5 mM 
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Na2HPO4 (pH 7.12)] was added drop-wise whilst vortexing. DNA mixture was then 
immediately mixed gently with the media on the plated cells  
At 14-16 h post-transfection, the medium was replaced with 18 ml of complete DMEM. 
Subsequently, at 48 h post-transfection, media containing viral particles were harvested 
and media replaced with 18 ml complete DMEM. A further harvest was done at 72 h 
post transfection. 
The harvested viral supernatant was cleared by centrifugation at 1000 X g for 10 min, at 
RT and then passed through 0.22 µm-pore-size filters (Nalgene, USA) to remove any 
suspended cells or debris. The filtered supernatant was then transferred to high-speed 
polyallomer centrifuge tubes (Beckman, USA) and concentrated by ultracentrifugation 
(50,000 X g, for 2 h, at 4 °C). Later, the supernatant was decanted; the pelleted viral 
particles were resuspended in 50 µl of serum free DMEM and transferred to 1.5 ml 
microfuge tubes. Viral suspensions were spun at 1000 X g for 10 min at 4 °C to remove 
debris, and then transferred to new microfuge tubes. Finally, the viral stock was 
adjusted to 10 mM MgCl2, DNase I was added at 5 U/ml and the mixture was incubated 
at 37 °C for 30 min to remove any residual DNA. Finally virus suspensions were 
aliquoted and frozen at -80 °C. 
Second-generation HIV-1-based vectors were produced by the method described above 
using three plasmids in molar ratio of 1:1:2 (packaging: envelope: transfer). 16.25 µg of 
integration-proficient packaging plasmid (pCMVΔR8.74) or integration-deficient 
(pCMVΔR8.74-int D64V), 7 µg of envelope pseudotyping plasmid (pMD2.VSV-G), 
and 32 µg of transfer plasmid of choice, were used for transfection of 293T cells.  
 
2.2.7.2 Lentiviral vector titration by flow cytometry 
Lentiviral vectors bearing enhanced green fluorescent protein (eGFP) expression 
cassettes were titrated by transduction of HeLa cells with serial dilutions of vector 
stock, followed by flow cytometry analysis (Nightingale et al., 2006). 1 X 105 HeLa 
cells were seeded per well in 6-well tissue culture treated plates. Next day, the medium 
was replaced with 1 ml of complete DMEM containing 16 µg/ml polybrene (Sigma 
Aldrich). For each lentiviral vector sample to be titrated, 1.2 µl of viral stock was ten-
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fold serially diluted (10-3, 10-4, 10-5 and 10-6) in 1.2 ml complete DMEM. 1 ml of each 
dilution was added to the cells and incubated for 3 days. Subsequently, the cells were 
harvested by trypsinization and then fixed in 1 % paraformaldehyde (PFA) in PBS. 
The samples were analysed using a FACSCanto II flow cytometer and FACSDiva 
software (BD Biosciences, USA) and the viral titre was estimated using the percentage 
of eGFP positive cells. A non-transduced (mock) sample was used to determine the 
gating of negative population and highly positive samples were used to set manual 
compensation. The viable cell population was selected in the forward scatter (FSC) 
versus side scatter (SSC) plot and the positive population determined in the FL1 (eGFP) 
versus FL2 (red auto- fluorescence) plot. Those dilutions that gave a range of 1-10 % 
eGFP positive cells were used to determine the titre applying the following formula:  
eGFP transducing units (TU)/ml=% green cells x105 (cells/well at the time of vector 
addition) X 1/vector dilution 
The plasmid pRRLsc-CEW used to prepare lentiviral vectors coding for eGFP driven by 
CMV was donated by Prof. Luigi Naldini; while the plasmid pHR’sc-SEW used to 
prepare lentiviral vectors coding for eGFP driven by SFFV was kindly donated by Prof 
Adrian Thrasher (University College London). 
2.2.7.3 Lentiviral vector titration by Real time qPCR 
All lentiviral vectors were titrated by real-time quantitative polymerase chain reaction 
(qPCR). For each sample two viral dilutions (1:2000 and 1:20000) were prepared in 
complete DMEM and HeLa cells were seeded in 6-well plates at a density of 1 X 
105/well. The following day, the medium was replaced with 1 ml of complete DMEM 
containing 16 µg/ml polybrene and 1 ml of viral dilution. For each titration one well of 
cells were mock-infected with all the same reagents but without the addition of virus. At 
24 h post-transduction, the cells were trypsinised, spun (350 X g for 5 min), and 
resuspended in 200 µl PBS. Then, Genomic DNA was extracted from the cell 
suspension using Qiagen DNeasy® tissue kit (Qiagen, UK). Q-PCR was used to 
quantify human β actin gene copies and lentiviral late reverse transcript (LRT).  
Two separate qPCR reaction were run per sample: SYBR green was used in one set of 
reactions as a fluorescent dye to measure cDNA copies of Bushman’s LRT (Butler et 
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al., 2001) and, a Taqman-type fluorescent probe was used to measure β-actin 
housekeeping gene copy number (Marras, 2006). LRT DNA standards were made using 
the plasmid pRRLsin_CEW to give known copy numbers (102-107 copies/ reaction). 
DNA standards for the β-actin reaction were made using serial dilutions of HeLa cell 
genomic DNA. For this DNA from a known number of viable HeLa cells was extracted 
by DNeasy extraction kit (Qiagen) and then diluted to have 100-105 cell equivalents/ 
reaction. 
For the LRT reaction, in a 20 µl reaction volume, 10 µl of (2 X) ABI universal master 
mix (Bioline, UK), 0.06 µl of 100 µM of corresponding primers, 0.4 µl of SYBR green 
(Bioline, UK), 3.23 µl of ddH2O and 6.25 µl of the DNA samples (including those from 
mock infected cells), DNA standard, or water as a non-template control, were mixed 
together. DNA standards, water and mock were prepared in triplicate while DNA 
samples were amplified in duplicate. 
The following primers were used (Sigma Aldrich): 
LRT-forward 5'-TGTGTGCCCGTCTGTTGTGT-3'  
LRT-reverse 5’-GAGTCCTGCGTCGAGAGAGC-3' 
For the β-actin reaction, in a 20 µl reaction, 10 µl of (2 X) universal Taqman master mix 
(Roche, Germany), 0.06 µl of 100 µM of corresponding primers, 0.4 µl of 100 µM of β-
actin probe (Applied Biosystems, USA), 4.84 µl of ddH2O and 5 µl of the DNA 
samples, DNA standard or water as a non-template control, were mixed together. 
Genomic HeLa DNA standards, water and mock were prepared in triplicate and DNA 
samples in duplicate. 
The following primers were used (Sigma Aldrich): 
β-actin-forward 5'-TCACCCACACTGTGCCCATCTACGA-3'  
β-actin-reverse 5'-CAGCGGAACCGCTCATTGCCAATGG-3' 
Actin probe 5'-(VIC)-ATGCCCTCCCCCATGCCATCCTGCGT-(TAMRA)-3' 
The standard cycling for both reactions was started with initial heating at 50 °C for 2 
min, then 95 °C for 10 min, 50 cycles of [95 °C 15 sec, 60 °C 1 min]. 
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2.2.8 Immortalisation of BALB/c 3T3 scid fibroblasts 
2.2.8.1 Titration of puromycin resistance 
In order to determine the minimum concentration of puromycin for selection of 
transduced fibroblast clones, BALB/c 3T3 scid fibroblasts were grown in increasing 
concentrations of puromycin with a range from 1- 10 µg/ml. Puromycin stock solution 
was prepared 1 mg/ml (w/v), filtered with 0.22 µm filter, and kept frozen at -20 o C. In a 
6-well plate, 5 X 104 cells/well were seeded in complete DMEM. The next day, 
puromycin was added and cells were grown for another 3 days. When emerging 
puromycin-resistant cells started to be visible as a monolayer, incubation was 
terminated and colonies were stained with crystal violet. 
2.2.8.2 Crystal violet staining 
Crystal violet (Sigma Aldrich) stock was prepared at 1 % (w/v) in ethanol, kept at RT 
and a working solution was made up by 10-fold dilution in ddH2O. The colonies to be 
stained were first gently washed with PBS, and then fixed with 1 % w/v PFA PBS for 
10 min. The colonies were washed again with PBS and then 1 ml of crystal violet 
working solution was added and left for 5 min. Next, crystal violet was discarded and 
wells were washed for a few seconds until excess crystal violet was removed. Finally, 
the plates were left open upside down to dry and then purple colonies were counted by 
eye making the final count as colonies/well. 
2.2.8.3 Preparation of retroviral vectors  
The telomerase reverse transcriptase (Tert) gene encodes the catalytic subunit of mouse 
telomerase. Retroviral vectors encoding the mouse Tert (mTert) gene expression 
cassette were produced by transient transfection of HEK-293T cells using calcium 
phosphate coprecipitation method (Swift et al., 2001). The pBABEpuro retroviral 
transfer plasmid encoding mTert and Pac was kindly donated by Manuel Serrano 
(CNIO, Madrid, Spain). The other two plasmids required for retroviral vector 
production (Figure  2.1) were the packaging plasmid pGagpol (M57), and envelop 
plasmid pEnv (K73-Eco).They were a kind gift of Dr. Christopher Baum (Hannover 
Medical School, Germany). The HEK-293T cells were transfected using a similar 
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protocol to that for lentiviral vectors production (section  2.2.7.1 above), but with a 
plasmid molar ratio of 5:1:4 (packaging: envelope: transfer). At 48 and 72 h post-
transfection, the filtered supernatant was directly treated with DNase and frozen at -80 o 
C without ultracentrifugation.  
 
Figure 2.1: Plasmid constructs used for retroviral production.  (A) Genetic map of 
retroviral construct coding for mTert. (B)& (C) Genetic map of retroviral packaging 
plasmids. mTert: mouse telomerase fragment, Puro: puromycin resistance gene, LTR: 
retroviral long-terminal repeat and Gag, Pol & Env: viral specific genes.  
 
2.2.8.4 Titration of retroviral vectors   
Retroviral supernatant was titrated by transduction of BALB/c 3T3 fibroblasts with 
serial supernatant dilutions, followed by scoring of puromycin-resistant colonies. A 6-
well plate was seeded with 5 X 104 BALB/c 3T3 scid fibroblasts per well. The 
following day, serial ten-fold dilutions (100 to 10-7) of freshly harvested retroviral 
supernatant were prepared in complete DMEM. The cell medium was replaced with 1 
ml fresh DMEM and 1 ml corresponding dilution in presence of 8 µg/ml of polybrene. 
Two days post transduction, puromycin was added to a final concentration of 3 µg/ml. 
Three days later puromycin-resistant isolated colonies were visible. The colonies were 
then stained by crystal violet to facilitate counting of colony forming units (CFUs). To 
calculate the retroviral titre the following formula was used: retroviral vector titre 
(TU)/ml = number of CFUs X 105 (cells/well at the time of vector addition) X 1/vector 
dilution. 
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2.2.8.5 Transduction by retroviral vectors 
To immortalise BALB/c 3T3 scid fibroblasts by transduction with mTert-bearing 
retroviral vectors, a 75 cm2 flask was seeded with 5 X 105 cells in 10 ml complete 
DMEM. Next day, the culture medium was replaced with 10 ml of retroviral 
supernatant in the presence of 8 µg/ml polybrene. At 24 h post-transduction, the 
transduction was repeated again by replacing the retroviral supernatant with another 10 
ml of retroviral supernatant from second viral harvest in the presence of 8 µg/ml 
polybrene. Next day transduced cells were selected by the addition of 3 µg/ml 
puromycin. The cells were maintained under puromycin selection, passaged as required, 
and some cells were kept frozen in liquid nitrogen. These immortalised fibroblasts will 
be referred to as BALB/c 3T3 scid mTert fibroblasts in later sections. 
2.2.8.6 Clonal efficiency and growth curve 
The clonal efficiency experiment was done as follows: in complete DMEM, a specific 
cell number of (10 or 100) per well of either BALB/c 3T3 scid fibroblasts or BALB/c 
3T3 scid mTert fibroblasts were seeded in 6 wells of 6-well plate. Over the next 4 days, 
when visible colonies started to emerge, the plates were washed with PBS and then 
stained with crystal violet and finally, CFUs were counted. 
Similarly, to show that immortalised cells were growing more efficiently, the growth 
curve comparison between immortalised and non-immortalised cells was done as 
follows: in complete DMEM, 5 X 105 per well of either BALB/c 3T3 scid fibroblasts or 
BALB/c 3T3 scid mTert fibroblasts were seeded in 6-well plate. Then cells were 
washed with PBS trypsinised and then counted in triplicate at 24, 48, 72 and 96 h post-
culturing.  
 
2.2.9 Testing the efficiency of ZFN cutting 
The mismatch-specific plant DNA endonuclease Surveyor® Cel-I mutation detection kit 
for standard gel electrophoresis (Transgenomic, USA) was used to detect known point 
mutations and polymorphisms in heteroduplex DNA. The key component of the kit is 
the Surveyor endonuclease which is a member of the CEL family of plant 
endonucleases (Oleykowski et al., 1998). This endonuclease is able to generate site-
88 
 
specific DNA cleavage with high efficiency at sites of base substitution mismatch and 
other alterations (Yang et al., 2000). The Surveyor is able to cleave both strands of a 
DNA heteroduplex on the 3’-side of the mismatch site leading to recognition of DNA 
insertion/deletion (InDel) mismatches and all base-substitution mismatches (Qiu et al., 
2004; Sokurenko et al., 2001). This assay will be referred to as Surveyor Cel-I assay in 
later sections. 
The Surveyor assay protocol typically includes four main steps (for more details see 
Figure  4.14): 
• Sample PCR amplification.  
• Hybridization of mixed amplicons to produce heteroduplex and homoduplex 
DNA. 
• Treatment with Surveyor endonuclease. 
• Analysis of DNA fragments by PAGE. 
2.2.9.1 Cel-1sensitivity testing 
For the purpose of finding out what was the minimum percentage of DNA mismatches 
that can be detected by this assay, control samples were prepared containing different 
combinations of BALB/c 3T3 wt and scid mTert fibroblasts. The cells were cultured in 
complete DMEM, harvested, counted, and then mixed in the following combinations in 
total cell number of 1 X 106 cells per combination (Table  2.1). Later genomic DNA was 
extracted by DNeasy® kit. 
 
Table 2.1: Designed control combination percentages 
BALB/c type   Combination (%) 
mTert scid  99 95 90 80 70 60 50 
Wt 1 5 10 20 30 40 50 
 
The following primers (Eurofins MWG, Germany) were selected using Primer3 
(version 0.4.0) from scid mouse genome.  
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Forward primer: 5' -GCAGACAATGCTGAGAAAAGG- 3'  
Reverse primer: 5' -GCACAAAACAGACAAGGGTGT- 3' 
The PCR amplification should generate a 304 bp parental fragment (for DNA sequence 
please see Appendix, Box 1) and when cleaved by Surveyor’s (at the scid point 
mutation mismatch) should give rise to two cleaved smaller products of 88 and 216 bp. 
The designed controls were tested using same protocol as in section  2.2.9.2 below. 
2.2.9.2 ZFN-treated sample testing 
 
DNA mismatches in designed controls or unknown samples treated with ZFNs were 
tested using the same protocol. 1 X 106 cells were spun at 270 X g for 5 min, the 
supernatant was gently discarded, and genomic DNA was extracted by Qiagen DNeasy® 
kit. Then, 100 μl of TE buffer containing eluted genomic DNA was transferred into 
PCR-compatible tubes and incubated as follows: 68 ºC for 15 min; 95 ºC for 8 min; then 
held at 4 ºC. Next, 2 μl of DNA sample from the previous step, 5 μl of 10 X AccuPrime 
buffer II (Invitrogen, USA), 2.5 μl of each primer 10 μM, 0.2 μl (1 unit) of AccuPrime 
Taq DNA polymerase (Invitrogen, USA) and 40.3 μl sterile ddH2O were mixed for  
PCR. The cycling conditions were: 95 ºC for 5 min; 35 cycles of [95 ºC for 30 sec, 60 
ºC for 30 sec, and 68 ºC for 40 sec]; 68 ºC for 2 min; hold at 4ºC. Subsequently, the 
amplification was verified by running 5 μl of PCR reaction on PAGE. For hybridisation, 
6 μl of 1 X AccuPrime buffer II was mixed with 3 μl of PCR product and run in 
thermocycler as follows for annealing: 
95 ºC for 10 min then 95 ºC to 85 ºC (-2.0 ºC/s) 
85 ºC for 1 min then 85 ºC to 75 ºC (-0.3 ºC/s) 
75 ºC for 1 min then 75 ºC to 65 ºC (-0.3 ºC/s) 
65 ºC for 1 min then 65 ºC to 55 ºC (-0.3 ºC/s) 
55 ºC for 1 min then 55 ºC to 45 ºC (-0.3 ºC/s) 
45 ºC for 1 min then 45 ºC to 35 ºC (-0.3 ºC/s) 
35 ºC for 1 min then 35 ºC to 25 ºC (-0.3 ºC/s) 
25 ºC for 1 min and finally hold at 4 ºC. 
The digestion reaction for Surveyor nuclease was set up as follows: 9 µl of reaction 
mixture (from step 2), 1 µl of Surveyor enhancer, and 1 µl Surveyor nuclease were 
mixed and incubated at 42 ºC for 60 min in the thermocycler. 
Finally digested DNA samples were analysed by PAGE (section  2.2.2.2 above) using 3 
µl of loading buffer mixed with products from (step 3) and then loaded and 
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electrophoresed. Images were captured under UV illumination using a Bio-Rad Gel Doc 
2000 system and analysed by ImageJ/ V-2 software.  
 
2.2.10 Gene targeting in BALB/c 3T3 scid mTert fibroblasts 
The plasmid containing Prkdc-neo template (9210 bp) pPrkdcHindPmlIneoF (Figure 
4.8 b) was designed to encode a neo cassette which should confer resistance to G418 in 
gene-targeted cells. Importantly, regardless whether site-specific gene targeting or 
random integration has occurred, positive-selected cells should generate visible 
colonies, which can be counted at the end of experiment. 
Two different gene targeting experiments were done to target BALB/c 3T3 scid mTert 
fibroblasts. Firstly, since there were two different ZFN plasmids available I set out to 
investigate which ZFN version (or combination of both ZFNs) was more efficient in 
terms of producing more G418 resistant colonies as an indicator of ZFN-induced DSBs. 
This was done by plasmid co-transfection of wild type Prkdc-neo corrective template of 
(9210 bp) plus plasmids encoding the two different ZFN monomers either alone or in 
combination.  
To do this initial gene repair experiment: 1 X 106 BALB/c 3T3 scid mTert fibroblasts 
were seeded in 10 cm tissue culture plates using complete DMEM. The cells were 
allowed 4 hours for attachment, and then the cells were transfected with plasmids [for 
quantities please see Table 4.2] encoding for Prkdc-neo corrective template and/or 
ZFNs. Two days later, the cells were twice washed with PBS and incubated in complete 
DMEM containing 800 µg/ ml of G418 (Sigma Aldrich) for positive selection [G418 
stock solution was 80 mg/ml (w/v) PBS]. The G418 minimum killing dose for these 
cells had been previously determined (Rafael Yáñez, personal communication). Five 
days post-transfection, DMEM medium was replaced with complete DMEM containing 
G418. After four days, visible colonies emerged which were stained with crystal violet 
and counted. Simultaneously before staining some of these colonies were picked and 
transferred into a new 96-well, then into a 24-well, and finally into 6-well plates to 
continue growing. Then they were harvested either to be stored frozen in liquid nitrogen 
or to be used for further gene targeting events analysis. 
 
Secondly, having identified the best combinations of ZFNs (in previous experiment), it 
was important to verify the functionality of ZFN cassettes as they were expressing from 
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prepared ZFN lentiviral vectors. This was done by plasmid transfection of Prkdc-neo 
corrective template plus viral transduction of only efficient ZFN versions and 
combinations demonstrated in previous experiment. A 1 X 106 BALB/c 3T3 scid mTert 
fibroblasts were seeded in 10 cm tissue culture plates using complete DMEM. The cells 
were allowed 4 hours for attachment, and then transduced with 50 MOI of ZFN IPLVs. 
Later, at intervals of 12, 24, 48 or 72 h post-transduction, the cells were transfected with 
donor plasmid (containing Prkdc-neo corrective template of 9210 bp). Next, the same 
steps were followed as in previous experiment and crystal violet stained colonies were 
counted.  
2.2.10.1 Molecular analysis of G418r colonies 
G418-resistant BALB/c 3T3 scid mTert fibroblasts from previous experiments (gene-
targeted by Prkdc-neo template and two ZFN plasmids) were further analysed by a PCR 
based assay to demonstrate gene targeting events. The genomic DNA was extracted by 
Qiagen DNeasy® kit. Then two primers (Sigma-Aldrich) were designed using Primer3 
software (version 0.4.0). The forward primer was selected from the donor template 
plasmid (template-internal primer); whereas the reverse one was selected from the 
genomic DNA outside the homologous recombination region and very close to the 
expected end of the donor template (template-external primer), (see Figure 4.10 E for 
more details). The amplicon length was 1335 bp. The primers sequences were as 
follows:  
Forward primer 5’- TCGCCTTCTTGACGAGTTCT-3’  
Reverse primer 5’- TTTTCCCCCTCATGTCACTC -3’  
For PCR amplification, 50 µl reactions were prepared containing 10 µl 5 X GoTaq® 
(Promega, UK) reaction buffer, 1.5 µl of 10 mM dNTPs, 4 µl of 25 mM MgCl2, 1.5 µl 
of 10 µM of each forward and reverse primer, 200 ng DNA template (genomic DNA 
extracted from gene-targeted cells), and 0.5 µl of 5 u/µl GoTaq DNA polymerase. 
Thermo-cycling conditions were: initial denaturation at 95 °C for 2 min, then 35 cycles 
of 95 °C for 45 sec, 59 °C for 60 sec, 72 °C for 72 sec, followed by final extension at 72 
°C for 5 min. Subsequently, PCR amplicons were purified by Qiagen purification 
columns from the reaction. 
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Vector NTI software (Invitrogen) was used to predict restriction enzymes that could cut 
within the PCR product to confirm the sequence of the amplicons. All those samples 
that showed amplification of the right size of (1335 bp) were digested with BglII 
restriction enzyme. Then, one sample that showed amplification of the right size was 
selected to be digested separately with HindIII, BglII and XhoI for further confirmation 
purposes.  
 
2.2.11 Isolation of Murine Lin- HSCs 
For the purpose of isolation of murine lin- (lineage negative) HSCs from both wild type 
and scid mice the following steps were conducted as previously described by Mikkola 
(Mikkola et al., 2000). Mice strains BALB/cOlaHsd as wild type or 
BALB/cJHan(tm)Hsd-Prkdcscid (Harlan, UK) as scid mutants were used. 6-week old 
mice were killed using a schedule 1 procedure. Femurs and tibias were collected, 
muscles were removed and the bone ends were cut off. 23G needles were used to collect 
the bone marrow by flushing the bone shafts using ice-cold serum-free DMEM. The 
cells were disaggregated by pipetting and then filtered using 30 μm nylon mesh filters 
(Millipore, USA) to remove cells clumps. 
Subsequently, MACS® Linage cell depletion kit (Miltenyi Biotec, Germany) was used 
as directed by the manufacturer, to deplete lin+ HSCs with a cocktail of biotinylated 
antibodies against a collection of “lineage” antigens (CD5, CD11b, CD45R, Anti-Gr-1 
(Ly- 6G/C), 7-4, and Ter-119 antibodies) and Anti-Biotin microbeads. As a result, lin+ 
cells were magnetically labelled and column-retained; whereas the lin- HSCs were 
eluted (Orlic, 2002).In brief, bone marrow cells were washed twice with cold buffer [2 
mM EDTA 0.2 % (w/v) BSA PBS] spun at (300 X g for 10 min at 4 °C). Next, the cells 
were resuspended in buffer (40 µl per 107 cells) and biotin antibody cocktail (10 µl per 
107 cells) and then incubated for 20 min at 4 °C. Later, buffer (30 µl per 107 cells) and 
anti-biotin magnetic microbeads (20 µl per 107 cells) were added and incubated for 30 
min at 4 °C. The cells were washed, centrifuged, applied in the magnetic separation 
columns and finally collected. 
Purified lin- HSCs were typically cultured in non- treated tissue culture 24-well plates at 
density of 7.5 X 104 - 1 X 105 cells/well using the culture conditions previously 
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mentioned in section  2.2.4.2 above. Lin- HSCs were transduced with different LVs or 
adenoviral vectors (at different MOIs) and harvested after 72 h to be tested with BsaWI 
assay and/or deep sequencing, or analysed by flow cytometry to detect eGFP positive 
cells. Their viability was checked by staining with DAPI stain (1 µg/ml final 
concentration) followed by analysis by flow cytometry at the same time of eGFP 
detection.  
 
2.2.12 BsaWI Assay  
This experiment was designed to detect homologous recombination events in cells that 
were treated with ZFN and homologous Prkdc corrective template lentiviral vectors. A 
silent diagnostic restriction site of the enzyme BsaWI has been introduced via site-
directed mutagenesis (previously performed in Dr Yáñez’s laboratory) 2 nucleotides 
upstream from the scid point mutation in the Prkdc corrective template. The presence of 
BsaWI sites in genomic DNA were assayed using PCR and Southern blotting protocols 
as described below steps.  
2.2.12.1 Prkdc template cloning 
The plasmid pHind-TKBsaWI encoding for a HindIII fragment (7573 bp) of mouse 
Prkdc gene, was used as a template to amplify by PCR the Prkdc-BsaWI corrective 
template amplicon of 1626 bp. The following primers (Sigma-Aldrich) were selected by 
Primer3 software (version 0.4.0):  
Forward primer 5’- TGCCGGGACCCAATGTTTAGTTTTTATGAGTGTTTTGC-3’  
Reverse primer 5’- AACGGGACCCCAAGCCATCTCTCTAGCCCTAC-3’ 
The sequence GGGACCC was SanDI recognition site while TGCC and AAC were 
added to facilitate the digestion. For PCR amplification, a 100 µl reaction mix 
containing 20 µl 5 X GoTaq® (Promega, UK) reaction buffer, 2 µl 10 mM dNTPs, 3 µl 
25 mM MgCl2, 6 µl of 10 µM of each forward and reverse primers, 200 ng DNA 
template, and 0.5 µl GoTaq DNA polymerase was prepared. Thermo-cycling conditions 
were: initial denaturation at 95 °C for 2 min, then 35 cycles of 95 °C for 60 sec, 74°C 
for 60 sec, 72 °C for 90 sec, and final extension at 72 °C for 5 min. Subsequently, PCR 
amplicons were retrieved from the gel and purified by Qiagen purification columns, and 
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then digested with SanDI restriction enzymes (NEB, UK) to generate cohesive ends, at 
37 °C for 15 h. The samples were purified again by Qiagen columns to remove the 
residual DNA small fragments. The amplified Prkdc template was then cloned in 
reverse orientation, to prevent any possibility of RNA splicing, into new lentiviral 
vector backbones encoding for Prkdc template alone or ZFN monomer and Prkdc 
template together. The sequence of that Prkdc template was verified by sequencing (for 
full sequence please see Appendix 1 Box 2). This corrective Prkdc template will be 
referred to as “Prkdc-BsaWI template” in later sections. 
2.2.12.2  Transduction with lentiviral vectors 
The lentiviral vectors were prepared and qPCR titrated as explained earlier (section 
 2.2.7 above) using ZFN/template or template alone backbones.10000 cells of BALB/c 
3T3 scid mTert fibroblasts or scid HSCs were transduced with several qPCR-
determined MOIs and ratios of ZFNs: template. The cells were cultured for 10 days 
(fibroblasts) or 3 days (HSCs), then harvested and finally their DNA extracted by 
DNeasy® Qiagen kit.  
2.2.12.3 PCR of the targeted Prkdc template  
Two primers (Sigma-Aldrich) were chosen, from mouse genome, outside the region of 
homology of the corrective template (external to the Prkdc- BsaWI template) using 
Primer3 software (version 0.4.0).  
Forward primer 5’-AACAATCCTCCTCCGAACCT -3’  
Reverse primer 5’-TGGAGGTGGAAGAACCAAAC -3’ 
The extracted genomic DNA from targeted cells (section  2.2.12.2 ) was used to amplify 
a Prkdc amplicon of 1708 bp (for full sequence please see Appendix 1 Box 3). For PCR 
amplification, 5 µl 5 X Longamp Taq (NEB, UK) reaction buffer, 0.75 µl 10 mM 
dNTPs, 1 µl of 10 µM of each forward and reverse primers, 100 ng DNA template 
(genomic DNA), 1 µl (2.5 units) Longamp Taq DNA polymerase and up to 25 µl sterile 
nuclease-free water, were prepared. Thermo-cycling conditions were: initial 
denaturation at 95°C for 30 sec, then 35 cycles of 95 °C for 30 sec, 59 °C for 60 sec, 65 
°C for 75 sec, and final extension at 65 °C for 10 min. Subsequently, PCR products 
were visualised by gel electrophoresis. 
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2.2.12.4 Digestion with BsaWI  
The samples that were targeted with Prkdc template and then PCR amplified with 
template external primers, were digested with BsaWI restriction enzyme at 60 °C for 16 
h.  
2.2.12.5 Southern blotting 
2.2.12.5.1 Preparation of hot ladder 
To set up hot (radioactively-labelled) ladder, 1 µg DNA ladder (HyperLadder I, 
Bioline), 2 µl 10x nick translation buffer (NTB) [0.5 M Tris HCl pH 7.5, 0.1 M MgSO4, 
1 mM Dithiothreitol (DTT)], 4 µl CGT [0.5 mM each dCTP, dGTP and dTTP in 10 mM 
Tris HCl pH 7.5], 1 µl (10 µCi) of [α -32P] dATP (Perkin Elmer, USA), and 5 U Klenow 
(5 u/µl), were mixed together in a 20 µl reaction volume. The mixture was incubated at 
room temperature for 90 min, and then 40 µl of TE [10 mM tris-HCl, 1 mM EDTA pH 
8.0] buffer was added and mixed. A 1 µl sample of labelled was counted in Biomax 
Geiger counter. Next, a MicroSpin S-300 column (GH Healthcare, UK) was packed and 
spun at 3000 X g for 1 min then samples were loaded into column and spun at 3000 X g 
for 2 min to remove any unincorporated radiolabel. Finally, 1 µl of eluate was counted 
in Biomax Geiger counter. 15-45 Geiger counts worth of ladder was loaded per gel lane. 
The remainder of hot ladder was kept frozen at -20°C. 
2.2.12.5.2 Probe Labelling  
Two probes were used for southern blotting. Both probes were amplified from the same 
genomic Prkdc template (for sequence please see Appendix 1 Bbox 3), the first was 
full-length PCR amplified fragment of 1708 bp; the second was shorter and generated 
after digestion of the first one with BsaWI and purification of the bigger fragment 
(1068bp). The longer probe (1708 bp) was prepared by PCR amplification with Prkdc 
template external primers (section  2.2.12.4 above). For the shorter probe: the 1708 bp 
Prkdc amplicon was prepared by PCR amplification with Prkdc template external 
primers and digested with BsaWI, fragments were visualised by gel electrophoresis, and 
the 1068 bp fragment was cut from the gel and purified using Qiaquick® gel extraction 
kit. 
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100 ng of DNA probe to be labelled was transferred to 1.5 ml screw cap microfuge tube 
and made up to 4 µl with TE buffer. Then, 1 µl of 60ng/µl random hexanucleotides 
(dN6) (SIGMA Aldrich) was added. The samples were kept at 95 °C for 5 min in 
thermo-block and transferred onto ice for 2 min and then spun down briefly. Next, 3 µl 
of 10x random priming (RP) buffer [0.5 M Tris HCl pH 6.9, 0.1 M MgSO4, 1 mM 
DTT], 3 µl of CGT [0.6 mM of each dCTP, dGTP and dTTP in 10 mM Tris HCl pH 
7.5] and 12 µl of water were mixed together. Then 12 µl of this mixture was added to 
each probe sample followed by 2 µl (20 µCi) of [α-32P] dATP. 1 µl Klenow (5 u/µl) was 
added and the mixture was incubated at RT, for 1 hour.  
40 µl of TE buffer was added before 1 µl of the mixture was counted in Biomax Geiger 
counter. Subsequently, MicroSpin S-300 column were packed and spun at 3000 X g for 
1 min and then samples were loaded into column and spun at 3000 X g for 2 min. 
Finally, a 1 µl of eluate was assayed in a Biomax Geiger counter to check the radio 
nucleotide incorporation efficiency. 
2.2.12.5.3 Gel preparation 
A 0.7 % agarose gel was cast in 1 X TAE with final EtBr concentration of 0.5 μg/ml, 
and the lanes were loaded with BsaWI- digested DNA (section  2.2.2.1 above) or hot 
ladder. Then, the gel was run in TAE-EtBr over night in cold room at 35 V constant 
voltage. Next day, a photo was taken and image saved using a Bio-Rad Gel Doc 2000 
system. 
2.2.12.5.4 Membrane Transfer and UV Fixation  
The gel was agitated in 0.25 N HCl for 10 min, washed twice with water, agitated in 
denaturing solution [0.4 N NaOH and 0.6 M NaCl] for 30 min, then washed twice with 
water, and agitated in neutralising solution [1.5 M NaCl and 0.5 M Tris HCl pH 7.5] for 
30 min. Next, GeneScreen Plus membrane (Perkin Elmer, USA) was cut, pre-wetted in 
water for a few seconds and was equilibrated in 10 X SSC [1.5 M NaCl, 0.15 M 
trisodium citrate dihydrate] for 15 min. Later, a capillary blot was set up using 10 X 
SSC buffer, and transfer was left overnight. Next day, transfer was dismantled. The 
membrane was agitated in 0.4 N NaOH for 1 min and then agitated in 0.2M Tris-HCl, 1 
X SSC, pH 7.5 for 1 min. Subsequently, the membrane was rinsed with 2xSSC and then 
fixed in UV cross-linker (UVP, USA). 
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2.2.12.5.5 Hybridisation 
The membrane was kept wet throughout hybridisation, washing and exposure steps. For 
hybridisation, first the membrane was wetted in 2 X SSC, spread in hybridisation tube 
and the 2 X SSC was drained out from tube. Then, 15 ml of Church mix [1 % (w/v) 
BSA, 7 % (w/v) SDS in 0.5 M phosphate buffer] was added to hybridisation tube. The 
hybridisation oven (Techne, UK) was pre-warmed by rotating for at least 1 hour at 68 
°C. Next, the labelled probe was boiled at 95 °C for 5 min, then transferred onto ice for 
2 min and added to the membrane inside a hybridisation tube. The hybridisation was left 
overnight at 68 °C, and next day the membrane was washed several times with 0.5 % 
(w/v) SDS in 2 X SSC at 65 °C. Finally the membrane was sealed in a bag and exposed 
to phosphoimager screen and scanned by Typhone-8600 scanner (Amersham Pharmacia 
Biotech, UK) and analysed by ImageJ/ V-2 software. 
 
2.2.13 DNA-PKcs activity assay  
 
Gene repair of mutated Prkdc will lead to restoration of normal gene function of DNA-
PKcs activity. To assay for restoration of DNA-PKcs in gene repaired cells, the 
SignaTECT® DNA-dependent protein kinase assay system (Promega, USA) was used to 
quantitate DNA-PK activity in purified nuclear cell extracts. The assay quantifies the 
phosphorylation of a biotinylated p53-derived peptide substrate captured onto a 
streptavidin coated membrane. What is important is that the streptavidin matrix 
provides rapid and quantitative capture of biotinylated substrate molecules, based on the 
strong affinity of biotin for streptavidin (Goueli, 1997; Loong et al., 2004). 
2.2.13.1 Extraction of nuclear protein 
 
The cells that were corrected by gene repair via ZFNs and corrective Prkdc template 
subsequently had their DNA-PK activity assessed. The nuclear protein extraction 
protocol was based on CelLytic Nuclear Extraction kit (Sigma Aldrich, USA) but all the 
required buffers were prepared in the laboratory. To perform nuclear protein extraction 
the cells were allowed to swell with hypotonic buffer, their plasma membranes 
disrupted, the cytoplasmic fraction was removed, and the nuclear proteins were released 
from the nuclei by a high salt buffer. 
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Briefly, scid corrected cells were collected, washed with PBS, and lysed with hypotonic 
lysis buffer [10 mM HEPES, pH 7.9, with 1.5 mM MgCl2 and 10 mM KCl] or isotonic 
lysis buffer [5 mM Tris HCl, pH 7.5, with 2 mM MgCl2, 3 mM CaCl2, and 300 mM 
Sucrose] for mTert fibroblasts or HSCs, respectively as the HSCs were more delicate 
cells. In both lysis buffers were included 1 mM DTT and 10 % (v/v) protease inhibitor 
cocktail (Roche, UK). Next, the samples were incubated on ice for 30 min, later 10 % 
IGEPAL (Sigma Aldrich) was added and then vortexed and immediately spun at 11000 
X g for 30 sec at 4 °C. 
Subsequently, the samples were resuspended in Extraction buffer [20 mM HEPES, pH 
7.9, with 1.5 mM MgCl2, 0.42 M NaCl, 0.2 mM EDTA, and 25 % (v/v) Glycerol] with 
1 mM DTT and 5 % (v/v) protease inhibitor cocktail; and then kept on ice for 30 min 
with agitation. Next, they were spun at 11000 X g for 6 min at 4 °C, transferred into 
clean tubes and snap-frozen in liquid nitrogen and then kept at -80 °C. The final protein 
content was quantified by Bradford protein assay (Bio-Rad, UK).  
2.2.13.2 DNA-PKcs assay protocol 
 
The nuclear extract was used as a source for the DNA-PKcs assay and the samples were 
tested in the presence of activation buffer which includes calf-thymus DNA and 
corrected for background phosphorylation by nonspecific kinases in the absence of calf 
thymus DNA. Enzyme samples were serially diluted in a two-fold dilution series down 
to 1:16 (enzyme: diluent) using 1 X enzyme dilution buffer and 0.1 mg/ml BSA. The 
ATP mix was prepared using 5.0 μl ATP and 0.05μl [γ-32P] ATP (Perkins Elmer, USA) 
per reaction. 
Then, for each sample reaction with activator 2.5 μl activation buffer, 5.0 μl 5 X 
reaction buffer, 2.5 μl biotinylated peptide substrate, 0.2 μl BSA (10 mg/ml) and 5.0 μl 
ATP mix were added. Whereas for each sample reaction without activator: 2.5 μl 
control buffer, 5.0 μl 5 X reaction buffer, 2.5 μl biotinylated peptide substrate, 0.2 μl 
BSA (10 mg/ml) and 5.0 μl ATP mix were added. Next, the reaction was initiated by 
adding the appropriate amount of enzyme sample, adjusted to a final volume of 25 μl 
using deionised water and incubated at 30 °C for 5 min. 
The reaction was then terminated by adding 12.5 μl of termination buffer. Subsequently, 
10 μl of each terminated reaction was spotted onto the SAM 2 membrane which was 
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washed once for 30 sec and three times for 2 min, with 2 M NaCl; then  four times for 2 
min with 2 M NaCl in 1 % H3PO4 and finally twice for 30 sec with deionised water. The 
SAM2 membrane was left to dry and incorporation of [γ -32P] into the biotinylated 
peptide was scanned by phosphoimager (Typhone-8600 scanner, Amersham Pharmacia 
Biotech, UK) and confirmed by scintillation counting. Finally, Prkdc-mediated 
phosphorylation was calculated by subtracting the activity of the enzyme in the absence 
of activator (control buffer) from that of the enzyme in the presence of activator 
(activation buffer). The following formula was applied: 
Enzyme specific activity in pmol ATP/minute/μg of protein = [(cpm reaction with 
activator – cpm reaction without activator) × (37.5)] / [(10) × (time min) × (μg of 
protein in reaction) × (specific activity of [γ-32P] ATP)] 
Where: 37.5 are the reaction volume in μl, 10 is the volume in μl of the sample, time in 
min was (5), and (specific activity of [γ-32P] ATP) was calculated as follows: 
The specific activity of [γ-32P] ATP in cpm/pmol = [(37.5 ÷ 5) X] / 2,500 
Where: 37.5 are the reaction volume in μl, 5 is the volume in μl of sample, X is the 
average cpm of the 5μl sample and 2,500 is the number of picomoles of ATP in the 
reaction. cpm is counts per minute.  
 
2.2.14 Enrichment of corrected cells 
Melphalan belongs to the class of nitrogen mustards that generate DNA interstrand 
cross-links, inducing DSBs that will be repaired by NHEJ pathway. Importantly, DNA-
PK is crucial to the cellular response to this DNA damaging agents (Muller et al., 
2000). Those cells that showed homologous recombination events detected by BsaWI 
assay (section  2.2.12 above) were subjected to enrichment using the drug melphalan to 
further demonstrate their phenotype correction. First, the drug cytotoxic dose for 
BALB/c 3T3 wt and scid fibroblasts was detected using the MTT assay. Then corrected 
cells were enriched by culturing in presence of this optimised dose of melphalan. 
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2.2.14.1 MTT assay 
 
The MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) assay was 
used to detect the cell viability at different melphalan concentrations. The assay 
principle depends on the conversion of the water soluble MTT into insoluble MTT-
formazan crystals by mitochondrial dehydrogenases of living cells. The crystals are then 
solubilised, and the concentration determined by optical density at 570 nm (van 
Meerloo et al., 2011). The MTT (Sigma Aldrich) stock solution was prepared in the 
dark at 4 mg/ml in PBS then filtered and kept at 4°C till use. In a 24-well plate, 1 X 104 
wt or scid mTert fibroblasts were seeded in complete DMEM. After 24 h, the culture 
medium was replaced with fresh complete DMEM containing different melphalan 
concentrations (0.01 -50 µM). After one hour of incubation at 37 °C, medium 
containing the drug was replaced by fresh complete DMEM. 
 
The plates were then incubated for 5 days prior to determine cell viability by 
measurement of MTT conversion. 200 µl MTT of stock solution were added to each 
sample, incubated for 4 h and then the medium removed gently without disturbing the 
formazan crystals. The plates were left for 1 hour to dry then DMSO was added to 
dissolve the crystals, and incubated with agitation for 10 min. Later, 100 µl from each 
sample were transferred into 96-well plate to measure the optical density at 570 nm 
using GloMax®- Microplate Multimode Reader (Promega, USA) The optical density in 
samples from cells with zero melphalan concentration was considered as 100 % 
viability. 
2.2.14.2 Potential enrichment by melphalan  
To verify that the corrected cells can be enriched by melphalan they were cultured under 
melphalan selection for three weeks. The stock solution of 150 mM melphalan (Sigma 
Aldrich) was prepared by dissolving 14 mg melphalan 95 % purity in 290.47 µl absolute 
ethanol acidified with 3 drops of concentrated hydrochloric acid. Triplicate cell samples 
of 1 X 105 BALB/c 3T3 mTert scid fibroblasts transduced with IDLVs encoding for 
SFFV ZFNs and corrective Prkdc-BsaWI template were seeded in 9 cm dishes with 
complete DMEM. The following day, the optimised cytotoxic dose of melphalan (from 
above section 2.2.14.1) was added for 1 hour and then replaced with fresh complete 
101 
 
DMEM. The cells were kept in culture for 3 weeks with weekly melphalan exposure 
until the emergence of visible colonies. Finally, melphalan resistant CFUs were 
counted.  
After counting, melphalan-enriched cells from previous part were collected and 
subjected to the BsaWI assay (section  2.2.12 above) and compared alongside to non-
enriched corrected cells to further demonstrate phenotype restoration.  
 
2.2.15 Ex vivo studies 
All ex vivo procedures in this study were performed at the Institute of Child Health 
(ICH) - UCL/ London and approved by UK Home Office regulations under project 
licence number 70/7024. Two mice strains (BALB/cOlaHsd) as wt and (BALB/ cJHan 
(tm)Hsd-Prkdcscid) as scid  from Harlan, UK were used 
Animals were housed in a specific-pathogen-free animal facility at ICH and fed sterile 
normal diet.  
2.2.15.1 Murine transplantation 
Donor animals were either wt or scid males; whereas recipients were always scid 
females. The lin- HSCs were isolated as described earlier (section  2.2.11 above) then 
transduced where applicable with ZFN and corrective template lentiviral vectors by 
adding concentrated lentiviral stock directly to the growth media and the cells were 
transduced overnight at the conditions described in (section  2.2.4.2 above). 
The following day the transduced cells were harvested for intravenous injection into 
irradiated mice. Before injections; recipients were sub-lethally irradiated with a total of 
2.5 Gy/mice in a one single dose using caesium 137 gamma irradiation in IBL 437C0 
irradiator (RAD SOURCE, USA). 1 X 106 transduced lin- cells, resuspended in 200 μl 
PBS, were intravenously injected into the tail veins of irradiated scid mice using a 27 G 
bevel needle attached to a tuberculin syringe. This procedure was carried out by Dr 
Mike Blundell.  
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2.2.15.2 Animal bleeding 
 
In order to analyse whether ex vivo correction of the scid mutation in lin-HSCs could 
result in immune reconstitution, animals were bled at weeks 9, 16 and 24 post-
transplantation and peripheral blood cells were assayed by multicolour flow cytometric 
analysis for expression of lineage markers. At week 9 post-transplantation, blood 
samples were collected (~50 μl/ animal) from mice tail veins using a 27 G bevel needle 
attached to a tuberculin syringe. Then, hematopoietic cells were lysed in erythrocytes 
lysis solution to eliminate erythrocytes before labelling with specific antibodies. The 
lysis was performed by adding 2 ml/sample of 1 X RBC lysis buffer (Biolegend, USA), 
kept in dark at RT for 10 min and then spun at 300 X g for 10 min at RT. Later, the 
supernatants were discarded, the blood sample volumes were made up to 100 μl using 
sterile PBS. Then, the samples were stained with different monoclonal antibodies raised 
against mouse different differentiation markers by adding to each sample: 1 μl of each 
of anti-human/mouse CD45R (B220) PE antibody to target B lymphocytes, anti-mouse 
CD3e PerCP-Cy5.5 antibody to target T lymphocytes and anti-mouse CD11b APC to 
target myeloid cells (macrophages, natural killer cells and granulocytes). One mock 
unstained sample was also prepared. The samples were then mixed and kept for 30 min 
at 4 °C. Next, the samples washed with 3 ml of 0.5 % FCS-PBS and then spun at 300 X 
g for 10 min. Finally, the supernatants were discarded and samples were analysed by 
flow cytometry on CyAn™ ADP (Beckman Coulter, USA) and analysed with FlowJo 
Software (TreeStar Inc).  
 
Control beads samples were prepared along with the prepared blood samples by adding 
one drop of each of positive and negative Copmbeads™ anti-mouse Ig, K/negative 
control (FBS) compensation particles set (BD Biosciences, USA) to 100 μl PBS. Then,1 
μl of rat IgG2a K isotype control PE, Armenian hamster IgG isotype control PerCP-
Cy5.5, or rat IgG2b K isotype control APC; or all of them together were added to beads 
samples, washed and prepared as above. Likewise, a 1 μl of anti-human/mouse CD45R 
(B220) PE antibody, anti-mouse CD3e PerCP-Cy5.5 antibody or anti-mouse CD11b 
APC were added either separately or together to another bead samples and preparation 
continued as above.  
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At weeks 16 and 24 post transplantation, all animals were bled again and samples were 
stained with same antibodies used in week 9 applying same protocol. Two additional 
antibodies were used to target mature T cells: anti-Mouse CD4 PE to target helper T 
cells and anti-Mouse CD8a APC to target cytotoxic T cells. Detection of any cell 
population of these developed T cells will be an indicator of scid mouse phenotype 
correction. At the same time wt female mouse of strain BALB/c OlaHsd, was bled and 
used as a control alongside with staining against CD45R, CD3e and CD11b markers. 
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3 Cloning of ZFNs and homologous templates, and lentiviral 
production.   
This chapter describes the work undertaken to produce integration proficient lentiviral 
vectors (IPLVs) and integration deficient lentiviral vectors (IDLVs) expressing either 
ZFNs, wt corrective templates, or both of them, ensuring that ZFN genes are expressible 
and detectable. In order to complete this, ZFNs and homologous templates were cloned 
into lentiviral plasmid backbones as a first step to produce lentiviral vectors. Then, ZFN 
expression was confirmed by Western blotting of cell extracts obtained by transfection 
of ZFN constructs. Later in this chapter, ZFN IPLVs and IDLVs, homologous template 
IDLVs or ZFN/ homologous template IDLVs were produced. Other lentiviral vectors 
expressing eGFP reporter gene driven by either Cytomegalovirus (CMV) or Spleen 
focus-forming virus (SFFV) promoters were prepared for control/optimisation purposes. 
All prepared lentiviral vectors were titrated by qPCR and the eGFP vectors were 
additionally titrated by flow cytometry. Finally, ZFN expression from prepared 
lentiviral viral vectors was confirmed by Western blotting. 
All ZFNs were received from Sangamo Biosciences Inc. (California-USA) as pVAX 
plasmid constructs. Two wt mouse genomic DNA sequences, long of 9210 bp 
(including non homologous sequence of 1637 bp encoding neo cassette) and short of 
1626 bp, were used as donor corrective templates. Most of these DNA inserts were 
cloned into either pRRL or pCCL lentiviral backbones and only one construct was made 
in an intermediary plasmid. pRRL and pCCL are lentiviral transfer plasmids where the 
5’ HIV LTR promoter/enhancer has been replaced by either chimeric Rous sarcoma 
virus (RSV)-HIV or CMV–HIV LTRs, respectively. In pRRL, the enhancer and 
promoter from the U3 region of RSV are joined to the R region of the HIV-1 LTR. 
While in pCCL, the enhancer and promoter of CMV were joined to the R region of 
HIV-1. Additionally simian virus 40 (SV40) polyadenylation site and enhancerless 
origin of replication sequences are cloned downstream of the HIV LTR, replacing most 
of the human sequence remaining from the HIV integration site (Dull et al., 1998; 
Zufferey et al., 1998). 
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3.1 Cloning of plasmid constructs 
New constructs cloned in current study have encoded different features. The main 
features and their importance are listed in Table  3.1below:  
Table 3.1: Main features of newly constructed plasmids 
CMV The immediate early cytomegalovirus promoter is widely used to obtain 
stable, reliable and high level expression of transgenes in mammalian cells 
(Williams et al., 2005).  
SFFV The Spleen focus-forming virus LTR promoter is commonly used for 
sustained and long term expression in hematopoietic cells (Linemeyer et 
al., 1982). 
cPPT/ 
cTS 
cPPT/cTS: central polypurine tract/central termination sequence, during 
reverse transcription and synthesis of the second strand of DNA; only part 
of the initial RNA (cPPT) remains bound to the first DNA strand. The 
cPPT serves as a primer for the extension of the second strand, and allows 
reverse transcription to switch strand synthesis. (Follenzi et al., 2000). 
Gag Gag proteins comprise the encapsidation signal which is essential for the 
assembly of viral particles to provide viral basic physical infrastructure. 
PBS Primer-binding site, will act as a primer, binds to the cellular tRNA during 
the process of reverse transcription (Wakefield et al., 1996).  
RRE Rev responsive element is the binding site for the Rev protein, which 
facilitates export of the mRNA from the nucleus in response to the Rev 
protein expression (Fankhauser et al., 1991).  
RU5 and 
3’dLTR 
RU5 is a modified viral 5’dLTR containing the repeated R sequence and 
unique 5’ (U5) region. Whereas  3’dLTR contains the unique 3’ (U3) 
region in addition to a second copy of the 5’R region (Naldini et al., 1996).  
SV40 Simian virus-40 promoter/enhancer allows plasmid replication in cells that 
express T antigen. 
WPRE WPRE: Woodchuck hepatitis virus post-transcriptional regulatory element, 
its presence enhances a homogeneous length of mRNA polyA leading to 
improve nuclear export of mRNA which ultimately result in  increase both  
lentiviral vectors titer and expression (Schambach et al., 2006; Zanta-
Boussif et al., 2009). 
ZFN1 Zinc finger nuclease obligatory heterodimer 1 encoding for triple FLAG-
NLS-17373-FokKK domain. 
ZFN2 Zinc finger nuclease obligatory heterodimer 2 encoding for triple FLAG-
NLS-N2A-17834-FokEL2 domain. 
 
107 
 
3.1.1 Cloning of wt Prkdc long homologous template  
3.1.1.1 Construction of pCCLsc PrkdcHindBsaWIF  
The pCCLsc PrkdcHindBsaWIF plasmid was designed to encode the mouse Prkdc wt 
long corrective template with a unique site of BsaWI that was introduced by site 
directed mutagenesis previously in Dr. Yáñez’s laboratory. The genetic maps of the 
recipient transfer plasmid (pCCLsc ISce-IT), mouse wt template donor plasmid 
(pPrkdcHindBsaWI), and the new construct (pCCLsc PrkdcHindBsaWIF) are shown in 
Figure  3.1. The cloning was done by digesting pPrkdcHindBsaWI with XhoI and the 
resulting linear DNA was digested then with XmaI. The fragment of 5’ 
XmaI_PrkdcHindBsaWI_ XhoI 3’ (7389bp) was retrieved from a preparative gel and 
cloned into the vector pCCLsc ISce-IT, which was digested before using AgeI and SalI. 
The generated plasmid 13388 bp was verified by characteristic restriction using XmnI 
generating fragment sizes of 4600, 3235, 2959 and 2294 bp; and ScaI generating 
fragment sizes of 6760, 5596, and 1032 bp. 
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Figure 3.1: Construction and characterisation of pCCLsc PrkdcHindBsaWIF. (A), 
(B) and (C) show genetic maps of pCCLsc ISce-IT, pPrkdcHindBsaWI and pCCLsc 
PrkdcHindBsaWIF, respectively. (D) Restriction endonuclease analysis of generated 
pCCLsc PrkdcHindBsaWIF (13388 bp) construct on 0.7% agarose gel. Lane 1 
undigested product, lane 2 digestion with XmnI generating fragments of 4600, 3235, 
2959 and 2294 bp, and lane 3 digestion with ScaI generating fragments of 6760, 5596, 
and 1032 bp. DNA ladder: 5 µl of NEB 1 Kb. (E) A general schematic of pCCLsc 
PrkdcHindBsaWIF construct.  
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3.1.1.2 Construction of pCCLsc PrkdcHindBsaWIR  
The genetic maps of recipient transfer plasmid (pCCLsc ISce-IT), mouse wt template 
donor plasmid (pPrkdcHindBsaWI), and the new construct 
(pCCLscPrkdcHindBsaWIR) are shown in Figure  3.2. As in section  3.1.1.1 this plasmid 
was also designed to encode the mouse wt long homologous template containing a 
unique mutated site of BsaWI, but in the reverse orientation. The cloning was done by 
double digestion of pPrkdcHindBsaWI with XhoI and XmaI. The fragment of 5’ 
XmaI_PrkdcHindBsaWI_Xho I 3’ (7389bp) was retrieved from a preparative gel and 
cloned into the vector pCCL s c ISce-IT, which was previously digested with AgeI and 
then XhoI. The generated plasmid 13388 bp was verified by characteristic restriction 
using XmnI generating fragment sizes of 4600, 3916, 2959 and 1913 bp and ScaI 
generating fragments sizes 9100, 3256 and 1032 bp. 
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Figure 3.2: Construction and characterisation of pCCLsc PrkdcHindBsaWIR. (A), 
(B) and (C) show genetic maps of pCCLsc ISce-IT, pPrkdcHindBsaWI and pCCLsc 
PrkdcHindBsaWIR, respectively. (D) Restriction endonuclease analysis of generated 
pCCLsc PrkdcHindBsaWIR (13388 bp) construct on 0.7% agarose gel. Lane 1 
undigested product, lane 2 digestion with XmnI generating fragments of 4600, 3916, 
2959 and 1913 bp, and lane 3 digestion with ScaI generating fragments of 9100, 3256 
and 1032 bp. DNA ladder: 5 µl of NEB 1 Kb. (E) A schematic of pCCLsc 
PrkdcHindBsaWIR construct. 
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3.1.2 Cloning of ZFNs  
Three versions of Prkdc ZFNs were designed by Sangamo; the first was a first-screen 
product with monomers including wild-type FokI domains which allow 
homodimerisation; the second and third versions included second-screen zinc-finger 
binding domains, linked to either wild-type or obligatory heterodimer FokI domains. 
For all cloning strategies mentioned below, only the third version with obligatory 
heterodimeric ZFN monomers was used. 
3.1.2.1 Construction of pRRLsc_C_3FN-17373-FokKK_W 
This plasmid was designed to encode the first ZFN obligatory heterodimer monomer 
(ZFN1). The genetic maps of the recipient transfer plasmid (pRRLsc_C_W), the ZFN1 
donor plasmid (pVAX-3FN-17373-FokKK), and the new construct (pRRLsc_C_3FN-
17373-FokKK_W) are shown in Figure  3.3. The construction of lentiviral transfer 
plasmid expressing ZFN1 under the control of CMV promoter was completed as 
follows: pVAX-3FN-17373-FokKK was digested with EcoRI, subjected to Klenow 
treatment for end-filling, and then digested using XhoI. The 5’ EcoRI_3FN-17373-
FokKK_XhoI 3’ (1164 bp) fragment was retrieved from a preparative gel and cloned 
into the vector pRRLsc_C_W, which was previously digested with SalI and EcoRV. 
The generated plasmid (7889 bp) was verified by characteristic restriction using XbaI 
generating a single fragment of 7889 bp, AflII generating fragments of 4235 and 3654 
bp and NcoI generating fragments of 5225, 1911 and 753 bp. 
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Figure 3.3: Construction and characterisation of pRRLsc_C_3FN-17373-
FokKK_W.  (A), (B) and (C) show genetic maps of pRRLsc_C_W, pVAX-3FN-
17373-FokKK and pRRLsc_C_3FN-17373-FokKK_W, respectively. (d) Restriction 
endonuclease analysis of generated pRRLsc_C_3FN-17373-FokKK_W (7889 bp) 
construct on 0.7% agarose gel. Lane 1 undigested product, lane 2 digestion with XbaI 
generating fragment size of 7889 bp, lane 3 digestion with AflII generating fragment 
sizes of 4235 and 3654 bp and lane 4 digestion with NcoI generating fragment sizes of 
5225, 1911 and 753 bp. DNA ladder: 5 µl of NEB I Kb. (E) Depicts a general schematic 
of pRRLsc_C_3FN-17373-FokKK_W construct.  
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3.1.2.2 Construction of pRRLsc_C_N2A-3FN-17834-FokEL2_W 
This plasmid was designed to encode the second ZFN heterodimeric monomer (ZFN2). 
The genetic maps of the recipient transfer plasmid (pRRLsc_C_W), ZFN2 donor 
plasmid (pVAX- N2A-3FN-17834-FokEL2), and the new construct (pRRLsc_C_N2A-
3FN-17834-FokEL2_W) are shown in Figure  3.4. The construction of a lentiviral 
transfer plasmid expressing ZFN2 under the control of CMV promoter was completed 
as follows: pVAX- N2A-3FN-17834-FokEL2 was digested by EcoRI, then treated with 
Klenow fragment for end-filling, later was digested using XhoI. The 5’ EcoRI_N2A-
3FN-17834-FokEL2_XhoI 3’ (1065bp) fragment was retrieved from preparative gel and 
cloned into the vector pRRLsc_C_W, which was previously digested with SalI and 
EcoRV. The generated plasmid (7790 bp) was verified by characteristic restriction using 
XbaI generating fragment size of 7790 bp, KpnI generating fragment sizes of 6202 
and1588 bp and NcoI generating fragment sizes of 5225bp, 1501, 753 and 311 bp. 
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Figure 3.4: Construction and characterisation of pRRLsc_C_N2A-3FN-17834-
FokEL2_W. (A), (B) and (C) show genetic maps of pRRLsc_C_W, pVAX- N2A-3FN-
17834-FokEL2 and pRRLsc_C_N2A-3FN-17834-FokEL2_W, respectively. (D) 
Restriction endonuclease analysis of generated pRRLsc_C_N2A-3FN-17834-
FokEL2_W (7790 bp) construct on 0.7% agarose gel. Lane 1 undigested product, lane 2 
digestion with XbaI generating fragment size of 7790 bp, lane 3 digestion with KpnI 
generating fragment sizes of 6202 and1588 bp and lane 4 digestion with NcoI 
generating fragment sizes of 5225bp, 1501, 753 and 311 bp. DNA ladder: 5 µl of NEB I 
Kb. (E) A general schematic of pRRLsc_C_N2A-3FN-17834-FokEL2_W construct.  
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3.1.2.3 Construction of pCCLsc_S_3FN-17373-FokKK_W 
Here the aim was to construct a plasmid encoding one of the two ZFN heterodimerising 
monomers (ZFN1) under the control of SFFV promoter. The genetic maps of the 
recipient transfer plasmid (pCCLsc_S_W), ZFN1 donor plasmid (pVAX-3FN-17373-
FokKK), and the new construct (pCCLsc_S_3FN-17373-FokKK_W) are shown in 
Figure 3.5. The construction of the lentiviral transfer plasmid expressing ZFN1 was 
completed as follows: pVAX-3FN-17373-FokKK was digested with EcoRI, ends were 
filled with Klenow, and then digested using XhoI. The 5’ EcoRI_ 3FN-17373-
FokKK_XhoI 3’ 1164bp fragment was retrieved from a preparative gel and cloned into 
the vector pCCLsc_S_W, which was previously digested with AgeI, treated with 
Klenow for end filling and then digested with SalI. The generated plasmid (8248 bp) 
was verified by characteristic restriction using SpeI, generating a fragment of 8248 bp, 
EcoRI generating fragment sizes of 5934, 1791 and 523 bp, AflII generating fragment 
sizes of 4097, 2191 and 1960 bp and NcoI generating fragment sizes of 4054, 3441 and 
753 bp. 
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Figure 3.5: Construction and characterisation of pCCLsc_S_3FN-17373-
FokKK_W. (A), (B) and (C) show genetic maps of pCCLsc_S_W, pVAX-3FN-17373-
FokKK and pCCLsc_S_3FN-17373-FokKK_W, respectively. (D) Restriction 
endonuclease analysis of generated pCCLsc_S_3FN-17373-FokKK_W (8248 bp) 
construct on 0.7% agarose gel. Lane 1 undigested product, lane 2 digestion with SpeI 
generating a fragment 8248bp, lane 3 digestion EcoRI generating fragment sizes of 
5934, 1791 and 523 bp, lane 4 digestion with AflII generating fragment sizes of 4097, 
2191 and 1960 bp and lane 5 NcoI generating fragment sizes of 4054, 3441 and 753 bp. 
DNA ladder: 5 µl of Bioline Hyperladder I. (E) A general schematic of 
pCCLsc_S_3FN-17373-FokKK_W construct.  
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3.1.2.4 Construction of pCCLsc_S _N2A-3FN-17834-FokEL2_W 
This plasmid was designed to encode the other ZFN heterodimeric monomer (ZFN2) 
under the control of the SFFV promoter. The genetic maps of the recipient transfer 
plasmid (pCCLsc_S_W), ZFN2 donor plasmid (pVAX- N2A-3FN-17834-FokEL2), and 
the new construct (pCCLsc_S_N2A-3FN-17834-FokEL2_W) are all shown in Figure 
 3.6. The construction of lentiviral transfer plasmid expressing ZFN2 driven by SFFV 
promoter was done as follows: pVAX- N2A-3FN-17834-FokEL2 was digested by 
EcoRI, the ends were filled using Klenow, then digested using XhoI. The 5’ 
EcoRI_N2A-3FN-17834-FokEL2_XhoI 3’ (1065bp) fragment was retrieved from 
preparative gel and cloned into the vector pCCLsc_S_W, which was previously 
digested with AgeI, treated Klenow for end filling and then digested with SalI. The 
generated plasmid (8149 bp) was verified by characteristic restriction using SpeI 
generating fragment size of 8149 bp, NheI generating fragment sizes of 6625 and 1524 
bp, AflII generating fragment sizes of 4097, 20924 and 1960 bp and NcoI generating 
fragment sizes of 3441, 2454, 1501 and 753 bp. 
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Figure 3.6: Construction and characterisation of pCCLsc_S_N2A-3FN-17834-
FokEL2_W. (A), (B) and (C) show genetic maps of pCCLsc_S_W, pVAX-N2A-3FN-
17834-FokEL2 and pCCLsc_S_N2A-3FN-17834-FokEL2_W, respectively. (D) 
Restriction endonuclease analysis of generated pCCLsc_S_N2A-3FN-17834-
FokEL2_W (8149 bp) construct on 0.7% agarose gel. Lane 1 undigested product, lane 2 
digestion with SpeI generating fragment size of 8149 bp, lane 3 digestion NheI 
generating fragment sizes of 6625 and 1524 bp, lane 4 digestion with NcoI generating 
fragment sizes of 3441, 2454, 1501 and 753 bp and lane 5 AflII generating fragment 
sizes of 4097, 20924, and 1960 bp. DNA ladder: 5 µl of Bioline Hyperladder I. (E) A 
schematic of the pCCLsc_S_N2A-3FN-17834-FokEL2_W construct.  
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3.1.2.5 Construction of pVAX-3FN-17834-FokEL2-3FN-17373-FokKK 
For the main gene repair experiment, it is preferred to reduce the number of lentiviral 
vectors that co-transduce the targeted cells. In this regard, the expression of both ZFN 
monomers from one construct (with incorporation of a N2A self-processing polyprotein 
signal that allows monomers separation) would be better than express them from two 
different constructs. This construct was designed to be an intermediate plasmid 
encoding both ZFNs heterodimers (ZFN1+ZFN2) in a pVAX backbone which was then 
cloned into the lentiviral backbone. The genetic maps of recipient (ZFN1) transfer 
plasmid (pVAX-3FN-17373-FokKK), ZFN2 donor plasmid (pVAX- N2A-3FN-17834-
FokEL2) and the new construct (pVAX-3FN-17834-FokEL2-3FN-17373-FokKK) are 
all shown in Figure  3.7. The construction of intermediate plasmid expressing both 
ZFN1 and ZFN2 was done as follows: pVAX-3FN-17373-FokKK was digested with 
BglII and XhoI; then the fragment of 5’-BglII-3Flag-NLs-17373-FokKK-XhoI-3’ 
(ZFN1) of 1152 bp was retrieved from preparative gel and cloned into the plasmid 
pVAX- N2A-3FN-17834-FokEL2  (ZFN2) that was previously digested with BglII and 
XhoI. The generated plasmid (5157 bp) was verified by characteristic restriction using 
XhoI generating fragment size of 5157 bp, BamHI generating fragment sizes of 4011 
and 1146 bp, and NcoI generating fragment sizes of 3198, 16246 and 335bp bp. 
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Figure 3.7: Construction and characterisation of pVAX-3FN-17834-FokEL2-3FN-
17373-FokKK. (A), (B) and (C) show genetic maps of pVAX-3FN-17373-FokKK, 
pVAX- N2A-3FN-17834-FokEL2 and pVAX-3FN-17834-FokEL2-3FN-17373-
FokKK, respectively. (D) Restriction endonuclease analysis of generated pVAX-3FN-
17834-FokEL2-3FN-17373-FokKK (5157 bp) construct on 0.7% agarose gel. Lane 1 
undigested product,  lane 2 digestion with XhoI generating fragment size of 5157 bp, 
lane 3 digestion BamHI generating fragment sizes of 4011 and 1146 bp and lane 4 
digestion with NcoI generating fragment sizes of 3198, 16246 and 335bp bp. DNA 
ladder: 5 µl of Bioline Hyperladder I. (E) Depicts a schematic diagram of pVAX-3FN-
17834-FokEL2-3FN-17373-FokKK construct.  
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3.1.2.6 Construction of pRRLsc_C_3FN-17834-FokEL2-3FN-17373-FokKK_W 
This plasmid was constructed to allow expression of ZFN1 and ZFN2 heterodimers 
simultaneously from the same RRL backbone under the control of the CMV promoter. 
Figure 3.8 below shows the genetic maps of the recipient transfer plasmid 
(pRRLsc_C_W), ZFN1 and ZFN2 donor plasmids (pVAX-3FN-17834-FokEL2-3FN-
17373-FokKK) and the new construct (pRRLsc_C_3FN-17834-FokEL2-3FN-17373-
FokKK_W). The construction of lentiviral transfer plasmid expressing both ZFN1 and 
ZFN2 was done as follows: pVAX-3FN-17834-FokEL2-3FN-17373-FokKK was 
digested by EcoRI, subjected to Klenow treatment for end-filling, and then digested 
using XhoI. The 5’ EcoRI_3FN-17834-FokEL2-3FN-17373-FokKK_XhoI 3’ (2205 bp) 
fragment was retrieved from a preparative gel and cloned into the plasmid 
pRRLsc_C_W previously digested with SalI and EcoRV. The generated plasmid (8930 
bp) was verified by characteristic restriction using AgeI generating fragment size of 
8930 bp, AflII generating fragment sizes of 5276 and 3654 bp, BamHI generating 
fragment sizes of 7306, 1146 and 478 bp and NcoI generating fragment sizes of 5225, 
2641,753 and 311 bp. 
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Figure3.8: Construction and characterisation of pRRLsc_C_3FN-17834-FokEL2-
3FN-17373-FokKK_W. (A), (B) and (C) show genetic maps of (pRRLsc_C_W), 
(pVAX-3FN-17834-FokEL2-3FN-17373-FokKK) and (pRRLsc_C_3FN-17834-
FokEL2-3FN-17373-FokKK_W); respectively. (D) Restriction endonuclease analysis of 
generated pRRLsc_C_3FN-17834-FokEL2-3FN-17373-FokKK_W (8930 bp) construct 
on 0.7% agarose gel. Lane 1 undigested product, lane 2 digestion with AgeI generating 
fragment size of 8930 bp, lane 3 digestion with AflII generating fragment sizes of 5276 
and 3654 bp, lane 4 digestion with BamHI generating fragment sizes of 7306, 1146 and 
478 bp and lane 5 digestion with NcoI generating fragment sizes of 5225, 2641,753 and 
311 bp. DNA ladder: 5 µl of Bioline Hyperladder I. (E) Depicts a schematic diagram of 
the pRRLsc_C_3FN-17834-FokEL2-3FN-17373-FokKK_W construct.  
123 
 
3.1.2.7 Construction of pCCLsc_S_3FN-17834-FokEL2-3FN-17373-FokKK_W 
This plasmid was constructed to express ZFN1 and ZFN2 heterodimers simultaneously 
from same CCL backbone under the control of SFFV promoter. Figure 3.9 below shows 
the genetic maps of the recipient transfer plasmid (pCCLsc_S_W), ZFN1 and ZFN2 
donor plasmids (pVAX-3FN-17834-FokEL2-3FN-17373-FokKK) and the new 
construct (pCCLsc_S_3FN-17834-FokEL2-3FN-17373-FokKK_W). The construction 
of lentiviral transfer plasmid expressing both ZFN1 and ZFN2 was done as follows: 
pVAX-3FN-17834-FokEL2-3FN-17373-FokKK was digested with EcoRI, subjected to 
Klenow treatment for end-filling, and then digested using XhoI. The 5’ EcoRI_3FN-
17834-FokEL2-3FN-17373-FokKK_XhoI 3’ (2205 bp) fragment was retrieved from a 
preparative gel and cloned into the plasmid pCCLsc_S_W previously digested with 
AgeI then treated with Klenow and finally digested with SalI. The generated plasmid 
(9289 bp) was verified by characteristic restriction using SpeI generating fragment size 
of 9289 bp, PvuI generating fragment sizes of 8238 and 1051 bp, BamHI generating 
fragment sizes of 7669, 1146 and 474 bp and NcoI generating fragment sizes of 3441, 
2641, 2454 and 753 bp. 
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Figure 3.9: Construction and characterisation of pCCLsc_S_3FN-17834-FokEL2-
3FN-17373-FokKK_W. (A), (B) and (C) show genetic maps of (pCCLsc_S_W), 
(pVAX-3FN-17834-FokEL2-3FN-17373-FokKK) and (pCCLsc_S_3FN-17834-
FokEL2-3FN-17373-FokKK_W); respectively. (D) Restriction endonuclease analysis of 
generated pCCLsc_S_3FN-17834-FokEL2-3FN-17373-FokKK_W (9289 bp) construct 
on 0.7% agarose gel.  Lane 1 undigested product, lane 2 digestion with SpeI generating 
fragment size of 9289 bp, lane 3 digestion with PvuI generating fragment sizes of 8238 
and 1051 bp, lane 4 digestion with BamHI generating fragment sizes of 7669, 1146 and 
474 bp and lane 5 digestion with NcoI generating fragment sizes of 3441, 2641, 2454 
and 753 bp. DNA ladder: 5 µl of Bioline Hyperladder I. (E) Depicts a general schematic 
diagram of the pCCLsc_S_3FN-17834-FokEL2-3FN-17373-FokKK_W construct.  
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3.1.3 ZFN expression from ZFN constructs  
All ZFNs used in the work presented here were FLAG-tagged. Epitope tagging for 
antibody binding is a very useful technique to detect the expression (or over-expression) 
of a specific protein by immunoblotting assay (Western blotting). In order to verify 
expression of ZFN cassettes constructs, BALB/c 3T3 scid mTert fibroblasts were 
transfected with ZFN plasmids using the calcium phosphate coprecipitation protocol 
(section 2.2.5) followed by Western blotting analysis as previously described earlier 
using the ECL method (section 2.2.6.6.1). 
Here only plasmids encoding the second and third version of ZFN monomers were used 
to confirm ZFN expression. The results are shown below in Figure 3.10. Three ZFN 
plasmid sets were used; the first consisted of ZFNs as pVAX constructs, and the other 
two sets consisted of ZFNs as pCCL and pRRL-cloned constructs. In all sets there were 
two different ZFN monomers (ZFN1 or ZFN2) which have different molecular masses; 
ZFN1 is 42 kDa and ZFN2 is 38.5 kDa. For the two obligate heterodimeric ZFNs in 
dimeric constructs it is expected to notice 42 and 38.5 kDa proteins, but if they do not 
separate from each other by N2A self-processing polyprotein signal, the molecular 
masses would be 80.5 kDa. As expected, Western blot analysis revealed efficient 
expression from all the constructs in the ZFN pVAX and from most of the ZFN pCCL 
and pRRL cloned constructs. However, the dimeric constructs encoding for obligatory 
heterodimeric ZFN1 and ZFN2 together did not show expected expression of 42 and 
38.5 kDa proteins, which could be attributed to lack of a N2A self-processing 
polyprotein signal that helps to separate different protein coding sequences in a single 
open reading frame (ORF) transcription unit (Tang et al., 2009). These findings led to 
the conclusion that the dimeric constructs were not suitable for further experimentation. 
All the results were normalised to α-tubulin (49 kDa), detected with a separate antibody 
and used as a loading control.  
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Figure 3.10: Confirmation of FLAG-tagged ZFN monomer expression from ZFN 
constructs in BALB/c 3T3 scid mTert fibroblasts by Western blotting. BALB/c 3T3 
scid mTert fibroblasts were transfected with plasmid constructs by calcium phosphate 
coprecipitation. Western blotting was completed by ECL protocol. Efficient ZFN 
expression was detected in all monomeric constructs but not dimeric ones. (A) 
Expression from original pVAX constructs. Lanes: 1: Mock, 2: pVAX-3FN-17373-
FokKK (ZFN1 obligate heterodimer), 3: pVAX-N2A-3FN-17373-Fok (ZFN1 version 
2), 4: pVAX-N2A-3FN-17834-FokEL2 (ZFN2 obligate heterodimer), 5: pVAX-N2A-
3FN-17834-Fok. (ZFN2 version 2). (B) Expression from generated constructs. Lanes: 1: 
Mock, 2: pRRLsc_C_3FN-17373-FokKK_W, 3: pRRLsc_C_N2A-3FN-17834-
FokEL2_W, 4: pCCLsc_S_3FN-17373-FokKK_W, 5: pCCLsc_S_N2A-3FN-17834-
FokEL2_W, 6: pRRLsc_C_3FN-17834-FokEL2-3FN-17373-FokKK_W, 7: 
pCCLsc_S_3FN-17834-FokEL2-3FN-17373-FokKK_W. Lower panel is detection of 
mouse α-tubulin (49 kDa) as loading control.  
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3.1.4 Cloning of Prkdc short homologous template constructs 
The plasmid pPrkdcHindBsaWI was used as a template for PCR amplification of the 
homologous short Prkdc-BsaWI corrective template (of 1626 bp) in order to investigate 
homologous recombination events in targeted cells as described earlier in section 
2.2.12. This shorter template allows for inclusion of a ZFN monomer gene in the same 
lentiviral backbone. The generated short Prkdc template was used to construct new self-
inactivating lentiviral vectors encoding for either Prkdc template alone or ZFN 
monomers (driven by either CMV or SFFV promoters) and Prkdc template together. 
The short template was cloned upstream of either promoter and in reverse orientation 
and contained a diagnostic BsaWI restriction site created by site-directed mutagenesis. 
This part of work was done in collaboration with Dr. Céline Rocca at RHUL.  
 
3.1.4.1 Construction of pRRLsc_C_3FN-17373-FokKK_W-SanDI-Prkdc 
This plasmid was constructed to encode both CMV driven-ZFN1 and short Prkdc 
corrective template from the same lentiviral construct. The genetic maps of the recipient 
CMV driven-ZFN1 plasmid (pRRLsc_C_3FN-17373-FokKK_W), plasmid used as a 
PCR template (pPrkdcHindBsaWI), and the new construct (pRRLsc_C_3FN-17373-
FokKK_W-SanDI-Prkdc) are all shown in Figure  3.11. The construction of lentivector 
transfer plasmid expressing ZFN1 heterodimer driven by CMV promoter and Prkdc 
short template was completed as follows: PCR amplification was done as described in 
(section 2.2.12) using pPrkdcHindBsaWI generating a Prkdc short template which was 
then digested with SanDI. Next, the PCR amplicon of 1626 bp was cloned into 
pRRLsc_C_3FN-17373-FokKK_W previously digested with SanDI. A plasmid clone in 
which the Prkdc template had inserted in the reverse orientation was selected. The 
generated plasmid 9514 bp was verified by characteristic restriction digest using SpeI, 
generating a fragment of 9514 bp, and EcoRI generating fragments consisting of 5517 
and 3997 bp; whereas NcoI generated fragments of 6850, 1911 and 753 bp. 
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Figure 3.11: Construction and characterisation of pRRLsc_C_3FN-17373-
FokKK_W-SanDI-Prkdc. (A), (B) and (C) show genetic maps of (pRRLsc_C_3FN-
17373-FokKK_W), (pPrkdcHindBsaWI) and (pRRLsc_C_3FN-17373-FokKK_W-
SanDI-Prkdc); respectively. (D) Restriction endonuclease analysis of generated 
pRRLsc_C_3FN-17373-FokKK_W-SanDI-Prkdc (9514 bp) construct on 0.7% agarose 
gel.  Lane 1 undigested product, lane 2 digestion with SpeI generating fragment size of 
9514 bp, lane 3 digestion with EcoRI generating fragment sizes of 5517 and 3997 bp, 
lane 4 digestion with NcoI generating fragment sizes of 6850, 1911 and 753. DNA 
ladder: 5 µl of Bioline Hyperladder I. (E) Depicts a general schematic diagram of 
pRRLsc_C_3FN-17373-FokKK_W-SanDI-Prkdc construct.  
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3.1.4.2 Construction of pRRLsc_C_N2A-3FN-17834-FokEL2_W-SanDI-Prkdc 
This plasmid was constructed to encode both the CMV driven ZFN2 and the short 
Prkdc corrective template in the same lentiviral construct. The genetic maps of recipient 
CMV driven-ZFN2 plasmid (pRRLsc_C_N2A-3FN-17834-FokEL2_W), the plasmid 
used as a PCR template (pPrkdcHindBsaWI), and the new construct (pRRLsc_C_N2A-
3FN-17834-FokEL2_W-SanDI-Prkdc) are all shown in Figure 3.12. The construction of 
the lentiviral transfer plasmid expressing ZFN2 heterodimer driven by CMV promoter 
and Prkdc short template was completed as follows: PCR amplification was done as 
described in section 2.2.12 using pPrkdcHindBsaWI as a template, generating Prkdc 
short template which was then digested with SanDI. Next, the PCR amplicon of 1626 
bp was cloned into pRRLsc_C_N2A-3FN-17834-FokEL2_W which has been 
previously digested with SanDI. A plasmid clone in which the Prkdc template had 
inserted in the reverse orientation was selected. The generated plasmid (9415 bp) was 
verified by characteristic restriction using SpeI generating fragment size of 9415 bp, 
EcoRI generating fragment sizes of 5517 and 3898 bp and NcoI generating fragment 
sizes of 6850, 1501, 753 and 311 bp.  
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Figure 3.12: Construction and characterisation of pRRLsc_C_N2A-3FN-17834-
FokEL2_W-SanDI-Prkdc. (A), (B) and (C) show genetic maps of (pRRLsc_C_N2A-
3FN-17834-FokEL2_W), (pPrkdcHindBsaWI) and (pRRLsc_C_N2A-3FN-17834-
FokEL2_W-SanDI-Prkdc); respectively. (D) Restriction endonuclease analysis of 
generated pRRLsc_C_N2A-3FN-17834-FokEL2_W-SanDI-Prkdc (9415 bp) construct 
on 0.7% agarose gel. Lane 1 undigested product, lane 2 digestion with SpeI generating 
fragment size of 9415 bp, lane 3 digestion with EcoRI generating fragment sizes of 
5517 and 3898 bp, lane 4 digestion with NcoI generating fragment sizes of 6850, 1501, 
753 and 311. DNA ladder: 5 µl of Bioline Hyperladder I. (E) Depicts a general 
schematic of pRRLsc_C_N2A-3FN-17834-FokEL2_W-SanDI-Prkdc construct.  
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3.1.4.3 Construction of pCCLsc_S_3FN-17373-FokKK_W-SanDI-Prkdc 
Here the aim was to clone both SFFV driven-ZFN1 heterodimer and short Prkdc 
corrective template into the same lentiviral construct. The genetic maps of the recipient 
SFFV-driven ZFN1 plasmid (pCCLsc_S_3FN-17373-FokKK_W), the plasmid used as 
a PCR template (pPrkdcHindBsaWI), and the new construct (pCCLsc_S_3FN-17373-
FokKK_W-SanDI-Prkdc) are all shown in Figure 3.13. The construction of lentiviral 
transfer plasmid expressing ZFN1 heterodimer driven by a SFFV promoter and Prkdc 
short template was completed as follows: PCR amplification was carried out as 
described in section 2.2.12.1 using pPrkdcHindBsaWI generating Prkdc short template 
which was then digested with SanDI. Next, the PCR amplicon of 1626 bp was cloned 
into pCCLsc_S_3FN-17373-FokKK_W previously digested with SanDI. A plasmid 
clone in which the Prkdc template had inserted in the reverse orientation was selected. 
The generated plasmid (9872 bp) was verified by characteristic restriction using NotI 
generating fragment size of 9872 bp, SpeI generating fragment sizes of 7151 and 2721 
bp, NcoI generating fragment sizes of 5678, 3441 and 753 bp and EcoRI generating 
fragment sizes of 5960, 1791, 1598 and 523 bp. 
 
 
 
 
 
 
 
 
 
 
 
132 
 
 
Figure 3.13: Construction and characterisation of pCCLsc_S_3FN-17373-
FokKK_W-SanDI-Prkdc. (A), (B) and (C) show genetic maps of (pCCLsc_S_3FN-
17373-FokKK_W), (pPrkdcHindBsaWI) and (pCCLsc_S_3FN-17373-FokKK_W-
SanDI-Prkdc); respectively. (D) Restriction endonuclease analysis of generated 
pCCLsc_S_3FN-17373-FokKK_W-SanDI-Prkdc (9872 bp) construct on 0.7% agarose 
gel.  Lane 1 undigested product, lane 2 digestion with NotI generating fragment size of 
(9872) bp, lane 3 digestion with SpeI generating fragment sizes of 7151 and 2721 bp, 
lane 4 digestion with NcoI generating fragment sizes of 5678, 3441 and 753 bp and lane 
5 digestion with EcoRI generating fragment sizes of 5960, 1791, 1598 and 523 bp.DNA 
ladder: 5 µl of Bioline Hyperladder I. (E) Depicts a schematic diagram of the 
pCCLsc_S_3FN-17373-FokKK_W-SanDI-Prkdc construct.  
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3.1.4.4 Construction of pCCLsc_S _N2A-3FN-17834-FokEL2_W-SanDI-Prkdc 
This plasmid constructed to encode both the SFFV-driven ZFN2 heterodimeric 
monomer and the short Prkdc corrective template in the same lentiviral construct. The 
genetic maps of the recipient SFFV-driven ZFN2 plasmid (pCCLsc_S_N2A-3FN-
17834-FokEL2_W), plasmid used as a PCR template (pPrkdcHindBsaWI), and the new 
construct (pCCLsc_S _N2A-3FN-17834-FokEL2_W-SanDI-Prkdc) are shown in 
Figure 3.14. The construction of lentiviral transfer plasmid expressing ZFN2 
heterodimer driven by the SFFV promoter and Prkdc short template was completed as 
follows: PCR amplification was done as described in section 2.2.12 using 
pPrkdcHindBsaWI, generating Prkdc short template which was then digested with 
SanDI. Next, the PCR amplicon of 1626 bp was ligated into pCCLsc_S_N2A-3FN-
17834-FokEL2_W previously digested with SanDI. A plasmid clone in which the Prkdc 
template had inserted in the reverse orientation was selected. The generated plasmid 
(9774 bp) was verified by characteristic restriction using NotI generating fragment size 
of 9774 bp, SpeI generating fragment sizes of 7053 and 2721 bp, NcoI generating 
fragment sizes of 4079, 3441, 1501 and 753 bp and EcoRI generating fragment sizes of 
4079, 3441, 1501 and 753 bp. 
 
 
 
 
 
 
 
134 
 
 
Figure 3.14: Construction and characterisation pCCLsc_S _N2A-3FN-17834-
FokEL2_W-SanDI-Prkdc. (A), (B) and (C) show genetic maps of (pRRLsc_C_N2A-
3FN-17834-FokEL2_W), (pPrkdcHindBsaWI) and (pCCLsc_S_N2A-3FN-17834-
FokEL2_W-SanDI-Prkdc); respectively. (D) Restriction endonuclease analysis of 
generated pCCLsc_S _N2A-3FN-17834-FokEL2_W-SanDI-Prkdc (9774 bp) construct 
on 0.7% agarose gel.  Lane 1: undigested product, lane 2 digestion with NotI generating 
fragment size of 9774 bp, lane 3 digestion with SpeI generating fragment sizes of 7053 
and 2721 bp, lane 4 digestion with NcoI generating fragment sizes of 4079, 3441, 1501 
and 753 bp and lane 5 digestion with EcoRI generating fragment sizes of 4079, 3441, 
1501 and 753 bp. DNA ladder: 5 µl of Bioline Hyperladder I. (E) A schematic of 
pCCLsc_S _N2A-3FN-17834-FokEL2_W-SanDI-Prkdc construct.  
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3.1.4.5 Construction of pCCLsc-SanDI-Prkdc 
This construct was designed to only contain the Prkdc template. The genetic maps of 
the donor plasmid (pCCLsc_S_3FN-17373-FokKK_W-SanDI-Prkdc) and the new 
construct (pCCLsc-SanDI-Prkdc) are shown in Figure 3.15. The construction of the 
lentiviral transfer plasmid expressing only the Prkdc short template was completed as 
follows: the construct pCCLsc_S_3FN-17373-FokKK_W-SanDI-Prkdc was double 
digested with EcoRV and KpnI, then the largest fragment (7538 bp) was purified and 
self-ligated, generating the pCCLsc-SanDI-Prkdc construct. The generated plasmid 
7539 bp was verified by characteristic restriction using NcoI generating fragment sizes 
of 4098 and 3441 bp and SpeI generating fragment sizes of 4818 and 2721 bp.  
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Figure 3.15: Construction and characterisation of pCCLsc-SanDI-Prkdc. (A) and 
(B) show genetic maps of (pCCLsc_S_3FN-17373-FokKK_W-SanDI-Prkdc) and 
(pCCLsc-SanDI-Prkdc); respectively. (D) Restriction endonuclease analysis of 
generated pCCLsc-SanDI-Prkdc (7539 bp) construct on 0.7% agarose gel. Lane 1: 
undigested product, lane 2: digestion with NcoI generating fragment sizes of 4098 and 
3441 bp and lane 3: digestion with SpeI generating fragment sizes of 4818 and 2721 bp. 
DNA ladder: 5 µl of Bioline Hyperladder I. (E) A schematic of the pCCLsc-SanDI-
Prkdc construct.  
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3.1.5 ZFN expression from ZFN-Prkdc short homologous template constructs 
Lentiviral ZFN constructs that were generated in section  3.1.2 , were used again to 
clone the wt short Prkdc template upstream of both CMV & SFFV promoters and in 
reverse orientation (see section  3.1.4). Importantly all the original features were kept 
intact, including the FLAG-tag. Aiming to detect ZFN expression from ZFN-Prkdc 
short homologous template constructs, BALB/c 3T3 scid mTert fibroblasts were 
transfected with ZFN plasmids using the calcium phosphate coprecipitation method 
(section 2.2.5) followed by Western blotting analysis as previously described (section 
2.2.6.6.2). The results are shown below in Figure 3.16. Efficient expression from all 
constructs encoding for ZFN1 and ZFN2 (42 and 38.5 kDa, respectively) was observed. 
Mouse α-tubulin (49 kDa) was used as loading control.  
 
Figure 3.16: Confirmation of FLAG-tagged ZFN expression from ZFN-Prkdc short 
homologous template constructs in BALB/c 3T3 scid mTert fibroblasts by Western 
blotting. BALB/c 3T3 scid mTert fibroblasts were transfected with ZFN-Prkdc short 
homologous template constructs by calcium phosphate coprecipitation. Western blotting 
was completed by the Odyssey infrared imaging method. Efficient ZFN expression was 
detected from all constructs; mouse α-tubulin was used as a loading control. (A) 
Expression from ZFN-Prkdc short homologous template constructs. Lanes: 1: Mock, 
2:pRRLsc_C_3FN-17373-FokKK_W-SanDI-Prkdc, 3: pRRLsc_C_N2A-3FN-17834-
FokEL2_W-SanDI-Prkdc, 4: pCCLsc_S_3FN-17373-FokKK_W-SanDI-Prkdc, 5: 
pCCLsc_S_N2A-3FN-17834-FokEL2_W-SanDI-Prkdc. (B) Detection of mouse α-
tubulin (49 kDa) as loading control. 
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3.2 Lentiviral vector production  
The viral enzyme integrase plays a vital role in lentiviral integration. As I have 
described in the Introduction, mutations within the viral integrase gene have been 
identified which allow for production of two different types of lentiviral vectors: IPLVs 
which encode an active integrase, whereas IDLVs encode a catalytically inactive viral 
integrase due to a point mutation in the integrase coding region, creating a D64V 
change in the amino acid sequence (Yanez-Munoz et al., 2006). IDLVs are becoming 
increasingly promising in different gene therapy applications as they are 
transcriptionally active although at lower levels than the IPLVs (Negri et al., 2010). In 
addition, they also show efficient transgene expression (Chick et al., 2012), offering a 
reduced risk of insertional mutagenesis within targeted genomes due to their episomal 
nature (Wanisch and Yanez-Munoz, 2009).  
In current study, all lentiviral vectors were produced by calcium phosphate transient co-
transfection of HEK 293T cells. Table  3.2 lists all lentiviral vectors prepared throughout 
current study with their main features. All vectors were pseudotyped with the VSV-G 
envelop using the plasmid pMD2.VSV-G to express the VSV-G from the human CMV 
immediate early promoter as previously described  by (Naldini et al., 1996). Lentiviral 
vectors encoding Prkdc templates were only made in IDLV configuration as the 
genomic integration of the template should be avoided. All other vectors were made as 
IPLVs and IDLVs. ZFN-encoding lentiviral vectors produced obligatory heterodimers. 
Lentiviral vectors with eGFP cassettes were either driven by the CMV promoter (using 
transfer plasmid pRRLsc-CEW) or by the SFFV promoter (using transfer plasmid 
pHR'sc_SEW).  
Real time quantitative PCR (qRT-PCR) was used in this study to titrate all lentiviral 
vectors, as it allows for a simultaneous amplification and quantification of target DNA 
using a fluorescently labelled reporter. There are three possible configurations for 
lentiviral vector cDNA in transduced cells: linear double stranded DNA, 
chromosomally integrated provirus, or extrachromosomal circular products with 1 LTR 
or 2 LTRs. Real time qPCR titration was conducted as described in section 2.2.7.3. The 
HIV LRT reaction can measure all HIV cDNA varieties (Yoder and Fishel, 2008). All 
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prepared lentiviral vectors, including eGFP, were titrated by real time qPCR and their 
titre range was 2 X 109-6.0 X 1010.  
On the other hand, lentiviral vectors expressing eGFP were titrated by flow cytometry 
in addition to their titration by qPCR; flow cytometry titration was done as described in 
section 2.2.7.2 and based on preparation of serially diluted lentiviral vectors transduced 
into HeLa cells. As an example of eGFP titre calculation, Figure 3.17 shows a 
representative flow cytometric result. A series of ten-fold dilutions of the original viral 
suspension was used to transduce test cells. Those samples that gave a range of (1-10 
%) eGFP positive cells were used to determine the titre. The flow cytometry (eGFP) 
titre range for the lentiviral vectors used in this Thesis was 4 X 108 – 2 X 109.  
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Table 3.2: Main features of lentiviral vectors prepared throughout current study. 
≠ Transfer plasmid Transgene 
Integration 
efficiency 
Transgene 
promoter 
Figure 
≠ 
1 pRRLsc-CEW  eGFP cassette IPLV CMV N/A 
2 pRRLsc-CEW eGFP cassette IDLV CMV N/A 
3 pHR’sc-SEW  eGFP cassette IPLV SFFV N/A 
4 pHR’sc-SEW  eGFP cassette IDLV SFFV N/A 
5 pCCLsc_PrkdcHindBsaWIF_ISceIT Prkdc-BsaWI template (7389 bp)  IDLV CMV 3.1 
6 pCCLsc_PrkdcHindBsaWIR_ISceIT Prkdc-BsaWI template (7389 bp)  IDLV CMV 3.2 
7 pCCLsc-SanDI-Prkdc  Prkdc-BsaWI  template (1626 bp) IDLV CMV 3.15 
8 pRRLsc_C_3FN-17373-FokKK_W ZFN1 hetrodimer-V3 IPLV CMV 3.3 
9 pRRLsc_C_N2A-3FN-17834-FokEL2_W ZFN2 hetrodimer-V3 IPLV CMV 3.4 
10 pCCLsc_S_3FN-17373-FokKK_W ZFN1 hetrodimer-V3 IPLV SFFV 3.5 
11 pCCLsc_S _N2A-3FN-17834-FokEL2_W ZFN2 hetrodimer-V3 IPLV SFFV 3.6 
12 pRRLsc_C_3FN-17373-FokKK_W ZFN1 hetrodimer-V3 IDLV CMV 3.3 
13 pRRLsc_C_N2A-3FN-17834-FokEL2_W ZFN2hetrodimer-V3 IDLV CMV 3.4 
14 pCCLsc_S_3FN-17373-FokKK_W ZFN1 hetrodimer-V3 IDLV SFFV 3.5 
15 pCCLsc_S _N2A-3FN-17834-FokEL2_W ZFN2 hetrodimer-V3 IDLV SFFV 3.6 
3 pRRLsc_C_3FN-17373-FokKK_W-SanDI-Prkdc ZFN1 hetrodimer-V3 & Prkdc-BsaWI  template (1626 bp) IPLV CMV 3.11 
17 pRRLsc_C_N2A-3FN-17834-FokEL2_W-SanDI-Prkdc ZFN2 hetrodimer-V3 & Prkdc-BsaWI  template (1626 bp) IPLV CMV 3.12 
18 pCCLsc_S_3FN-17373-FokKK_W-SanDI-Prkdc ZFN1 hetrodimer-V3 & Prkdc-BsaWI  template (1626 bp)  IPLV SFFV 3.13 
19  pCCLsc_S _N2A-3FN-17834-FokEL2_W-SanDI-Prkdc ZFN2 hetrodimer-V3 & Prkdc-BsaWI  template (1626 bp) IPLV SFFV 3.14 
20 pRRLsc_C_3FN-17373-FokKK_W-SanDI-Prkdc ZFN1 hetrodimer-V3 & Prkdc-BsaWI  template (1626 bp) IDLV CMV 3.11 
21 pRRLsc_C_N2A-3FN-17834-FokEL2_W-SanDI-Prkdc ZFN2 hetrodimer-V3 & Prkdc-BsaWI  template (1626 bp) IDLV CMV 3.12 
22 pCCLsc_S_3FN-17373-FokKK_W-SanDI-Prkdc ZFN1 hetrodimer-V3 & Prkdc-BsaWI  template (1626 bp) IDLV SFFV 3.13 
23  pCCLsc_S _N2A-3FN-17834-FokEL2_W-SanDI-Prkdc ZFN2 hetrodimer-V3 & Prkdc-BsaWI  template (1626 bp) IDLV SFFV 3.14 
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Figure 3.17: Representative flow cytometry results for eGFP titration. HeLa cells were 
transduced with serial ten-fold dilutions of eGFP lentiviral vectors, harvested three days later 
and analysed by flow cytometry. The FITC-A channel was used to detect eGFP fluorescence, 
and the APC-A channel for cell auto-fluorescence. Dilutions that gave 1-10 % eGFP -positive 
cells were used to calculate the titre using the formula: eGFP transducing units (TU)/ml=% 
green cells x105 (cells/well at the time of vector addition) x 1/vector dilution. (A) Mock 
sample, (B, C&D) are tenfold dilution samples. Panel (D) represents the percentage of green 
cells that will be used in eGFP titre calculation for this vector (region P3).  
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3.2.1 ZFN expression from ZFN lentiviral vectors 
To test the level of expression of ZFN monomers expressed from lentiviral vectors, ZFN 
IPLVs and IDLVs encoding FLAG-tagged ZFN monomers driven from either CMV or SFFV 
promoters were used to transduce BALB/c 3T3 scid mTert fibroblasts. The MOI of 100 
(qPCR) was used in the presence of polybrene (8 µg/ml). The presence of the FLAG-tagged 
ZFN protein was then confirmed by Western blotting using Odyssey infrared imaging 
method.  Results are shown below in Figures 3.18, 3.19 & 3.20. The expected molecular 
mass of ZFN1 is 42 kDa and of ZFN2 is 38.5 kDa. Mouse α-tubulin (49 kDa) was used as 
loading control. Western blot analysis revealed a strong expression from ZFN IPLVs, while 
lower expression (particularly from SFFV promoter) was observed with ZFN IDLVs, as 
expected for transduction of dividing cells. There was no noticeable difference between 
expression level from CMV or SFFV promoters in either the IPLV or IDLV ZFNs 
configuration.  
 
Figure 3.18: Confirmation of FLAG-tagged ZFN expression from CMV-ZFN lentiviral 
vectors in BALB/c 3T3 scid mTert fibroblasts by Western blotting. BALB/c 3T3 scid 
mTert fibroblasts were transduced with CMV ZFN IPLVs or IDLVs fibroblasts with qPCR 
MOI 100 in presence of polybrene (8 µg/ml). Western blotting was performed by the 
Odyssey infrared imaging method. Efficient ZFN expression was detected from ZFN IPLVs, 
whereas lower expression was observed from ZFN IDLVs. (A) FLAG-tagged ZFN 
expression from IPLVs and IDLVs. Lanes: 1& 4: Mock, 2& 5: ZFN1, 3 &6: ZFN2. (B) 
Detection of mouse α-tubulin (49 kDa) as loading control. 
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Figure 3.19: Confirmation of FLAG-tagged ZFN expression from SFFV-ZFN lentiviral 
vectors in BALB/c 3T3 scid mTert fibroblasts by Western blotting. BALB/c 3T3 scid 
mTert fibroblasts were transduced with SFFV ZFN IPLVs or IDLVs fibroblasts with qPCR 
MOI 100 in the presence of polybrene (8 µg/ml). Western blotting was performed by the 
Odyssey infrared imaging method. Efficient ZFN expression was detected from ZFN IPLVs, 
whereas significantly lower expression was observed from ZFN IDLVs. (A) FLAG-tagged 
ZFN expression from IPLVs and IDLVs. Lanes: 1& 4: Mock, 2& 5: ZFN1, 3 &6: ZFN2. (B) 
Detection of mouse α-tubulin (49 kDa) as loading control. 
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Figure 3.20: Confirmation of FLAG-tagged ZFN expression from ZFN-Prkdc short 
template IDLVs in BALB/c 3T3 scid mTert fibroblasts by Western blotting. BALB/c 3T3 
scid mTert fibroblasts were transduced with ZFN-Prkdc short template IDLVs with qPCR 
MOI 100 in presence of polybrene (8 µg/ml). Western blotting was performed by the 
Odyssey infrared imaging method. ZFN expression was detected from all ZFN IDLVs. (A) 
FLAG-tagged ZFN expression from IDLVs. Lanes: 1: Mock, 2: Prkdc/CMV ZFN1, 3: 
Prkdc/CMV ZFN2, 4: Prkdc/SFFV ZFN1, 5: Prkdc/SFFV ZFN2. (B) Detection of mouse α-
tubulin (49 kDa) as loading control. 
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Chapter Four 
ZFN activity in scid fibroblasts 
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4 ZFN activity in scid fibroblasts  
This chapter can be divided into two parts, in the first part I describe three preliminary 
experiments performed with the aim of generating tools or optimising procedures to be used 
in the context of the current study. First, BALB/c 3T3 scid fibroblasts were immortalised to 
overcome their self senescence which was followed by assessing the effect of polybrene on 
transduction efficiency of BALB/c 3T3 scid mTert fibroblasts, and optimisation of plasmid 
transfection by calcium phosphate coprecipitation method. The second and main part of the 
chapter presents data to use the tools generated in previous experiments to test the ZFNs in 
vitro by using BALB/c 3T3 scid mTert fibroblasts. The vital aims were to test how efficiently 
the ZFNs would recognize their targets, to detect gene repair events and to demonstrate 
restoration of Prkdc functionality. In order to do so, first of all I examined different ZFN 
variants using a gene targeting assay to select ZFNs that could induce higher levels of DSB-
mediated HR. Then I analysed gene targeting results with PCR assay and subsequent 
digestion with restriction enzymes to confirm HR events. Later, I repeated gene targeting 
experiment but with ZFN IPLVs this time to check out ZFN cassettes expression from 
prepared ZFN lentiviral vectors. Next I worked on demonstration of efficiency of ZFNs 
cutting by surveyor’s Cel-I assay. I have done another gene repair experiment and examined 
HR events by BsaWI assay. Subsequently, in order to check restoration of functionality of 
Prkdc; DNA-PK activity assay was performed. Moreover; to further confirm restoration of 
Prkdc activity, first, melphalan drug cytotoxic dose for BALB/c 3T3 wt and scid fibroblasts 
was detected by MTT assay. Then corrected cells were enriched by culturing them in 
presence of melphalan optimised dose and then their growth was analysed. Finally BsaWI 
assay was repeated to compare between gene repair levels of corrected cells before and after 
enrichment with melphalan.  
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4.1 Immortalisation of BALB/c 3T3 scid fibroblasts 
BALB/c 3T3 scid fibroblasts were used in the current study as convenient target cells to 
demonstrate ZFN cutting and gene repair. Work performed prior to my arrival in the 
laboratory had demonstrated that these cells suffered from extensive senescence upon 
cloning. With the intention of extending their life-span and overcoming senescence, BALB/c 
3T3 scid fibroblasts were immortalised by transduction with retroviral vectors encoding 
mouse telomerase reverse transcriptase (Tert), the gene encoding for the catalytic subunit of 
TERT. Immortalised fibroblasts are referred to as BALB/c 3T3 scid mTert fibroblasts and 
they were widely used in this study. 
 
4.1.1 Titration of puromycin resistance of mouse scid fibroblasts 
As mentioned above, initial work carried out using BALB/c 3T3 scid fibroblasts was 
hindered by their extensive senescence. The retroviral vector used for the immortalisation 
encoded both the puromycin resistance gene Pac and mTert, the former allowing selection of 
transduced cells. Puromycin resistance is conferred by the acquisition and expression of the 
Pac gene, encoding a puromycin N-acetyl transferase (Sanchez-Puig and Blasco, 2000). It 
was important to titrate puromycin susceptibility in those fibroblasts before immortalisation 
because BALB/c 3T3 scid mTert fibroblasts would be positively selected with puromycin. 
Puromycin titration was done as described in (Materials and Methods section 2.2.8.1). 
Briefly, 5 X 104 cells/well were plated out in a 6-well plate cells and 24 hrs later puromycin 
was added. Cells were maintained in culture for 4 days post-plating before staining with 
crystal violet. The result (Figure  4.1) revealed that a concentration of 3 µg/ml puromycin was 
sufficient to kill BALB/c 3T3 scid fibroblasts.  
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Figure 4.1: Titration of puromycin killing in BALB/c 3T3 scid fibroblasts. BALB/c 
3T3 scid fibroblasts were treated from day 1 post-plating with concentrations of puromycin 
ranging 1-10 µg/ml (numbers shown in the figure denote puromycin concentrations). Cells 
were kept in culture until the untreated control reached confluency (4 days post-plating) and 
stained with crystal violet. 3µg/ml puromycin was adopted for selection. 
 
 
4.1.2 Preparation and titration of retroviral vectors  
A bicistronic retroviral vector encoding both mTert and Pac was prepared as described in 
(Materials and Methods section 2.2.8.3). Retroviral vectors prepared for immortalisation were 
titrated in BALB/c 3T3 scid fibroblasts in presence of 8 µg/ml polybrene as mentioned earlier 
(Materials and Methods section 2.2.8.4). The effect of polybrene on these cells will be 
examined below in section 4.2. As shown in Figure  4.2, the results demonstrated that CFUs 
were too confluent to account in dilutions (100 to 10-3 dilutions) indicating high retroviral 
titre. For all other dilutions the following formula was used to calculate the retroviral titre: 
Retroviral (TU)/ml = number of CFUs x 105 (cells/well at the time of vector addition) x 
1/vector dilution. The calculations revealed that titre levels were 6 X 1010 and 5 X 1010 TU/ml 
on harvest day 1 and day 2 titres; respectively.  
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Figure 4.2: Titration of retroviral vectors in BALB/c 3T3 scid fibroblasts. Serial ten-fold 
dilutions (100 to 10-7) of retroviral vector supernatant of harvests day 1 or day 2 were 
prepared in 8 µg/ml polybrene. Two days post-transduction, 3 µg/ml of puromycin was added 
to each well and after three days the wells were stained by crystal violet to facilitate counting. 
The CFUs were TNTC in the dilutions of 100 to 10-3 of both harvest days 1 and 2. For other 
dilutions, retroviral vector titres were calculated and the results showed that harvest day 1 and 
day 2 titres were 6 X 1010 and 5 X 1010 TU/ml; respectively.   
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4.1.3 Immortalisation by retroviral vectors  
The prepared retroviral vectors were used to transduce BALB/c 3T3 scid fibroblasts in the 
presence of 8 µg/ml polybrene. The next day, cells were selected by adding (3 µg/ml) 
puromycin, and puromycin selection was maintained routinely for passaging of these cells. 
As a result of transduction, BALB/c 3T3 scid fibroblasts should be rendered puromycin 
resistant. In order to confirm that the transduced cells had acquired the resistance gene, the 
same puromycin titration was carried out as described above (section  4.1.1). The results in 
Figure  4.3 demonstrated that the fibroblast population was able to survive and resist to at 
least 10 µg/ml of puromycin, indicating that the BALB/c 3T3 scid fibroblasts has been 
transduced with the vector coding for Pac and mTert. 
 
 
Figure 4.3: Puromycin killing titration of BALB/c 3T3 scid mTert fibroblasts. 
BALB/c 3T3 scid mTert fibroblasts were grown in concentrations of puromycin ranged (1- 
10) µg/ml (numbers shown in the figure denote puromycin concentrations). Emerged 
puromycin-resistant cells were allowed to grow for 3 days post-plating to form a monolayer. 
Then, the wells were stained with crystal violet. The cells were able to grow in at least 
10µg/ml puromycin. 
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4.1.4 Enhanced clonal efficiency and growth rate of mTert scid fibroblasts 
The ability of individual cells to form colonies in culture is called clonal efficiency, and can 
be measured by counting visible CFUs. Previous work (in Dr. Yáñez’s laboratory) with 
BALB/c 3T3 scid fibroblasts had been impeded by cellular senescence. These cells showed 
low clonal efficiency and death before completion of the required experiments. In order to 
compare the clonal efficiency of immortalised and non-immortalised BALB/c 3T3 scid 
fibroblasts, an experiment was carried out by seeding low cell numbers of each and then 
assessment of CFUs (section 2.2.8.6). The results (see Figure  4.4) showed that for non-
immortalised cells (BALB/c 3T3 scid fibroblasts) the CFU average was 4 and 35 for 10 and 
100 seeded cells, respectively. While for immortalised cells (BALB/c 3T3 scid mTert 
fibroblasts) the CFU average was 25 and TNTC for 10 and 100 seeded cells, respectively. 
This finding indicated that immortalised cells (scid mTert fibroblasts) have significantly 
higher clonal efficiency than non-immortalised cells and they were more able to grow and 
expand i.e. possess higher clonal efficiency.  
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Figure 4.4: Clonal efficiency of BALB/c 3T3 scid and scid mTert fibroblasts. Either 10 or 
100 cells were seeded per well in 6-well plates. Four days later, emerged colonies were 
stained with crystal violet and then CFUs were scored. The results showed that CFU average 
was 4 and 35 for 10 and 100 seeded scid fibroblasts; or 25 and TNTC for scid mTert 
fibroblasts, respectively. Clearly the scid mTert fibroblasts have shown higher clonal 
efficiency than scid fibroblasts. Numbers on the left refers to the initial seeded cells/well. (A) 
BALB/c 3T3 scid fibroblasts; (B) BALB/c 3T3 scid mTert fibroblasts (in the presence of 3 
µg/ml puromycin).  
 
To compare the growth kinetics of BALB/c 3T3 scid fibroblasts and scid mTert fibroblasts, 
their growth curves were assessed (described in Materials and Methods section 2.2.8.6) by 
seeding specific cell numbers of each and then counting them in a haemocytometer at 24-
hour intervals. The results showed that BALB/c 3T3 scid mTert fibroblasts had divided 
noticeably faster (see Figure  4.5). In order to demonstrate significance, this experiment needs 
to be reapted. 
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Figure 4.5: Growth curve of mouse scid fibroblasts. 5 X 105 BALB/c 3T3 scid fibroblasts 
or scid mTert fibroblasts were seeded per well in 6-well plates. The cells were maintained in 
culture and counted (by haemocytometer) at 24 hours intervals. BALB/c 3T3 scid mTert 
fibroblasts divided faster than BALB/c 3T3 scid fibroblasts. 
 
4.2 Polybrene effect on BALB/c 3T3 scid mTert fibroblasts  
Polybrene improves the transduction efficiency in some cells like HeLa and HEK-293T 
(Lehmusvaara S.  et al., 2005) but not others like motor-neurons (Azzouz et al., 2004). In 
order to find out how BALB/c 3T3 scid mTert fibroblasts will be affected by polybrene, an 
experiment was carried out using different eGFP MOIs of eGFP IPLVs and IDLVs. BALB/c 
3T3 scid mTert fibroblasts were transduced with lentiviral vectors either in presence or 
absence of 8 µg/ml of polybrene. The results of flow cytometry analysis (Figure  4.6) showed 
that the use of polybrene enhanced transduction efficiency for both IPLV and IDLV, with no 
obvious detrimental effect on the cells; therefore all transduction experiments in these cells 
have been done in the presence of polybrene. In order to demonstrate significance, this 
experiment needs to be reapted 
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Figure 4.6: Polybrene effect on transduction’s efficiency of BALB/c 3T3 scid mTert 
fibroblasts. Cells were transduced at various MOIs with eGFP IPLVs and IDLVs in presence 
or absence of 8 µg/ml of polybrene. The transduction efficiency was estimated after three 
days, scoring eGFP-positive cells by flow cytometric analysis.  
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4.3 Optimisation of plasmid transfection 
In current study, calcium phosphate coprecipitation (described earlier in Materials and 
Methods in section 2.2.5) was used for plasmid transfection, hence an optimisation of cell 
density and DNA amount was deemed required. Initially cell numbers of BALB/c 3T3 scid 
mTert fibroblasts were tested; different cell numbers were seeded in 10 cm plates: (5X105, 
1x106, and 2x106). Then a fixed DNA amount of 10 µg/plate of eGFP-expressing plasmid 
(pRRLsc-CEW) was used for transfection. Three days later cells were analysed by flow-
cytometry. The results (Figure  4.7) showed that all samples displayed similar percentages of 
eGFP-positive cells (8.3-12.4%). The 1x106 cells per plate was chosen as it is more 
convenient cell density. 
 
Figure 4.7: Flow cytometric results of BALB/c 3T3 scid mTert fibroblasts density 
optimisation for plasmid transfection. Different cell densities were used (5X105, 1x106, 
and 2x106 cells per 10-cm plate), samples were then transfected with plasmid pRRLsc-CEW 
(10 µg/plate). Flow cytometric analysis showed that cell density of 1x106 gave higher eGFP 
expression percentage of 12.4. 
156 
 
Furthermore, the ideal DNA concentration to be used for transfection was established using 
the selected density of 1x106 cells/plate. Different amounts of pRRLsc-CEW were used: 0, 
10, 20, 25, and 30 µg/plate. The flow cytometric results indicated that the percentages of cells 
expressing eGFP were 0, 9.4, 27.2, 28.5 and 28.3, respectively. Thus, a DNA amount of 20 
µg/plate was considered optimal, as further increases did not lead to higher increase in eGFP 
expression. 
4.4 Gene targeting in BALB/c 3T3 scid mTert fibroblasts 
4.4.1 Optimisation of amount of wt template plasmid  
This experiment was conducted in order to optimise the required amount of wt homologous 
template plasmid pPrkdcHindPmlIneoF in plasmid-based gene targeting experiments (below 
in section  4.4.2). Adjusting template plasmid amount was important to avoid cytotoxic or 
overdosing effect in the targeted cells. This gene targeting experiment used cell density of 
1x106 cell /plate of BALB/c 3T3 scid mTert fibroblasts and 20 µg/plate of pRRLsc-CEW that 
were optimised in previous experiment (section 4.3). Additionally, to each plate an amount of 
0, 5, 10, 15, 20, 25, or 30 µg/plate of pPrkdcHindPmlIneoF were introduced by calcium 
phosphate coprecipitation followed by flow cytometric analysis after three days. In Table  4.1, 
the results showed that the DNA amount of 10 µg/plate of pPrkdcHindPmlIneoF was the 
appropriate amount as adding more DNA does not lead to major increase in % eGFP. 
 
Table 4.1: Flow cytometric results of optimisation of pPrkdcHindPmlIneoF amount. All 
plates received equal amounts of 20 µg/plate of pRRLsc-CEW in addition to increasing 
amounts (as indicated in the table) of plasmid pPrkdcHindPmlIneoF by calcium phosphate 
coprecipitation.  The flow cytometric results showed that the DNA amount of 10 µg/plate 
considered the most appropriate one.  
Sample (µg/plate of pPrkdcHindPmlIneoF  ) % eGFP 
Mock (non-transfected) 0.0 
0 27 
5 29 
10 39 
15 40 
20 33 
25 33 
30 30 
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4.4.2 Selection of optimum ZFN: Gene targeting using ZFN plasmids 
This gene targeting experiment was based on transfection of BALB/c 3T3 scid mTert 
fibroblasts with wild-type homologous corrective Prkdc-neo template plasmid 
(pPrkdcHindPmlIneoF) and ZFN constructs. It was designed to detect which ZFN version 
(and combination) induces higher DSBs that can be detected by number of G-418 resistant 
CFUs. As I mentioned before, three versions of Prkdc ZFNs were designed for current study 
by Sangamo BioScience (California, USA) as a collaboration: the first contained wild-type 
FokI domains which allow homodimerisation, the second contained modified wild-type FokI 
domains which could allow some homodimerisation, and the third contained only obligatory 
heterodimeric FokI domains. 
The plasmid pPrkdcHindPmlIneoF contains Prkdc-neo template of 9210 bp, with a neo 
cassette inserted at PmlI site in intron 84. Neo gene will confer resistance to G418 in gene-
targeted cells or cells in which plasmid is randomly integrated (for more description see 
Figure  4.8). Where HR occurs, the region of homology of the corrective Prkdc-neo template 
will be used as a template for re-building endogenous genome sequence meaning that the neo 
cassette sequence will be incorporated into the genome. Upon positive selection with G418 
and irrespective of the occurrence of site-specific gene repair or random integration, only 
those cells containing an integrated neo cassette would be able to generate visible G-418 
resistant CFUs, which can be counted at the end of experiment.  
G-418 is an analog of the antibiotic neomycin sulphate, its resistance is conferred by 
acquisition and expression the neo gene encoding the bacterial neomycin transferase 
(aminoglycoside 3’ phosphotransferase, APH3’III) (Fernex et al., 1997). Neomycin 
transferase catalyzes the ATP-dependent phosphorylation of kanamycin/neomycin  by 
transferring of the phosphoryl group of ATP to the 3’-hydroxyl of the antibiotic resulting in 
inhibition the antibiotic-ribosome interaction by blocking polypeptide synthesis at the 
elongation step in both prokaryotic and eukaryotic cells (Mondorf et al., 2012).  
This experiment was performed as described in (section 2.2.10) in triplicate and repeated 
three times by plasmid co-transfection of both Prkdc-neo template plasmid 
pPrkdcHindPmlIneoF and two ZFN plasmids of different versions and combinations. Table 
 4.2 summarises used ZFN versions, combination and added DNA amounts. For each plate the 
added DNA included: about 20 µg of ZFN plasmids (as optimised in section  4.3) or irrelevant 
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plasmid pCCLsc_ISceIT, and 10 µg/ plate of pPrkdcHindPmlIneoF (as optimised in section 
 4.4.1). The irrelevant plasmid was used to make sure that all plates received approximately 
32 µg of plasmid DNA. Latter plasmid was irrelevant to the ZFN and template plasmids and 
contained the same CMV promoter as that on ZFN constructs. The BALB/c 3T3 scid mTert 
fibroblasts were seeded and allowed 4 hours for attachment, and then the cells were 
transfected with plasmid constructs. At two and five days post-transfection the culture 
medium was replaced with fresh medium containing 800 µg/ ml of G418. Then at 9 days 
post-transfection the plates were stained with crystal violet, and visible G-418 resistant CFUs 
counted.  
The results (Figure  4.9) showed undoubtedly that the combination of obligate heterodimeric 
ZFN1 and ZFN2 (third version) generated the highest number of G-418 resistant (r) CFUs, as 
an indication of highest DSB generation. There was at least a 10-fold increase in G-418r 
CFUs between this combination and any other combination or negative control. Crucially, 
these findings were similar to what Olsen et al achieved earlier using very similar protocol. 
These authors had 9-fold increases in puromycin selected colonies when they transfected 
target cells with donor template and two separate ZFN monomers (Olsen et al., 2010). 
Only those obligatory heterodimeric ZFN that generated the highest number of G-418r CFUs 
were incorporated into lentiviral vectors. 
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Figure 4.8: General schematic of Prkdc gene and corrective templates. (A) Prkdc 
configuration, comprising of 86 exons extending across 193 kb, and an enlarged HindIII 
fragment of scid Prkdc showing the location of the designer ZFN target site 32 nucleotides 
downstream from scid point mutation.  (B) Prkdc-neo corrective template of 9210 bp. The 
floxed neo cassette was cloned into intron 84 for positive selection. Normal (wt) scid 
sequence and ZFN target sites are on the same 85 exon. (C) Prkdc-BsaWI corrective template 
of 1626 bp containing a diagnostic BsaWI restriction site introduced by site-directed 
mutagenesis at 2 nucleotides upstream from scid mutation site causing only silent changes, wt 
scid sequence and ZFN target sites 32 nucleotides downstream from scid mutation site.
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Table 4.2: Plan of gene targeting experiment for detection of efficient ZFNs.  
Three versions of Prkdc ZFNs were designed for current study; the first contained wild type non-optimised FokI domains which allow 
homodimerisation, the second was designed to include modified FokI domains which still allow some homodimerisation, and the third version 
contained only obligatory heterodimeric FokI domains. v: version. 
 
  
DNA added amounts (µg/plate) 
 
  ZFN plasmid (s) Irrelevant plasmid 
(IP) pCCLsc_ISceIT 
Prkdc-neo template plasmid 
pPrkdcHindPmlIneoF 
Total added 
DNA (µg/plate) 
Plate 
# 
Plate contents 
1 Mock (non-transfected) 0 0 0 0 
2 Negative control (without IP ) 0 0 10 10 
3 Negative control (with IP )   0 22.2 10 32.2 
4 ZFN1 (1st v) 11.4 10.8 10 32.2 
5 ZFN2 (1st v) 10.8 11.4 10 32.2 
6 ZFN1+ ZFN2 (1st v) 11.4 + 10.8  0 10 32.2 
7 ZFN1 (2nd v) 11.1 11.1 10 32.2 
8 ZFN2 (2nd v) 10.8 11.4 10 32.2 
9 ZFN1+ ZFN2 (2nd v) 11.1 + 10.8   0.3 10 32.2 
10 ZFN1 (3rd v) 11.1 11.1 10 32.2 
11 ZFN2 (3rd v) 10.8 11.4 10 32.2 
12 ZFN1+ ZFN2 (3rd v) 11.1 + 10.8   0.3 10 32.2 
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Figure 4.9: Gene targeting in BALB/c 3T3 scid mTert fibroblasts by plasmid 
transfection. I utilised a plasmid-based gene targeting protocol using calcium 
phosphate coprecipitation of Prkdc-neo template plasmid and pVax-based ZFN 
plasmids. The BALB/c 3T3 scid mTert fibroblasts were transfected with plasmid DNA 
(for quantities see Table  4.2). Two days later, the fibroblasts were washed with PBS and 
selected with G418 (800 µg/ ml). At 9 days post-transfection, the CFUs were stained 
with crystal violet and counted. Plates: Mock was non-transfected, negative control (no 
irrelevant plasmid) was transfected with only Prkdc-neo template plasmid 
(pPrkdcHindPmlIneoF), negative control (with irrelevant plasmid) was transfected with 
pPrkdcHindPmlIneoF and pCCLsc_ISceIT, ZFN1 and ZFN2 were the zinc-finger 
monomer plasmids, IP: irrelevant plasmid  and v: version. (A) Representative photos of 
gene targeting experiment. There was a considerable increase in G-418 r CFU number 
when the ZFN obligate heterodimers were supplied together, in the presence of donor 
homologous template.  (B) Quantitation of G-418r CFUs. The two obligate 
heterodimers together induced the highest number of G-418r CFUs, generating more 
than a 10-fold increase.  
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4.4.2.1 Molecular analysis of G418r colonies 
 
With the aim of demonstrating of ZFN specificity, a PCR analysis for targeted 
integration events was carried out on G418-resistant colonies from the previous 
experiment (section 4.4.2). 36 CFUs were picked randomly from two separate 
transfections of BALB/c 3T3 scid mTert fibroblasts with corrective Prkdc-neo template 
(pPrkdcHindPmlIneoF) and third version ZFN obligate heterodimeric (ZFN1 and 
ZFN2) plasmids.  
The selected CFUs were allowed to grow into monolayers and then analysed by a PCR 
based protocol as described in section 2.2.10.1. The forward primer was designed to be 
internal to the targeting construct, and selected within the neo expression cassette 
sequences of the Prkdc-neo template plasmid (pPrkdcHindPmlIneoF). The reverse 
primer was designed to be external to the Prkdc-neo template and selected from the 
genomic DNA immediately outside the short arm of homology (see Figure  4.10 for 
further description). PCR amplification of a 1335-bp product (for full sequence please 
see Appendix 1, Box 4) in tested samples is assumed to be diagnostic of ZFN-induced 
DSBs and HR (i.e. gene targeting) occurrence at these DSBs.  
The results revealed that among 36 examined samples, there were 20 positive 
amplifications representing an impressive demonstration for ZFN-mediated gene 
targeting at the mutated Prkdc locus. The analysis of some representative sample clones 
is shown in Figure  4.11. Furthermore, to show that the right amplicons had been 
amplified these 20 positive products were subjected to enzymatic digestion with BglII, 
generating two smaller fragments of 746 and 589bp in all cases (see example in Figure 
 4.12 A). Additionally, among 20 positive amplicons, one sample was randomly selected 
to be subjected to further enzymatic digestion with HindIII, generating fragments of 
1216 and 119 bp, and XhoI generating fragments of 1014 and 321 bp (see Figure  4.12 
B). 
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Figure 4.10: Gene targeting strategy with Prkdc-neo targeting construct. (A) 
Original plasmid pPrkdcHindPmlIneoF containing the corrective Prkdc-neo template; 
(B) corrective Prkdc-neo template of 9210 bp encoding for wt (normal) sequence at scid 
mutation site, positive selection neo cassette and forward primer for gene targeting 
analysis; (C) proposed HR crossing-overs between corrective template and mouse 
genome; (D) scid mouse genome with scid mutation site and reverse gene targeting 
primer from outside the region of homology; and (E) PCR product of 1335 bp amplified 
using template–internal (forward) and template–external (reverse) primers, showing 
sites of BglII, XhoI and Hind III enzymes that will be used for subsequent confirmation.  
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Figure 4.11: Gene targeting at Prkdc locus in representative samples of BALB/c 
3T3 scid mTert fibroblast clones. G-418 resistant CFUs resulting from potential gene 
targeting by ZFN and donor template plasmids were screened for HR by PCR 
amplification of a DNA sequence of 1335 bp extending from the Prkdc-neo corrective 
template into adjacent genomic DNA. Presence of positive amplification is diagnostic 
for gene targeting; out of 36 examined CFUs, 20 samples showed positive results. PCR 
products were run on a 0.7% agarose gel; lane 1 mock (non-transfected), lanes 2, 3 & 4 
(clone numbers 3, 10 & 13) were samples failed to show amplification and lanes 5, 6 & 
7 (clone numbers 1, 27 & 29) were samples with positive amplification. DNA ladder: 5 
µl of Fermentas GenRuler 1 Kb plus. 
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Figure 4.12: Restriction endonuclease analysis of PCR amplicons of gene targeting. 
PCR products from gene targeted BALB/c 3T3 scid mTert fibroblasts were digested 
with selected restriction enzymes to verify the presence of correct amplicons. Digested 
products were run on a 0.7% agarose gel. (A) All 20 PCR products were digested with 
BglII; one representative sample (clone number 1) is shown here. Lane 1 undigested 
product of 1335 bp; and lane 2 BglII-generated smaller fragments of 746 and 589 bp. 
(B) One sample (clone number 5) was randomly selected out of 20 PCR products to be 
digested with another two restriction enzymes; lane 1 undigested product of 1335 bp, 
lane 2 digestion with HindIII generating fragments of 1216 and 119 bp, and lane 3 
digestion with XhoI generating fragments of 1014 and 321 bp.  
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4.4.3 Gene targeting using ZFN IPLVs 
Following the success of the all-plasmid gene targeting experiment described in the 
previous section, I set out to study whether gene targeting could be achieved through 
transduction with IPLVs encoding ZFN monomers driven by either CMV or SFFV; and 
transfection of Prkdc-neo template plasmid pPrkdcHindPmlIneoF. The aim here was to 
verify the functionality of ZFNs expressed from lentiviral vectors. As I mentioned 
above (section  4.4.2), only obligate heterodimeric ZFNs were incorporated into 
lentiviral vectors, as they generated the highest number of G-418 resistant CFUs in 
targeted fibroblasts. Because I was unsuccessful in incorporating the Prkdc-neo 
template corrective plasmid into lentiviral vectors, ZFNs and Prkdc-neo template were 
introduced into the targeted fibroblasts by transduction and transfection, respectively. 
Different time intervals between ZFN transduction and template plasmid transfection 
were set up to give the ZFN lentiviral vectors varying times for gene expression ahead 
of plasmid template transfection.  
This experiment was carried out in the presence of 8 µg/ml polybrene using the cell 
density of 1X106 cells/plate. Four hours post-seeding, the fibroblasts were transduced 
with qPCR MOI 50 each of ZFN IPLV pairs (ZFN1 and ZFN2) driven by either CMV 
or SFFV promoters. Later the Prkdc-neo corrective template plasmid was introduced by 
plasmid transfection at different time intervals of 12, 24, 48 or 72 hours post-
transduction. Two days after the corresponding transfection, the cells were selected with 
G418, and eventually the G-418 resistant CFUs were stained with crystal violet and 
counted. As shown in Figure  4.13, the results revealed clearly that ZFN IPLVs were 
able to express ZFNs efficiently producing G418 resistant CFUs as an indicator of 
induced DSBs. Additionally, transfection at 48 hours post-transduction was the most 
suitable time-point, judging by the number of G418-resistant colonies, and expression 
levels from CMV and SFFV ZFN IPLVs were similar in the targeted fibroblasts. 
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Figure 4.13: Quantitation of G-418 resistant CFUs in BALB/c 3T3 scid mTert 
fibroblasts following combined ZFN IPLV transduction and plasmid template 
transfection. The fibroblasts were transduced with qPCR MOI 50 of ZFN IPLVs driven 
by either CMV or SFFV promoters in the presence of 8 µg/ml polybrene. Later, at 12, 
24, 48 or 72 hours post-transduction, the fibroblasts were transfected with the corrective 
Prkdc-neo template plasmid. Two days after the corresponding transfection, the cells 
were selected with G418 and eventually the G-418 resistant CFUs were stained with 
crystal violet and counted. The ZFN IPLVs driven by CMV or SFFV were able to 
express ZFNs efficiently and an interval of 48 hours between transduction and 
transfection was the optimum timing. (Upper panel) Transduction with CMV ZFN 
IPLVs; (lower panel) Transduction with SFFV ZFN IPLVs. Negative control was 
corrective Prkdc-neo template plasmid only, while positive control was transfection 
with obligate heterodimeric (ZFN1 & ZFN2) and corrective template plasmids. 
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4.5 Testing the efficiency of ZFN cutting  
In order to study ZFN abilities to generate site-specific cuttings at their genomic target 
site (32 nucleotides downstream from scid point mutation at the Prkdc locus), a 
Surveyor Cel-I mutation detection assay was used (section 2.2.9). In the absence of 
homologous template, ZFN-induced DSBs would be repaired by NHEJ, resulting in the 
introduction of InDels (small insertions or deletions) at high frequency. These InDels 
are detected by the Surveyor Cel-I nuclease assay (see Figure  4.14). The Surveyor 
nuclease detects mismatches in heteroduplex DNA produced in the assay, cleaving both 
strands of a DNA heteroduplex on the 3’‐side of the mismatch site (Qiu et al., 2004). 
The Surveyor’s Cel-I assay was used as described earlier (Materials and Methods 
section 2.2.9). Any polymorphic mismatches or introduced InDels (via repaired DSBs), 
eventually, will be recognised by Cel-I nuclease. Similarly, the detection will include 
those modifications introduced at the ZFN target site upon repair by NHEJ machinery in 
absence of any supplied donor homologues templates.  
 
4.5.1 Sensitivity of Cel-I assay  
This experiment was designed in order to find out the minimum modification 
percentage that can be detected by the Surveyor’s Cel-I assay (described in Materials 
and Methods section 2.2.9.1). Having detected the minimum amount of ZFN cutting by 
this assay, will be crucial to optimise ZFN cleavage efficiency for the next experiments. 
As the only expected difference between BALB/c 3T3 wt fibroblast and BALB/c 3T3 
scid fibroblast DNAs is the scid point mutation (T- to -A change), by mixing different 
amounts of each it should be possible to generate different proportions of homoduplex 
and heteroduplex DNA molecules. This was carried out by PCR amplification of a 304-
bp region around the scid mutation from mixed genomic DNA (for full sequence please 
see Appendix 1, Box 1), followed by a final denaturation/hybridisation step. Any 
heteroduplexes would be detected and cut by the Surveyor’s nuclease at the mispaired 
site (the scid mutation), generating two smaller fragments of 88 and 216 bp. The results 
of this test (see Figure  4.14) demonstrated that the minimum percentage of modification 
(mismatch) that could be detected by the Cel-I assay was 5%. 
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Figure 4.14: Surveyor’s Cel-I endonuclease detects ZFN activity.  (1) Transduction 
of cells with ZFN lentiviral vectors (2) ZFNs recognise their target sites creating DSBs 
in a portion of the cells. (3& 4) Those DSBs repaired by NHEJ, which will produce 
small insertions or deletions (InDels,  ), DNA extraction from targeted cells and PCR 
amplification of target sites. (5) Denaturation of PCR products (6) Heteroduplex 
formation between normal and mutated products by reannealing. (7) Heteroduplex 
cleavage by Surveyor endonuclease. (8) Separation of Surveyor digests by 
electrophoresis and analysis of band sizes and proportions. U: Uncut, C: Cut. 
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Figure 4.15: Detection limit of Surveyor’s Cel-I assay. Different percentages of 
BALB/c 3T3 wt and scid mTert fibroblasts were mixed, genomic DNA purified and 
DNA fragments of 304 bp around the scid mutation were PCR amplified. The PCR 
products were then subjected to the Cel-I assay, in which cutting by Cel-I nuclease (at 
scid point mutation) produced two smaller fragments of 88 and 216 bp (red arrows) in 
addition to the parental amplicon. The minimal percentage of modification that was 
detected by this assay was 5%. (A) PCR amplification and (B) Surveyor’s Cel-I 
nuclease cutting.  Lane (1) 99% of wt and 1% of scid, lane (2) 95% of wt and 5% of 
scid, lane (3) 90% of wt and 10% of scid, lane (4) 80% of wt and 20% of scid, lane (5) 
70% of wt and 30% of scid, lane (6) 60% of wt and 40% of scid and lane (7) 50% of wt 
and 50% of scid. Marker: Bioline Hyperladder V.  
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4.5.2 Testing the efficiency of ZFN cutting in scid mTert fibroblasts   
The BALB/c 3T3 scid mTert fibroblasts were transduced with either CMV or SFFV 
ZFN IPLVs and IDLVs at qPCR MOI 50, 125 or 250, and maintained in culture for 
three days. The cells were then collected, genomic DNA was extracted and subjected to 
the Surveyor Cel-I mutation detection assay. A PCR amplification across the target site 
generated a 304-bp parental fragment (for DNA sequence please see Appendix 1, Box 
1). Denaturation followed by reannealing of this PCR product generated DNA 
heteroduplexes if ZFN-induced InDels were present. After cleavage by Surveyor’s 
nuclease, two smaller products of 184 and 126 bp (Figure  4.16) were generated. Then 
samples were run in PAGE, visualized under UV light, images were taken and finally 
cutting percentages were calculated with ImageJ. The results showed that there was 
efficient dose- and dimer-dependent ZFN-mediated cutting at the target site, suggesting 
that ZFN expression under CMV or SFFV promoters reached similar levels. 
Furthermore and as expected in these proliferative cells, the expression level from 
IPLVs was more efficient than that from IDLVs for both CMV or SFFV-controlled 
ZFN cassettes.  
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Figure 4.16: Site-specific ZFN cutting in scid fibroblasts. BALB/c 3T3 scid mTert 
fibroblasts were transduced at the indicated qPCR MOIs of 50, 125 or 250 with either 
CMV ZFN lentiviral vectors (upper panel) or SFFV ZFN lentiviral vectors (lower 
panel). Three days later cells were harvested, genomic DNA was extracted and then 
samples were subjected to Surveyor Cel-I mutation detection assay. The PCR 
amplification generates a 304-bp parental fragment, and after denaturation/reannealing 
and cleavage by Surveyor’s nuclease, two smaller fragments of 184 and 126-bp (red 
arrows) are produced wherever InDels are present. The results demonstrated site-
specific cutting, suggested similar levels of ZFN expression under CMV or SFFV 
promoters, and that the expression level from IPLVs was more efficient than that from 
IDLVs for both CMV or SFFV-driven IPLVs. Percentages at the bottom of each image 
represent ZFN cutting percentage calculated with ImageJ. M: mock, C1: CMV ZFN1, 
C2: CMV ZFN2, S1: SFFV ZFN1 and S2: SFFV ZFN2.  
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4.6 Detection of gene repair by BsaWI assay in scid mTert fibroblasts 
The aim behind this experiment was to detect HR events in targeted fibroblasts using a 
silent diagnostic restriction site for the enzyme BsaWI, previously introduced via site-
directed mutagenesis two nucleotides upstream from the scid mutation site in the Prkdc-
BsaWI corrective template. The scid fibroblasts were transduced with lentiviral vectors 
encoding the Prkdc-BsaWI corrective template of 1626 bp and either CMV or SFFV 
driven ZFNs. The sequence of the Prkdc-BsaWI corrective template was verified by 
DNA sequencing (for full sequence please see Appendix 1, Box 2). Upon gene repair, 
the supplemented Prkdc-BsaWI template including the diagnostic BsaWI site will be 
used as a template to repair the genomic locus. The BsaWI assay is based on PCR 
amplification across the target site using primers external to the targeting construct, 
amplicon’s digestion with BsaWI and then Southern blotting to detect the generated 
bands (see Figure  4.17 for more description). This work has been done in collaboration 
with Dr. Céline Rocca at RHUL.  
In this context two Southern blot probes were prepared as described (section 2.2.12.5.2), 
both from the same Prkdc-BsaWI template but differing in their length: a long probe of 
1708 bp and a short probe of 1068 bp (see Figure  4.18). The first and longer was the full 
PCR amplicon of 1708 bp, amplified using the primers external to the Prkdc-BsaWI 
template, purified and electrophoresed to check size and purity. On other hand, the 
shorter one was prepared by BsaWI digestion of the long probe of 1708 bp, preparative 
electrophoresis, retrieval of the 1068-bp fragment from the gel and purification. Firstly, 
the 1708 bp probe was used, but because the smaller band (of 640 bp) detected on the 
gel tends to overlap with non-specific smear, making the calculation of gene repair 
percentage potentially inaccurate, the shorter probe of 1068 bp was used instead.  
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Figure 4.17: BsaWI assay detects ZFN-mediated gene repair. (1) Transduction of the 
mTert scid fibroblasts with Prkdc-BsaWI template and ZFN lentiviral vectors (2) 
Genomic DNA extraction from targeted cells and PCR amplification of region of 
interest (1708 bp) using external primers to Prkdc-BsaWI template (3) Digestion 
overnight (~ 16 h) with BsaWI (4) Electrophoresis of the samples on Southern 
blotting gel and then transfer onto nylon membrane (5) Hybridization with radio-
labelled probe and imaging. U: Unrepaired, R: Repaired.  
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Figure 4.18: Long and short probes for BsaWI assay on 1% agarose gel. The long 
probe (1708 bp) was amplified using primers external to the corrective Prkdc-BsaWI 
template (1626 bp), purified, and electrophoresed to check for expected size and purity; 
whereas the shorter one (1068 bp) was prepared by BsaWI digestion of the long probe, 
electrophoresed, retrieved from the gel and finally purified. DNA ladder: 5 µl of NEB 1 
Kb ladder. 
 
In order to estimate HR at the Prkdc locus in this BsaWI assay, BALB/c 3T3 scid mTert 
fibroblasts were transduced as described earlier (section 2.2.12.2). Many transduction 
scenarios were tested using different MOIs, ratios and combinations of ZFNs and Prkdc 
template. Remarkable results were observed with two transduction plans. The first was 
a three-vector transduction used for ZFN IPLVs (ZFN1 and ZFN2) and Prkdc-BsaWI 
template IDLV at a ratio of ZFN1: ZFN2: template (1: 1: 2). While the second was a 
two-vector transduction used for Prkdc/ZFN IDLVs, where each vector encoded the 
Prkdc-BsaWI template and one of the ZFN monomers, keeping the molar ratio of 
ZFN1: ZFN2: template (1: 1: 2). Tests were conducted in which ZFNs were driven by 
either CMV or SFFV on both IPLV and IDLV configurations.  
Ten days post-transduction, cells were split into two samples: the first was kept aside 
for further analysis (see next sections) and the second used here for this BsaWI assay. 
For this part, the genomic DNA was extracted and the scid target region was PCR 
amplified using external primers to the corrective Prkdc-BsaWI template. Next, the 
amplicons were digested overnight with BsaWI. The digestion products were 
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electrophoresed, transferred onto nylon membrane, hybridised with radio-labelled 
probe, and the blot was scanned and imaged. Finally, gene repair percentages were 
determined using ImageJ by quantification of each band’s intensity (I), 1708 and 1068-
bp bands were imaged, and the following formulas were applied: 
When the long (1708-bp) probe was used, molecules of the full-length 1708-bp uncut 
band are more intense than those of the 1068-bp band, and a correction factor is needed. 
The correction factor enhances the intensity of the 1068-bp band to make it equal to that 
of the 1708-bp band.  Correction factor = 1708/1068=1.60.  
Gene repair % = (100 X 1.6 X I1068) / (I1708 + [1.6 X I1068]). 
While If the small (1068-bp) probe was used, hybridising molecules of the full-length 
1708-bp uncut band or the 1068-bp band produce the same intensity. No correction 
factor is needed in this case.  
Gene repair % = (100 X I1068bp) / (I1708bp+ I1068bp). 
A non transduced (mock) sample was used as a negative control, while a positive 
control was prepared by PCR amplification using the plasmid pHind-TKBsaWI 
(containing a fragment of Prkdc around the scid site and the BsaWI target sequence 
introduced by site-directed mutagenesis) as a template. The positive control was 
amplified using the same primers that were used previously to amplify long probe of 
1708 bp (Material and method section 2.2.12.3). Additional negative controls were 
prepared by transduction of the cells with IDLVs encoding either template only (MOI 
10000) or one ZFN monomer only (MOI 5000). The results revealed (see Figure  4.19) 
that gene repair can be detected when SFFV driven ZFNs were used in both IPLVs and 
IDLVs, as unequivocal detection of the 1068 bp was diagnostic for gene repair. 
Furthermore, gene repair was vector dose-dependent. Surprisingly, no diagnostic band 
was noticed in the case of CMV driven ZFNs used in both IPLVs (data not shown) and 
IDLVs. 
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Figure 4.19: Gene repair at Prkdc locus in BALB/c 3T3 scid mTert fibroblasts 
measured by BsaWI assay. Ten days post-transduction, the BsaWI assay was used to 
detect gene repair events. The presence of the 1068-bp band was diagnostic for gene 
repair. Gene repair percentages were determined using ImageJ by quantification of band 
intensities as described in main text using the long (1708-bp) probe. Gene repair was 
detected when SFFV-driven ZFNs were used in both IPLVs and IDLVs; whereas no 
correction was noticed in case of IDLVs ZFNs driven by CMV. Controls: mock was 
non-transduced fibroblasts, pHind-TKBsaWI was PCR amplification of original 
plasmid containing the template modified by site directed mutagenesis, template/10000 
and SFFV ZFN1/5000 were transduced fibroblasts with IDLVs encoding for Prkdc-
BsaWI template (MOI 10000) and SFFV ZFN1 (MOI 5000); respectively. IPLV 
samples: fibroblasts were transduced at the indicated MOIs with IPLVs driven by 
SFFV. Three vectors were used: ZFN1 and ZFN2 IPLVs; and Prkdc-BsaWI template 
IDLVs at ratio of ZFN1: ZFN2: template (1: 1: 2). For example the number 500 at the 
bottom means that the cells were transduced with MOI 500 of each ZFN IPLV and MOI 
1000 of Prkdc-BsaWI template. IDLV samples: fibroblasts were transduced at the 
indicated MOIs with IDLVs driven by either CMV or SFFV. Two vectors were used: 
template/ZFN1 and template/ ZFN2 IDLVs at molar ratio of ZFN1: ZFN2: template (1: 
1: 2). For example the number 2500 at the bottom means that the cells were transduced 
with MOI 2500 of each of template/ZFN1 and template/ ZFN2 IDLVs.  
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4.7 Rescue of DNA-PK activity 
Gene repair of the mutated genotype should lead to restoration of functional phenotype; 
in this context correction of scid point mutation in the Prkdc gene is expected to restore 
the DNA-PK activity as Prkdc encodes this kinase. Therefore; this experiment was 
designed to investigate whether the activity of DNA-PK was restored after gene repair 
of Prkdc was observed in section  4.6. In order to do that DNA-PK activity was 
measured using SignaTECT DNA-dependent protein kinase assay as described earlier 
(section 2.2.13). This work has been done in collaboration with Dr. Céline Rocca. 
In brief, those samples that showed positive gene repair results in the above BsaWI 
assay (i.e. SFFV ZFN IPLVs and IDLVs) were collected at ten days post-transduction. 
Non-transduced BALB/c 3T3 scid mTert fibroblasts were used as a negative control 
(mock), whereas wt BALB/c 3T3 fibroblasts were used as a positive control. Nuclear 
proteins from the selected samples were extracted using CelLytic nuclear extraction kit. 
Later, these nuclear proteins were incubated with a biotinylated p53-derived DNA-PK 
peptide substrate, an activation buffer containing double strand DNA and [γ-32P] ATP. 
Next, the biotinylated peptide substrate was captured by spotting reactions on individual 
squares on the high binding capacity capture membrane characterized by a high density 
of streptavidin. After several washes of the membrane, the DNA-PK activity was 
quantified by two different systems for more accuracy: scintillation counter and 
phospho-imaging system. Finally the specific activity of DNA-PK was calculated as 
explained earlier (section 2.2.13.2) in pmol ATP/minute and μg of protein. This assay 
was repeated twice.  
 
In Figure  4.20, the results are plotted as a ratio of enzyme specific activity of DNA-PK 
in tested samples relative to that in mock (negative control). There was a vector dose-
dependent restoration of DNA-PK activity when scid fibroblasts were transduced with 
corrective Prkdc-BsaWI template IDLVs and SFFV driven ZFN IPLVs or IDLVs. The 
enzymatic activity of gene-repaired samples was obviously lower than that of wt 
BALB/c 3T3 fibroblasts, due to the fact that the tested samples were polyclonal 
populations (of mutated and repaired cells) in which only a small proportion was gene-
repaired.  
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Figure 4.20: DNA-PK specific activity in gene-repaired BALB/c 3T3 scid mTert 
fibroblasts. Scid fibroblasts were transduced with corrective Prkdc-BsaWI template 
IDLVs and SFFV-driven ZFN IPLVs or IDLVs at the indicated MOIs. Ten days post-
transduction, nuclear proteins were extracted by CelLytic nuclear extraction kit and 
DNA-PK activity of samples was measured by SignaTECT DNA-dependent protein 
kinase assay. The results showed that there was a vector dose-dependent restoration of 
DNA-PK activity which correlated with gene repair. 
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4.8   Enrichment of corrected cells 
Rescue of Prkdc functionality in corrected cells should restore the ability to respond to 
DNA damaging agents, this being further evidence of phenotype rescue of scid cells 
after gene repair. Gene-repaired polyclonal populations from the BsaWI assay (section 
 4.6) were subjected melphalan treatment to assess their phenotype correction. This part 
of the work was carried out in collaboration with Dr. Céline Rocca. 
 
4.8.1 Determination of optimum melphalan dose 
To optimise the cytotoxic dose of melphalan on wt and scid fibroblasts, the MTT assay 
was used to measure cell viability at different melphalan concentrations. The optimum 
dose for enrichment of corrected cells would be chosen to maximise killing of DNA-PK 
deficient cells (mutated scid cells) and survival of DNA-PK proficient cells (gene 
repaired cells).  
 
As described earlier in section 2.2.14.1, the BALB/c 3T3 wt and scid mTert fibroblasts 
were separately seeded and in the next day different melphalan concentrations ranged 
(0.01 -50 µM) were added for 1 hour. After 5 days, MTT was added and left for 4 
hours, and then DMSO was added and only 100 µl from each sample were used to 
measure the optical density at 570 nm. The viability of the cells was worked out using 
that optical density at melphalan zero concentration, which was considered as 100% 
viability. The results showed differential viability of wt and scid fibroblasts, as 
expected. The main finding in this experiment was that a concentration of 10 μM of 
melphalan provided the maximum differential, with approximately 80 % of DNA-PK 
deficient cells and 40 % of DNA-PK proficient cells being eliminated (see Figure  4.21). 
These findings suggested that 10 μM melphalan could be used to attempt to enrich 
polyclonal populations of gene-repaired cells. 
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Figure 4.21: Determination of optimum cytotoxic dose of melphalan in BALB/c 
3T3 wt and scid fibroblasts measured by MTT assay. The fibroblasts were seeded, 
and the next day the culture medium was replaced with fresh medium containing 
different melphalan concentrations (0.01 -50 µM). After one hour of incubation at 37°C, 
medium containing drug was removed and fresh medium added. The plates were then 
incubated for 5 days before adding MTT to determine cell viability. Optical density was 
measured at 570 nm and melphalan zero concentration was considered as 100% 
viability. At concentration of 10 μM of melphalan, approximately 80% of DNA-PK 
deficient cells and 40% of DNA-PK proficient cells were eliminated.  
  
4.8.2 Potential enrichment by melphalan  
To study the possible enrichment of gene-repaired cells in polyclonal populations by 
melphalan treatment, those samples that showed positive gene repair results in the 
above BsaWI assay (section  4.6) were again used in this experiment. These mTert scid 
fibroblasts had been transduced (in triplicate as in section 2.2.14.2) with IDLVs 
encoding for SFFV ZFNs and Prkdc-BsaWI template at a ratio of ZFN1: ZFN2: 
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Template (1:1:2) at MOI 500, 1000, 2500 or 5000. Mock (non-transduced), template 
only IDLVs (MOI 10000) and SFFV ZFN1 IDLVs (MOI 5000) transduced fibroblasts 
were used as negative controls. The samples were allowed to grow for 3 weeks post-
transduction, with weekly treatments with 10 μM melphalan.  
Melphalan belongs to the nitrogen mustard family of cross-linking anticancer drugs (De 
Silva et al., 2000) that can induce DSB by a genotoxic mode not affecting cell survival 
at low concentrations (Vock et al., 1999). Melphalan induced-DSBs can be repaired by 
NHEJ, and most crucially DNA-PK is determinant factor in the cellular response to this 
DNA damaging agent (Muller et al., 2000). In a mixed cell population, DNA-PK 
proficient (gene-repaired) cells could be enriched with melphalan as they possess intact 
DNA repair mechanism whereas other DNA-PK deficient (scid) cells will be eliminated 
because of their faulty NHEJ DNA repair. 
The results show (Figure  4.22) that the number of melphalan-resistant CFUs was 
remarkably vector dose-dependent: the higher the MOI used, the more melphalan 
resistant CFUs emerged. It is noteworthy that it was impossible to keep in culture the 
cells transduced with ZFN IPLVs, most likely because the continuous expression of the 
ZFNs in the cells may mediate cytotoxicity and cell loss.   
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Figure 4.22: Melphalan resistant CFUs after enrichment of gene repaired cells. 
Gene-targeted cells with IDLVs encoding for SFFV ZFNs and corrective Prkdc-BsaWI 
template were seeded in triplicate at the indicated MOIs. The next day, 10 μM of 
melphalan was added for 1 hour and then replaced by fresh medium. The cells were 
kept in culture for 3 weeks with weekly melphalan exposure, stained with crystal violet 
and finally CFUs were counted. The number of melphalan-resistant CFUs was 
significantly dose-dependent. 
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4.9 Detection of gene repair in melphalan enriched cells  
To study whether melphalan-mediated enrichment in CFUs of the population of targeted 
mTert scid fibroblasts from the previous experiment (section  4.8.2) has correlated with 
gene repair at the molecular level, the BsaWI assay was repeated. For this, melphalan-
enriched samples were subjected to this assay alongside to untreated gene-repaired cells.  
Recapping, the mTert scid fibroblasts were transduced in triplicate with IDLVs 
encoding SFFV-ZFNs and corrective Prkdc-BsaWI template using a ratio of ZFN1: 
ZFN2: Template (1:1:2) at MOI 500 or 2500. Mock (non-transduced), Prkdc-BsaWI 
template only IDLVs (MOI 10000) and SFFV ZFN1 IDLVs (MOI 5000)-transduced 
fibroblasts were used as negative controls. The positive control was prepared by PCR 
amplification of plasmid pHind-TKBsaWI using the same primers that were used 
previously to amplify long probe of 1708 bp (Material and method section 2.2.12.3). 
The melphalan non-treated cells of controls and samples were harvested after 10 days 
and kept aside; while all melphalan-treated cells were maintained in culture for 3 weeks 
with weekly melphalan exposure. At three weeks post-transduction, melphalan resistant 
CFUs were counted (this part was completed above in section  4.8.2), then the CFUs 
were harvested and finally genomic DNA was extracted and subjected to the BsaWI 
assay.  
The results showed (Figure  4.23) that for both IDLV MOIs there was a considerable 
increase in gene repair frequency detected after enrichment with melphalan, compared 
to that without drug treatment. This suggests that gene-repaired cells have a selective 
advantage over uncorrected scid cells in the presence of melphalan.  
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Figure 4.23: Gene repair levels at Prkdc locus in polyclonal gene-repaired scid 
fibroblast populations, with or without melphalan enrichment. The mTert scid 
fibroblasts were transduced with IDLVs encoding the ZFNs and Prkdc-BsaWI template 
at the indicated MOIs. The melphalan non-treated cells were harvested at ten days post-
transduction, while other cells were subjected to weekly treatments of 10 μM melphalan 
for one hour, for 3 weeks. Finally genomic DNA was extracted and the BsaWI assay 
was performed. The percentage of gene-repaired cells was determined as described 
earlier in main text using the small (1068-bp) probe. A considerable increase in gene 
repair frequency was detected after treatment with melphalan. 
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Chapter Five 
ZFN activity in scid HSCs 
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5 ZFN activity in scid HSCs  
In this part of work, I have optimised vectors and experiments to explore ZFN activity 
ex vivo. Two main objectives were planned for: (i) achieving the highest possible 
transduction efficiency in scid HSCs, as they are delicate to culture and hard to 
transduce; and (ii) demonstrating ZFN cutting by Surveyor Cel-I assay and then gene 
repair events by BsaWI assay. To do this, I used wt HSCs to optimise HSC purification 
by magnetic cell depletion, transduced HSCs with eGFP lentiviral vectors, cultured the 
cells for three days and then assessed transduction efficiency and viability by flow 
cytometry. Having set up these parameters, I conducted working with scid HSCs, 
testing their viability and transduction with different lentiviral and adenoviral vectors 
driven by different promoters. Optimal parameters and vectors were then used to study 
ZFN cutting and gene repair. 
 
5.1 Isolation of lin- HSCs 
5.1.1 Isolation, depletion and transduction of wt lin- HSCs 
Here I conducted a preliminary experiment to test the efficiency of isolation of wt lin- 
HSCs and to explore lentiviral transduction efficiency in those cells. The wt mice strain 
BALB/cOlaHsd was used to isolate wt bone marrow HSCs as described earlier (section 
2.2.11). On the other hand, a lentiviral transfer plasmid pRRLsc-CEW was used to 
prepare IPLVs and IDLVs encoding for CMV-driven eGFP and WPRE element (CEW 
vectors). The aims of these experiments were to explore efficiency of isolation, 
transduction with CEW vectors and viability 72 hours post-transduction. Optimisation 
of these parameters will be helpful to set the major experiment with scid HSCs. 
The average of total bone marrow isolated wt HSCs was ~ 4.8 X 107 per 7-week old 
male mouse; whereas average of recovered lin- wt HSCs was ~ 6.5 X 105 per mouse, ~ 
1.4 % of original total cells. Lin- depleted population of wt HSCs were cultured at 
maximum density of 1 X105 cells/well and subsequently transduced with CEW IPLVs 
or IDLVs using qPCR MOIs 500, 1000 or 2000. After 72 hours the culture was 
terminated and eGFP expression and cell viability were examined by flow-cytometry. 
The viability was determined by DAPI staining at final concentration of 1µg/ml. In flow 
cytometric analysis loss of membrane integrity is an indicator of cell death; hence the 
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cells that exclude the dye are considered viable, while cells with non-intact membranes 
allow the dye inside the cell. 
The results revealed (Figure  5.1) that the viability for the mock was 78 % and for other 
samples gradually decreased with increasing MOIs. eGFP transduction efficiency was 
28 %, 41 % and 76 % when HSCs were transduced with CEW IPLVs at MOI 500, 1000 
and 2000, respectively; it was 21 %, 35 % and 52 % when HSCs were transduced with 
CEW IDLVs at MOI 500, 1000 and 2000, respectively.  
 
 
Figure 5.1: Transduction of mouse wt lin- HSCs with CEW lentivectors. Depleted 
lin- wt HSCs were transduced at the indicated qPCR MOIs with CEW IPLVs or IDLVs.  
(A) Viability (measured by DAPI staining) and (B) transduction efficiency were 
determined three days post-transduction by flow cytometry.  
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5.1.2 Isolation, depletion and transduction of scid lin- HSCs 
The ultimate target cells to be corrected by gene repair in this project are the scid HSC 
progenitors, ideally using efficient non integrating vectors coding for ZFNs. Therefore; 
a series of experiments were carried out to explore the highest possible transduction 
efficiency that could be achieved in these cells. The scid mouse strain BALB/ cJHan 
(tm)Hsd-Prkdcscid was used to isolate scid lin- HSCs. The only known genetic 
alteration in these scid mice is the point mutation at Prkdc gene. The same protocol that 
was used to deplete and culture wt HSCs (section  5.1.1 above) was used again but this 
time using scid mice. These experiments aimed again at exploring: efficiency of 
isolation, transduction eGFP and viability 72 hours post-transduction.  
For the aim of achieving the highest possible transduction in these cells, lentiviral 
vectors driven by different promoters or adenoviral vectors (serotype 5) driven by CMV 
promoter, all encoding an eGFP cassette, were used.  
The average of total bone marrow isolated scid HSCs was ~ 2 X 107 per 7-week old 
male mouse; whereas average of recovered lin- scid HSCs was ~ 5 X 105 per mouse, 
~2.5 % of original total cells. Lin- scid HSCs were cultured at same density and 
conditions used for wt HSCs. Initially I used CEW IPLVs and IDLVs to transduce lin- 
depleted population of scid HSCs using qPCR MOIs 500, 1000, 2500 or 5000. After 72 
hours the culture was terminated and eGFP expression and viability were examined by 
flow-cytometry. The viability was determined by DAPI staining. The results obtained 
from this experiment (Figure  5.2) showed that the viability for the mock scid cells and 
IPLV-transduced HSCs was more than 80 % and about 70 % for the IDLV-transduced 
HSCs. Transduced cells had approximately the same viability levels regardless of MOI, 
suggesting that there were no toxic lentivector effects related to MOI increase. On the 
other hand, transduction efficiency of CEW IPLVs and IDLVs was similar and MOI 
dose-dependent, reaching more than 75 % of total population at MOI 5000. However; 
mean fluorescent intensity (MFI) index, which is an indicator of the cell’s eGFP 
intensity, showed MOI-related increases eGFP for IPLVs but not for IDLVs. 
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Figure 5.2: Transduction of mouse scid HSCs with CEW lentivectors. Depleted lin- 
scid HSCs were transduced at the indicated qPCR MOIs with CEW IPLVs or IDLVs.  
(A) Viability (measured by DAPI staining), (B) transduction efficiency and (C) MFI 
index were determined three days post-transduction by flow cytometry. Transduction 
efficiency was MOI dose-dependent for both vector types, but MFI index eGFP 
increased with dose only for IPLVs. There was no obvious vector-related toxicity.  
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Additionally, I used lentiviral transfer plasmid pHR’sc-SEW to prepare IPLVs and 
IDLVs encoding for SFFV-driven eGFP cassette and WPRE element (SEW vectors). 
Then I transduced lin- depleted population of scid HSCs with SEW IPLVs and IDLVs at 
qPCR MOI 500, 1000, 2500 or 5000. Three days later, I examined eGFP expression and 
viability (DAPI) by flow-cytometry.  
The results (Figure  5.3) showed that the viability for the mock scid cells, IPLV- and 
IDLV-transduced HSCs was similar and above 75 %, suggesting that there were no 
lentivector-related toxic effects. Importantly, transduction efficiency of SEW IPLVs 
was MOI dose-dependent, reaching more than 90 % of total population at MOI 5000. 
Furthermore, the MFI index showed a dose-dependent increase eGFP with IPLVs. Yet 
SEW IDLVs transduction efficiency was very poor in these cells. 
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Figure 5.3: Transduction of mouse scid HSCs with SEW lentivectors. Depleted lin- 
scid HSCs were transduced at the indicated qPCR MOIs with SEW IPLVs or IDLVs.  
(A) Viability (measured by DAPI staining), (B) transduction efficiency and (C) MFI 
index were determined three days post-transduction by flow cytometry. Transduction 
efficiency and MFI index were MOI dose-dependent for IPLVs, but very poor with 
IDLVs eGFP. There was no vector-related toxicity.  
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In collaboration with Miss. Sara Oliván at RHUL a set of IDLVs encoding for eGFP but 
driven by different promoters was prepared. They included vectors prepared using the 
following lentiviral transfer plasmids (1) pRRLsc-eGFP-W to prepare control IDLVs 
coding for eGFP without external promoter, (2) pRRLsc-GFAP-eGFP-W to prepare 
IDLVs coding for eGFP driven by glial fibrillary acidic protein (GFAP) promoter, (3) 
pRRLsc-PGK-eGFP-W to prepare IDLVs coding for eGFP driven by phosphoglycerate 
kinase (PGK) gene promoter, (4) pRRLsc-SV40-eGFP-W to prepare IDLVs coding for 
eGFP driven by SV40 promoter, (5) pRRLsc-P11.5-eGFP-W to prepare IDLVs coding 
for eGFP driven by the African swine fever virus (ASFV) P11.5 promoter and (6) 
pRRLsc-P54-eGFP-W to prepare IDLVs coding for eGFP driven by the ASFV P54 
promoter. Both P11.5 and P54 promoters are PCR-amplified from the ASFV genome. 
This virus is the etiological agent of a highly lethal hemorrhagic disease of domestic 
swine (Tulman et al., 2009). 
The scid HSC lin- depleted population was then transduced with eGFP IDLVs 
controlled by different promoters at qPCR MOI 200, 1000 or 5000. Three days later, 
eGFP expression and viability (DAPI) were examined by flow cytometry. The results 
showed (see Figure  5.4) that the viability for the mock and IDLV-transduced cells was 
similar and higher than 70 %, suggesting that there were no lentiviral-related toxic 
effects. Unfortunately, none of the tested promoters led to efficient eGFP expression in 
lin- HSCs even at MOI 5000, the highest eGFP expression achieved being ~ 14 % with 
the P54 promoter followed by ~ 12 % with control IDLVs which could be explained to 
possible cryptic promoter active in HSCs in promoterless backbone, or residual activity 
of SIN LTR. 
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Figure 5.4: Transduction of mouse scid HSCs with eGFP IDLVs driven by 
different promoters. Depleted lin- scid HSCs were transduced at the indicated qPCR 
MOIs with eGFP IDLVs driven by either no external promoter (control), GFAP, P11.5, 
P54, PGK or SV40 promoters. (A) Viability (measured by DAPI staining), (B) 
transduction efficiency and (C) MFI index were determined three days post-transduction 
by flow cytometry. There was no vector-related cytotoxicity; yet the transduction 
efficiency was very poor. 
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Alternatively and for the same reason of exploring maximum possible transduction 
efficiency that could be obtained in these cells, three different adenoviral vectors (Ad 5) 
were used. They were a kind gift from Dr. Ramon Alemany, Institut Català 
d´Oncologia, IDIBELL, Spain. These adenoviral vectors were modified Ad5, 
expressing eGFP under the constitutive CMV promoter replacing E1 region. The 
mechanism of Ad5 cell infection involves two chronological virus–cell interactions; 
first binding of ﬁber knob domain to the primary CAR then followed by interaction of 
the Arg–Gly–Asp (RGD) motif of the penton base with cellular integrins initiating a 
faster adenovirus cell entry. The 3 received adenoviral vectors were: TL (AdTL) 
unmodified Ad 5, KKT (AdTKRGDK) modified adenovirus that has heparin sulfate 
glycosaminoglycans putative-binding site KKT inserted in the Ad5 fiber shaft domain, 
and TLRGD (AdTLRGD) modified adenovirus that has RGD motif inserted in the HI 
loop of the fiber knob. These insertions results in adenoviral enhanced cellular entry and 
different biodistribution proﬁle  (Alemany and Curiel, 2001; Bayo-Puxan et al., 2009; 
Sandovici et al., 2006). For gene therapy applications, adenovirus serotype 5 could be 
good vectors as they can be produced at high titres and efficiently transduce a broad 
range of cell types (Bayo-Puxan et al., 2006). 
This experiment was done by transduction of scid HSCs lin- depleted population with 
the said eGFP adenoviral vectors controlled by CMV promoter at qPCR MOI 10000, 
25000, 50000, 100000, 200000 or 400000. Then after three days, eGFP expression and 
viability (DAPI) were examined by flow-cytometry. The results revealed (Figure  5.5) 
that the viability for the mock scid HSCs, AdTL and AdTKRGDK-transduced cells was 
more than 70 %. However; viability of AdTLRGD-transduced cells decreased 
particularly with increasing MOI, suggesting that there was a related cytotoxic effect. 
This experiment showed clearly that while the MFI achieved could be relatively high, 
the percentage of eGFP expression was very poor even at a very high MOI of 400000. 
The highest eGFP expression, noticed with AdTLRGD adenoviral vectors, was 
correlated with reduced viability. It can be concluded from this experiment that none of 
the tested adenoviral vectors expressed eGFP efficiently in these cells and they were not 
investigated further. The main conclusion that can be made from these experiments is 
that among the tested vectors, configurations and promoters, SFFV IPLVs and CMV 
IDLVs were the most efficient. 
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Figure 5.5: Transduction of mouse scid HSCs with CMV eGFP adenoviral vectors. 
Purified lin- scid HSCs were transduced at the indicated qPCR MOIs with CMV eGFP 
adenoviral vectors. (A) Viability (measured by DAPI staining), (B) transduction 
efficiency and (C) MFI index were determined three days post-transduction by flow 
cytometry.  Transduction with AdTL and AdTKRGDK did not cause cytotoxicity; in 
contrast to AdTLRGD. Clearly, adenoviral transduction efficiency was very poor. 
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5.2 Testing the efficiency of ZFN cutting in scid HSCs 
I have shown in the previous chapter that ZFN-induced-DSBs repaired by NHEJ in scid 
fibroblasts can be detected by the Surveyor Cel-I mutation detection assay; likewise I 
used the same assay to examine ZFN-induced-DSBs in scid HSCs. The Surveyor Cel-I 
assay, described earlier in section 2.2.9, can detect mismatches in heteroduplex DNA 
following target site repair by NHEJ.  
Lin- scid HSCs were purified and transduced with either CMV or SFFV ZFN IPLVs or 
IDLVs. IPLV transduction was done with qPCR MOI 200, 500, 1000 or 2500, and for 
IDLVs qPCR MOI 200, 500, 1000, 2500 or 5000 was used. Three days post-
transduction, the samples were collected and viability was determined by flow 
cytometry using DAPI staining. Genomic DNA was extracted and then subjected to 
Surveyor Cel-I assay. Same as in fibroblasts, PCR amplification generates a 304-bp 
parental fragment (for DNA sequence please see Appendix 1, Box 1) and upon cutting 
by Surveyor’s nuclease (at ZFN repaired DSB) two smaller fragments of 184 and 126 
bp are generated. Samples were run in PAGE, visualized under UV light, images taken 
and finally cutting percentages were calculated using ImageJ. 
The results shown in Figure  5.6 demonstrate efficient ZFN cutting (and hence 
expression) when SFFV IPLVs were used, while nothing could be detected by this 
assay in the other samples tested (SFFV IDLVs, CMV IPLVs and IDLVs). 
Furthermore, cell viability (see Figure  5.7 ) was strongly affected proportionally to 
Surveyor ZFN cutting with SFFV IPLVs. Additionally, those samples that were treated 
with CMV IDLVs had lower viability than those treated with SFFV IDLVs and CMV 
IPLVs samples; this could be ascribed to the fact that the CMV IDLV titre was lower 
than that of others, requiring a higher volume of viral suspension for transduction to 
obtain the desired MIOs. Adding a higher volume of viral suspension would dilute the 
HSC medium, perhaps causing a reduction in viability. 
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Figure 5.6: Site-specific cutting by ZFNs determined by Surveyor Cel-I assay in 
scid HSCs. Purified lin- scid HSCs were transduced at the indicated qPCR MOIs with 
either CMV ZFN lentivectors (upper panel) or SFFV lentivectors (lower panel). Three 
days later cells were harvested, genomic DNA was extracted and then samples were 
examined by Surveyor Cel-I assay. The PCR amplification generates a 304-bp parental 
fragment and upon Surveyor’s nuclease cutting (at ZFN target) two smaller fragments 
of 184 and 126 bp (red arrows) are produced and visualised in 10 % PAGE. The results 
confirmed that there was efficient ZFN expression and cutting with SFFV IPLVs but 
not with other combinations. Percentages represent ZFN cutting percentage calculated 
using ImageJ. M: mock, C1: CMV ZFN1, C2: CMV ZFN2, S1: SFFV ZFN1 and S2: 
SFFV ZFN2. + Control was a mixture of scid/wt fibroblasts (50/50) % used as a 
positive control; Surveyor’s nuclease cut at scid point mutation site generates fragments 
of 88 and 216 bp. 
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Figure 5.7: Viability of scid HSCs transduced with either CMV or SFFV ZFN 
IPLVs and IDLVs. Scid HSCs were transduced at the indicated MOIs with ZFN IPLVs 
or IDLVs driven by either CMV or SFFV. Viability was determined three days later by 
flow cytometry using DAPI staining. Cell viability was strongly affected in a manner 
proportional to ZFN cutting when cells were transduced with SFFV IPLVs. C1: CMV 
ZFN1, C2: CMV ZFN2, S1:SFFV ZFN1 and S2: SFFV ZFN2. 
 
I have shown earlier in section 4.5.1 that the minimal percentage of mismatches that can 
be detected by Surveyor Cel-I assay was 5 %. In order to improve the sensitivity of 
InDel detection in samples that did not show clear cutting in the Surveyor Cel-I assay, a 
selected set of samples (SFFV IDLV-treated) was subjected to deep sequencing. This 
was done in collaboration with Dr. Manfred Schmidt at National Center for Tumor 
Diseases, Heidelberg, Germany. Depending on the depth of coverage, each base can be 
read hundreds of times during the sequencing process allowing identifying of very rare 
sequence mutations (Morozova et al., 2009). 
The PCR amplicons of 304-bp resulting from transduction of scid HSCs with SFFV 
IDLVs at qPCR MOI 200, 500, 1000, 2500 or 5000 were shipped to complete this 
analysis. The results in Table  5.1 revealed that ZFNs driven by SFFV in non integrating 
lentivector configuration can induce low but detectable levels of DSBs that can be 
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repaired by NHEJ and measured as InDel events. The highest % of InDels was observed 
at MOI 2500, being approximately 0.5 %.   
 
Table 5.1: Deep sequencing results in SFFV IDLV-treated scid HSCs 
Sample Sequenced molecules InDels InDels % 
Mock 15163 12 0.08% 
SFFV IDLVs (S1+S2) 200 4214 4 0.09% 
SFFV IDLVs (S1+S2) 500 5723 15 0.26% 
SFFV IDLVs (S1+S2) 1000 12832 45 0.35% 
SFFV IDLVs (S1+S2) 2500 18262 90 0.49% 
SFFV IDLVs (S1+S2) 5000 11234 52 0.46% 
 
 
5.3 Detection of gene repair by BsaWI assay in scid HSCs 
The BsaWI assay was used again in this experiment so that HR events in targeted scid 
HSCs could be detected exploiting the silent diagnostic restriction site for BsaWI in the 
Prkdc-BsaWI corrective template. During the process of gene repair, the supplemented 
corrective template containing the diagnostic BsaWI site would mediate the transfer of 
the site to the host genome. Eventually the presence of the BsaWI site in Prkdc-BsaWI 
template would be diagnostic of gene repair occurrence. This work was done in 
collaboration with Dr. Céline Rocca at RHUL. 
 
The BsaWI assay was done as described earlier (section 2.2.12); in brief the lin- scid 
HSCs were targeted with lentivectors encoding the Prkdc-BsaWI corrective template of 
1626 bp and either CMV or SFFV ZFNs. For CMV or SFFV ZFN IPLVs three vectors 
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were used for cell co-transduction: two ZFN IPLVs (ZFN1 and ZFN2) and Prkdc-
BsaWI template IDLVs with a ratio of ZFN1: ZFN2: template (1: 1: 2). For CMV or 
SFFV IDLVs two vectors were used for transduction, where the template and each of 
the ZFN monomers were encoded by the same vector, keeping ratios of ZFN1: ZFN2: 
template (1: 1: 2). A non-transduced (mock) sample was used as a negative control, 
while the plasmid pHind-TKBsaWI (containing a 9210 bp fragment of Prkdc around the 
scid site and with the BsaWI target sequence introduced by site-directed mutagenesis)  
was used as a template to amplify the positive control by PCR.  
 
Three days post-transduction, genomic DNA was extracted and the sequence around the 
scid target site was PCR amplified using primers external to the Prkdc-BsaWI 
corrective template. Next, the amplicons were digested with BsaWI to assay for the 
presence of the diagnostic feature (BsaWI site). Later, the transferred blot was 
hybridised with the long radiolabelled probe (1708 bp), scanned and imaged. Finally, 
gene repair percentages were determined using ImageJ by quantification of band 
intensities (i.e. 1708 and 1068) then the following formula was applied: 
 
Gene repair % = (100 X 1.6 X I1068) / (I1708 + [1.6 X I1068]). 
 
The results (see Figure  5.8) revealed that a faint band of gene repair could be detected 
only when SFFV ZFN IPLVs were used at MOI 100, with detection of the 1068 bp 
being diagnostic for gene repair. No detectable gene repair could be observed with 
SFFV IDLVs or CMV IPLVs and IDLVs. 
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Figure 5.8: Gene repair at Prkdc locus in scid HSCs, measured by BsaWI assay. 
Three days post-transduction, the BsaWI assay was used to detect gene repair events. 
The presence of the smaller 1068-bp band was diagnostic for gene repair. Gene repair 
percentages were determined using ImageJ by quantification of band intensities as 
described in main text. Gene repair could be detected only when SFFV ZFN IPLVs 
were used at MOI 100. Controls: mock were non-transduced fibroblasts and pHind-
TKBsaWI plasmid containing the template modified by site-directed mutagenesis. IPLV 
samples: scid HSCs were transduced at the indicated MOIs with IPLVs driven by either 
CMV or SFFV. Three vectors were used: ZFN1 and ZFN2 IPLVs, and template IDLVs, 
at a ratio of ZFN1: ZFN2: template (1: 1: 2). For example, the number 500 on the figure 
indicates that the cells were transduced with MOI 500 of each ZFN vector and MOI 
1000 of Prkdc-BsaWI template vector. IDLV samples: scid HSCs were transduced at 
the indicated MOIs with IDLVs driven by either CMV or SFFV. Two vectors were 
used: template/ZFN1 and template/ ZFN2 IDLVs, at a ratio of ZFN1: ZFN2: template 
(1: 1: 2). For example the number 2500 on the figure indicates that the cells were 
transduced with MOI 2500 of each of template/ZFN1 and template/ ZFN2 IDLVs.  
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6 Ex vivo gene repair and transplantation  
Here I conducted the main experiment in the current study; the ex vivo gene repair of 
scid HSCs and transplantation after optimisation of ex vivo protocol. The recipient mice 
were divided into four groups of five animals each. I carried out the purification of lin- 
HSCs then I transduced them overnight with lentiviral vectors where applicable 
according to animal groups. Next I did the transplantation of potentially corrected scid 
HSCs into irradiated scid recipients. The recipient mice were bled at weeks 9, 16 and 24 
post-transplantation. The multicolour flow cytometric analysis was performed for all 
animals by targeting specific CD markers in B cells, T cells and other haematopoietic 
cells. The transplantation experiment was completed with help of Dr. Michael Blundell; 
while the multicolour flow cytometric analysis was done with help of Dr. Maria 
Alonso-Ferrero.  
6.1 Transplantation of lin- HSCs 
In the previous chapters I developed a new gene therapy strategy based on gene repair 
using ZFN technology and IDLV platform delivery to rescue the classical scid mouse 
(Prkdc point mutant). Importantly, I have already demonstrated by Cel-I assay and deep 
sequencing in scid fibroblasts and HSCs that the ZFNs cut specifically their target site. 
Furthermore; I used ZFN- and template-mediated gene targeting to correct the Prkdc 
point mutation via the incorporation of "neo" selection cassette and/or a diagnostic 
feature of BsaWI restriction site from the donor templates into the targeted locus. Also I 
showed restoration of DNA-PKcs functionality and increased resistance to DNA 
damage upon gene repair in scid fibroblasts; while in scid HSCs, gene repair was 
confirmed only when the ZFN genes were delivered by IPLVs. Considering all above 
promising finding, I proceeded to the ex vivo gene repair transplantation of corrected 
scid HSCs into scid recipients to attempt immune system reconstitution. 
 
6.1.1 Transplantation experiment design  
 
In this transplantation experiment, I designed 4 different groups contained 5 animals 
each: wt control, eGFP control, ZFN IPLVs and ZFN IDLVs (see Table  6.1). The 
donors were either wt male BALB/c OlaHsd mice for the wt control (group 1) or scid 
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male BALB/c JHan(tm)Hsd-Prkdcscid mice for the eGFP control (group 2) and ZFN 
groups (3 and 4). I used scid female BALB/c JHan(tm)Hsd-Prkdcscid mice as recipients 
(Table  6.1). The donor mice were euthanized by inhalation of a 75 % CO2 / 25 % O2 
mixture and hematopoietic cells were harvested from the bone marrow of femurs and 
tibia then the lineage cell depletion kit was used as usual for lin- HSCs purification as 
described before (section 2.2.11).  
Table 6.1: Animal groups used in transplantation experiment. 
Group 
# 
Group name Donors (males) 
qPCR 
MOI 
Recipients (females) 
1 Wt control (BALB/c OlaHsd) - 
BALB/c JHan(tm)Hsd-
Prkdcscid 
2 eGFP control 
BALB/c JHan(tm)Hsd-
Prkdcscid transduced 
with CEW IPLVs 
400 
BALB/c JHan(tm)Hsd-
Prkdcscid 
3 ZFN IPLV  
BALB/c JHan(tm)Hsd-
Prkdcscid transduced 
with template IDLVs, 
SFFV IPLVs ZFN1 and 
ZFN2 
200: 100: 
100 
BALB/c JHan(tm)Hsd-
Prkdcscid 
4 ZFN IDLV  
BALB/c JHan(tm)Hsd-
Prkdcscid transduced 
with IDLVs 
template/CMV ZFN1 and  
template/CMV ZFN2 
500: 500 
BALB/c JHan(tm)Hsd-
Prkdcscid 
 
Then the scid lin- HSCs in eGFP control group were transduced overnight (see next 
section) with CEW IPLVs at 400 qPCR MOI to match the total MOI that will be used 
for ZFN IPLVs group. In parallel the sample of ZFN IPLV group were transduced 
overnight with Prkdc-BsaWI template IDLVs, SFFV ZFN1 and ZFN2 IPLVs at qPCR 
MOI 200: 100: 100, respectively. This combination is similar to that one I used earlier 
in (section 5.3) which demonstrated gene repair of 8.3% in scid HSCs. Simultaneously 
the sample of ZFN IDLV group were transduced overnight with Prkdc-BsaWI 
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template/CMV ZFN1 and Prkdc-BsaWI template/CMV ZFN2 IDLVs at qPCR MOI 
500: 500; respectively. 
 
6.1.2 Overnight transduction and preparation for injection  
 
Following transduction, the lin- HSCs cells of wt control group and other transduced 
scid lin- HSCs for other groups were cultured at 106 cells/ml in Stemspan medium 
containing 100 ng/ml Murine SCF, 100 ng/ml Murine Flt-3, 20 ng/ml human IL-6 and 1 
% PenStrep at 5 % CO2, 37 °C for 16 hours. Next day the HSCs were prepared for 
intravenous injection into irradiated recipient mice; briefly the culture medium was 
removed and then the cells were washed and resuspended in PBS. All the recipients 
were sublethally irradiated with a total of 2.5 Gy/mouse in a single dose same day 
before injections. As these scid animals were Prkdc deficient and lacking efficient DNA 
damage response, I used a lower irradiation dose than that used earlier for other scid 
types (Fulop and Phillips, 1986; Mostoslavsky et al., 2006).  
 
6.1.3 Transplantation  
 
The recipient mice were used at 7 weeks of age and were maintained in specified 
pathogen free conditions. Each recipient was injected with 1 X 106 cells in 200 μl plain 
PBS using intravenous injection route into the tail vein by 27 G bevel needle attached to 
a tuberculin syringe. Other gene therapy strategies used to rescue other scid models 
have used lower numbers of injected cells than in this study as they were simply based 
on gene addition approach (Huston et al., 2011); here the transplantation was conducted 
with maximum experimentally feasible HSC numbers in order to maximise the chances 
of transplanting corrected cells into the recipients.  
Using DAPI staining and flow cytometry, the viability of all cells to be transplanted was 
checked out one hour before their injection. Additionally, the majority of the cells in 
eGFP control group were transplanted back into the recipients; however one well of 105 
cells of each of mock and eGFP IPLV-transduced scid lin- HSCs were kept in culture 
for 72 hours post-transduction to subsequently test their eGFP expression by flow 
cytometry. 
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The transplantation was done for two groups per day in two successive days: the control 
groups in the first day and the ZFN groups the next day. Flow cytometry results for 
viability of lin- HSCs before injection of all groups are shown in Figure  6.1. For wt lin- 
HSCs (wt control group) and scid mock or eGFP transduced (eGFP control group) the 
viability was about 45 %; while for ZFN groups was about 70 %. As in the current 
study the viability was normally close to 70 %, the lower viability values observed for 
the two control groups were likely due to technical issues noticed during lin- HSC 
depletion.  
 
Figure 6.1: Viability of mouse lin- HSCs one hour before transplantation. Purified 
wt and/or scid lin- HSCs of transplantation groups (wt control, eGFP control, ZFN 
IPLVs and ZFN IDLVs) were transduced where applicable with lentiviral vectors and 
cultured at 106 cells/ml for 16 hours. The viability was measured by DAPI staining 
followed by flow cytometry. The results showed that viability for the control samples 
(three leftmost columns) was about 45 %; while for the other groups was about 70 %.  
 
On the other hand, flow cytometry results for eGFP expression of mock and eGFP 
IPLV-transduced scid lin- HSCs of eGFP group at 72 hours post-transduction are shown 
in Figure  6.2. The results demonstrated that the eGFP expression of eGFP IPLV- 
transduced scid lin- HSCs was 28 %, this finding will be informative as it will be used 
as a reference to compare with in vivo eGFP expression in the myeloid lineage 
subsequently.  
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Figure 6.2: Transduction of scid lin- HSCs (eGFP control group) with CEW IPLVs. 
Purified scid lin-HSCs were transduced CEW IPLVs at qPCR MOI 400. Next 72 hours 
the culture was terminated and eGFP expression was determined by flow-cytometry. 
The results revealed that eGFP expression was 28 %. 
 
6.2 Scid phenotype correction.  
6.2.1 Animal bleeding  
In order to evaluate the engraftment and the immune system restoration in the 
transplanted animals by tracking immune cell reconstitution, all animals were bled at 
intervals of 9, 16 and 24 weeks post-transplantation. Samples of ~50 μl of freshly 
isolated peripheral blood from the tail vein were collected in EDTA tubes using a 27 G 
bevel needle attached to a tuberculin syringe. The samples were then prepared as 
described in (section 2.2.15.2). 
6.2.1.1 Week 9 bleeding  
 
Multicolour flow cytometric analysis of all samples, to test for gene-repaired scid lin- 
HSC engraftment, was done by staining each blood sample with three different 
antibodies. The first was anti-human/mouse CD45R (B220) PE antibody to target B-
lymphocytes. The CD45R is a 220-kDa cell-surface glycoprotein expressed mainly by 
the B-cell lineage from early pro-B to mature B cells. CD45R, along with other CD45 
isoforms, helps to control different cellular functions like cell growth, differentiation 
and mitotic cycle (Monteith et al., 1996; Paulovicova et al., 2010).  
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The second antibody was anti-mouse CD3e PerCP-Cy5.5, to target T-lymphocytes. The 
CD3e (e for epsilon) is a 20-kDa subunit of the T-cell receptor (TCR) complex, required 
together with other CD3 subunits, gamma and delta, for appropriate assembly, 
trafficking and surface expression of the TCR complex (Fernandes et al., 2012). CD3e 
expression correlates with T cell maturation, thus it is expressed by thymocytes (T cells 
precursor) in a developmentally regulated manner and by all mature mouse T cells (Lai 
et al., 1998).  
 
The third antibody was anti-mouse CD11b APC to target mainly myeloid cells. It is a 
commonly used marker for the monocyte/macrophage lineage, natural killer (NK) cells 
and granulocytes (Lai et al., 1998). CD11b is a 170 kDa glycoprotein non-covalently 
associated with CD18 to form The CD11b/CD18 integrin which helps to control 
inflammation by accelerating the apoptotic elimination of extravasated neutrophils 
(Castaigne et al., 2002). 
 
Additionally anti-mouse Ig, k /negative control (FBS) compensation beads were used 
(section 2.2.15.3) along with the other blood samples as negative control. The 
compensation was set using rat IgG2a K isotype control PE, Armenian hamster IgG 
isotype control PerCP-Cy5.5, rat IgG2b K isotype control APC or all of them together. 
Similarly anti-human/mouse CD45R (B220) PE antibody, anti-mouse CD3e PerCP-
Cy5.5 antibody or anti-mouse CD11b APC were used with control beads for gate 
compensation.  
 
Flow cytometric results revealed (Figure  6.3 and  6.4) that all scid recipient animals 
transplanted with wt HSCs were fully reconstituted, matching B and T cell levels in 
normal animals. These findings indicated that the transplantation approach was 
successful and all preparation steps before and during transplantation experiment were 
proficiently performed. In the group of scid animals transplanted with eGFP-transduced 
scid cells there was no reconstitution other than in the myeloid lineage, and the average 
of eGFP expression in peripheral blood mononuclear cells (PBMCs) was ~ 32 %. The 
presence of this control was very important as it showed the background levels of both 
B and T cells in non-rescued animals which will be helpful to compare with ZFN-
treated groups. At the same time, eGFP detected fluorescence will give an indication of 
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myeloid engraftment efficiency of lentiviral vector-transduced HSCs. Another finding 
in this group was that the average of total detected myeloid cells for the five animals 
was ~ 54 %, representing the main blood cell population. 
 
For groups ZFN IPLVs and ZFN IDLVs, there were no major increases observed in B 
and T cell levels. However animal number 2 and animal number 3 of ZFN IPLV and 
ZFN IDLV groups, respectively, showed promising results. The animal number 2 of 
ZFN IPLV group showed ~ 4.5 % of T cells, whereas animal number 3 of ZFN IDLV 
group showed ~ 1.5 % of T cells. Crucially, even more important than the percentage 
values was the observed appearance of the T-cell populations (Figure  6.3). Both 
observed populations were clearly isolated and well-shaped pointing out that they might 
be real rescued populations.  
 
On the other hand, no significant B-cell compartments were observed in either ZFN 
IPLV or ZFN IDLV groups. A previous study of murine scid-X1 (γ chain) model rescue 
has suggested that reconstitution of B cells is slower than that of T-cells and requires 
higher numbers of transplanted cells (Huston et al., 2011). As the correction strategy 
attempted in my study is based on gene repair, it is expected that slow reconstitution 
would be normal as a result of the number of rescued cells being low. My observation 
of detectable levels of T-cells but not of B-cells in ZFN-treated groups correlates with 
the published work.  
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Figure 6.3: Flow cytometry analyses of peripheral blood from selected samples at 9 
weeks post-transplantation. Blood samples were collected from recipient mice at 9 
weeks post-transplantation and multicolour flow cytometric analysis of HSC 
engraftment was completed for all animals by staining for CD45R, CD3e and CD11b. 
Images of representative animals of each control group and selected animals from 
treated groups are showed here. The animals of the wt control group were fully 
reconstituted, while only myeloid reconstitution was clearly observed in the eGFP 
control group (eGFP-positive cells are also CD11b-positive, not shown). However one 
animal from each of ZFN IPLV and ZFN IDLV groups showed promising increased 
levels of T cells. 
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Figure 6.4: Percentages of CD45R+, eGFP+, CD3e+ and CD11b+ cells in peripheral 
blood of all animals at 9 weeks post-transplantation. Recipient mice were subjected 
to 2.5 Gy irradiation and transplanted with either 1 × 106 wt lin- cells or scid lin- cells 
transduced with eGFP IPLVs, ZFN IPLVs or ZFN IDLVs. At week 9 post-
transplantation, animals were bled and multicolour flow cytometric analysis of 
engrafted HSCs was conducted for all animals by staining PBMCs for CD45R, CD3e 
and CD11b. All animals in group wt control were convincingly fully reconstituted 
demonstrating normal levels of B and T cells; while none were in eGFP control, ZFN 
IPLV and ZFN IDLV groups. However one animal in each group of ZFN IPLV and 
ZFN IDLV showed promising increased levels of T cells (red circles).  
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6.2.1.2 Week 16 bleeding 
As in week 9 above, all samples were stained with antibodies targeting CD45R (B220), 
CD3e and CD11b. Additionally, flow cytometric analysis for gene-repaired scid lin- 
HSCs engraftment was carried out using two additional antibodies to target mature T 
cells in selected samples of each animal group. The first was anti-Mouse CD4 PE to 
target helper T cells, a subset of mature T cells. The CD4 is a 55 kDa cell surface 
marker could be found in a majority of thymocytes, helper T cells and dendritic cells. 
This receptor plays a vital role both in T cell development and in optimal functioning of 
mature T cells as it is initiates the early phase of T-cell activation (Lai et al., 1998; 
Yucel et al., 2004). 
 
And the second: anti-Mouse CD8a APC to target cytotoxic T cells, a subset of mature T 
cells. The CD8a is an approximately 34 kDa cell surface marker expressed by a 
majority of thymocytes and a subpopulation of mature TCR T cells. CD8 plays a role in 
T cell development and activation of mature T cells by mediating T cell killing effector 
(Lai et al., 1998; Maldonado-Lopez et al., 1999). 
Simultaneously an age-matched wt female mouse of strain BALB/c OlaHsd was bled 
and used as a control by staining with antibodies against CD45R, CD3e and CD11b. As 
in week 9, compensation was set using rat IgG2a K isotype control PE, Armenian 
hamster IgG isotype control PerCP-Cy5.5 rat IgG2b K isotype control APC or all of 
them together. 
 
The results of flow cytometry confirmed again (as illustrated in Figure  6.5 and  6.6) that 
all recipient animals in wt control group were fully reconstituted and matched B and T 
cell levels in normal animals. Once more these findings proved that the transplantation 
experiment and procedure were successful. Meanwhile flow cytometric results of eGFP 
control group demonstrated that the average of eGFP expression was ~ 37 % and there 
was no reconstitution other than in myeloid lineage, as expected in this control group. 
Another finding in this group was that the average of total detected myeloid cells for the 
five animals was ~ 70 % representing the major population of blood cells. 
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Figure 6.5: Flow cytometry analyses of peripheral blood in selected samples at 16 
weeks post-transplantation. Blood samples were collected from recipient mice at 16 
weeks post-transplantation and multicolour flow cytometric analysis for HSC 
engraftment was completed in all animals by staining for CD45R, CD3e and CD11b. 
Images of representative control animals and selected ZFN animals are shown here. 
Animals of wt control group were fully reconstituted; while that was not the case in 
eGFP control group. Confirming the results from the 9-week bleed, one animal in each 
of ZFN IPLV and ZFN IDLV groups showed promising increased levels of T cells.  
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For groups ZFN IPLV and ZFN IDLV, there were no major increases observed in B and 
T cell levels. However animal number 2 and animal number 3 of ZFN IPLV and ZFN 
IDLV groups, respectively, demonstrate again promising results. Animal number 2 of 
ZFN IPLV group showed even higher (~ 7 %) T-cell levels than that in previous 
bleeding, whereas animal number 3 of ZFN IDLVs group showed ~ 1.5 % of T cells. 
Nevertheless the main finding here was that the appearance of the detected T cell 
populations, isolated and well shaped, again suggests that these two populations were 
real rescued populations (Figure  6.5). On the other hand, no increased levels were 
detected in B cell compartments in either ZFN IPLV and ZFN IDLV groups, as 
expected. 
 
In order to further explore whether those increased levels of T cell populations observed 
in the two animals of ZFN IPLV and ZFN IDLV groups represented mature and 
functional T cells, PBMCs from these animals were stained with anti CD4 and CD8a. 
The results obtained from multicolour flow cytometric analysis are presented in Figure 
 6.7. In the representative animal from wt control group, the results indicated that within 
the T-cell population there were two subpopulations belonging to mature T-cell subsets. 
They were ~ 24 % CD4+ and ~ 6 % CD8a+ T cells, representing the frequencies of 
normal BALB/c mouse peripheral blood. Conversely, in a representative animal from 
eGFP control group there were ~ 0.25 % CD4+ and ~ 0.13 % CD8a+ T cells, 
representing the observed reference of non-rescued animals.  
 
The clearer evidence observed in this experiment was with animal 2 from ZFN IPLV 
group, in which ~ 3.1 % CD4+ and ~ 0.62 % CD8a+ T cells were detected. Furthermore 
the results showed that these T-cell subpopulations were well isolated and compact, 
suggesting that they are real and potentially functional T cell populations. Similarly 
with animal 3 from ZFN IDLV group there were ~ 1.57 % CD4+ and ~ 0.5 % CD8a+ T-
cells. The overall conclusion from week 16 post transplantation bleeding suggested that 
there was an emergence of rescued, mature and possibly functional T cell populations, 
as an indicator of slow immune system reconstitution. 
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Figure 6.6: Percentages of CD45R+, eGFP+, CD3e+ and CD11b+ cells in peripheral 
blood of all animals at 16 weeks post-transplantation. Recipient mice were subjected 
to 2.5 Gy irradiation and transplanted with either 1 × 106 wt lin- cells or scid lin- cells 
transduced with eGFP IPLVs, ZFN IPLVs or ZFN IDLVs. At week 16 post-
transplantation, animals were bled and multicolour flow cytometric analysis for HSC 
engraftment was done for all animals by staining for CD45R, CD3e and CD11b. All 
animals in group wt control were fully reconstituted; while none were in eGFP control 
group. In ZFN IPLV and ZFN IDLV groups those two animals that showed increased 
levels of T cells in previous bleeding had even higher levels of T cells this time (red 
circles).  
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Figure 6.7: Flow cytometry analysis of CD4 and CD8 analyses in peripheral blood 
from selected samples at 16 weeks post-transplantation. Blood samples were 
collected from recipient mice at 16 weeks post-transplantation and multicolour flow 
cytometric analysis for HSC engraftment was completed for one animal of each group 
by staining with anti CD4 and CD8a. The animal from wt control group showed ~ 24 % 
CD4+ and ~ 6 % CD8a+, the eGFP control showed ~ 0.25 % CD4+ and ~ 0.13 % CD8a+, 
responder from ZFN IPLV group showed ~ 3.1 % CD4+ and ~ 0.62 % CD8a+ and that 
from ZFN IDLV group showed ~ 1.57 % CD4+ and ~ 0.5 % CD8a+ T cells. 
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6.2.1.3 Week 24 bleeding 
 
At 24 weeks post-transplantation, all animals were again bled and stained with 
antibodies targeting CD45R (B220), CD3e and CD11b in addition to matured T cell 
markers CD4 and CD8a as explained earlier. Age-matched wt female mice of strains 
BALB/c OlaHsd and BALB/c JHan(tm)Hsd-Prkdcscid were used as positive and 
negative controls, respectively. The compensation was set as before with rat IgG2a K 
isotype control PE, Armenian hamster IgG isotype control PerCP-Cy5.5 rat IgG2b K 
isotype control APC or all of them together. 
 
Flow cytometry results are shown in Figure  6.8 , 6.9, and  6.10. Altogether, the results 
confirmed again that all recipient animals in group wt control were fully reconstituted 
and matched B and T cell levels in normal animals, proving that the transplantation 
experiment and procedure were successful. Yet again flow cytometric results of eGFP 
control group showed that the eGFP expression average was ~ 27 % and there was no 
detected reconstitution beyond the myeloid compartment (as expected) in this control 
group. Another finding in this group was that the average of total detected myeloid cells 
for all animals in this group was ~ 75 % as the major population of blood cells. 
 
The responder animal from ZFN IPLV group (animal number 2) showed T cell levels 
even higher than previously observed, reaching ~ 12 % T cell, compared to the T-cell 
average of wt control group of ~ 45 %. This finding represents major evidence of T cell 
reconstitution in this scid animal. On the other hand, animal number 3 of group ZFN 
IDLV demonstrated again an increased level of T cells at ~ 2 %. In both animals, well 
isolated T cell populations and clear T cell level increases (see Figure  6.8) suggest that 
immune reconstitution has begun, albeit at different speed. In contrast, no increased 
levels were detected yet in B cell compartments in either ZFN IPLV or ZFN IDLV 
groups, most likely because gene repair strategy would lead to slow reconstitution in 
general and even slower for B cells.  
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Figure 6.8: Flow cytometry analysis of peripheral blood from selected samples at 
24 weeks post-transplantation. Blood samples were collected from recipient mice at 
24 weeks post-transplantation and multicolour flow cytometric analysis for HSC 
engraftment was completed for all animals by staining for CD45R, CD3e and CD11b. 
Images of one animal of each group are shown here. The animal of group wt control 
was fully reconstituted and representative of the group; no reconstitution beyond 
myeloid compartment was observed in eGFP control. However, the responder animals 
from groups ZFN IPLV and ZFN IDLV showed increased and well-isolated T cell 
populations. 
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Figure 6.9: Percentages of CD45R+, eGFP+, CD3e+ and CD11b+ cells in peripheral 
blood of all animals at 24 weeks post-transplantation. Recipient mice were subjected 
to 2.5 Gy irradiation and transplanted with either 1 × 106 wt lin- cells or scid lin- cells 
transduced with eGFP IPLVs, ZFN IPLVs or ZFN IDLVs. At week 24 post-
transplantation, animals were bled and multicolour flow cytometric analysis for HSC 
engraftment was done for all animals by staining with CD45R, CD3e and CD11b 
antibodies. All animals in group wt control were fully reconstituted, while none were in 
eGFP control group. The number 2 animal of group ZFN IPLV showed distinctly 
increased level of T cells, while number 3 animal of ZFN IDLV group remains at an 
increased but steady T-cell level. Those two animals are circled in red.  
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To confirm that the T-cell populations from the responder ZFN mice contained mature 
T-cell subpopulation as an indication of restoration of functional immune cells, PBMCs 
from representative controls and the responder animal from each ZFN group were 
stained with anti CD4 and CD8a. Multicolour flow cytometric analysis results are 
presented in Figure  6.10. The animal from wt control group showed two subpopulations 
of functional T cell subsets. There were ~ 26 % of CD4+ and ~ 5.5 % of CD8a+ T cells, 
similar to normal BALB/c mouse peripheral blood. In contrast the animal from the 
eGFP control group had ~ 0.5 % CD4+ and ~ 0.3 % CD8a+ T cells, indicative of the 
reference value of non-rescued animals.  
 
Evidence confirming restoration of mature immune cells was obtained from animal 
number 2 of ZFN IPLV group, which had ~ 10 % CD4+ and ~ 3 % CD8a+ T cells, 
observed as well-isolated T cell subsets. Animal number 3 of ZFN IDLV group showed 
~ 2.3 % CD4+ and ~ 0.8 % CD8a+ T cells, suggesting again the presence of two mature 
T cell subsets. It can be concluded that at week 24 post-transplantation there was clear 
evidence of rescued, mature T cell population in two responder mice, as an indicator of 
a possible slow immune system reconstitution. 
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Figure 6.10: Flow cytometry analysis of CD4 and CD8 populations in peripheral 
blood of selected samples at 24 weeks post-transplantation. Blood samples were 
collected from recipient mice at 24 weeks post-transplantation and multicolour flow 
cytometric analysis for HSC engraftment was completed for one animal of each group 
by staining with anti CD4 and CD8a. The animal of group wt control showed ~ 26 % 
CD4+ and ~ 5.5 % CD8a+, the eGFP control showed ~ 0.5 % CD4+ and ~ 0.3 % CD8a+, 
the ZFN IPLV responder showed ~ 10 % CD4+ and ~3 % CD8a+ and the ZFN IDLV 
responder showed ~ 2.3 % CD4+ and ~ 0.8 % CD8a+ T cells. 
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As a summary, the overall results obtained from staining with CD4 and CD8 at 16 and 
24 weeks post-transplantation were plotted in Figure  6.11. The tracking of T-cell 
reconstitution in peripheral blood of the animal of group wt control showed similar 
finding of two subpopulations of functional T cell subsets in the two periods matching 
wt mouse populations, while there was no detected reconstitution of any T cell 
subpopulations in the eGFP control. On the other hand, in the two responder animals (of 
groups ZFN IPLV and IDLV) there was a noticeable and gradual increase in the 
percentages of CD4+ and CD8+ T cell subpopulations in the same periods. In 
conclusion, T cells reconstitution in the two responder animals was achieved with slow 
kinetics. 
 
 
Figure 6.11: Tracking reconstitution of CD4+ and CD8+ T cell subpopulations at 16 
and 24 weeks post-transplantation. Top panel: control animals of 24 weeks old. 
Lower panel: transplanted animals. The animal of group wt control showed two 
subpopulations of mature T cell subsets in the two periods similar to wt mouse control; 
whereas no T cell reconstitution was observed in the eGFP control animal. The two 
responder animals (of groups ZFN IPLV and IDLV) clearly demonstrated gradual 
reconstitution of CD4+ and CD8+ T cell subpopulations. 
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7 Discussion and Conclusions 
7.1 General discussion 
PIDs are rare inherited disorders of the immune system developing from genetic 
mutations affecting specific immune cells (e.g., T or B lymphocytes, NK cells, 
neutrophils or antigen presenting cells). PID patients are unable to produce a proper 
protective immune response, leading to an increased susceptibility to life-threatening 
infections (Al-Herz et al., 2011; Chapel et al., 2003). Currently, there are more than 150 
different types of PIDs have been identified and characterized which range from mild to 
severe (Notarangelo et al., 2009). More than one million patients around the world are 
suffering from monogenic PIDs (Modell et al., 2011). SCID disorders are human 
monogenic PID inherited diseases caused by faulty alleles of an individual gene of 
immune cells leading to the onset of one or more different infections within the first few 
months of life. These infections are usually serious, and may even be life threatening, 
they may include pneumonia, meningitis or bloodstream infections. The first case of 
human DNA-PKcs (PRKDC) deficiency has been reported recently representing the 
first case of human PRKDC SCID disorder (van der Burg et al., 2009b).  
The PRKDC SCID patient presented immunologically as classical T- B- SCID and was 
characterized as lacking of V(D)J recombination mechanism which in turn has led to 
severe decrease in T and B lymphocytes numbers in peripheral blood and a composition 
of the precursor B-cell compartment in bone marrow. Clinically, the patient was highly 
vulnerable to opportunistic infections. Since the third month of life, she was suffering 
from frequent oral candidiasis and lower respiratory tract infections with progressive 
respiratory distress leading to hypoxia. At the age of 4 months she had developed a 
large oral aphthous lesion and minimal tonsillary tissue. The patient’s fibroblasts were 
sensitive to ionizing radiation, suggesting that she had a NHEJ defect (van der Burg et 
al., 2009a; van der Burg et al., 2009b).  
The treatment for PID patients is made available to only some of them by HSCT. 
Luckily, gene therapy is opening up a new era in medicine, it uses patient’s own cells 
and has the promise to cure many PIDs. The preferred approach applied to introduce 
precise genetic modification would be made by HR mediated gene repair. This involves 
harnessing of the cellular repair machinery to induce HR mechanism which mediates 
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exchange of DNA between a homologous corrective template and the genomic target 
(Olsen et al., 2010). Thus, HR-mediated gene repair has the potential to regain the 
original function of the defective gene reducing the risk of insertional mutagenesis and 
ensuring a sustained treatment because of stable expression level of repaired gene. 
Hence, it would be preferred to modify the existing faulty gene rather than deliver a new 
one (Kohn, 2010). 
Two possible approaches could be used for gene therapy: the first is in vivo therapy to 
correct faulty-gene cells directly without taking them out from the body; and the second 
is ex vivo therapy to correct faulty-gene cells indirectly by removing them out of the 
body, purifying, correcting, and then transplanting them back into the body (Connelly et 
al., 2010). Generally, the major challenge in ex vivo gene repair is to improve the 
natural low HR frequency which makes this strategy too far away to be considered as a 
therapeutic approach. In this respect, two promising developments have facilitated the 
task to look for successful possibilities to increase HR rate: the designer ZFNs and 
efficient gene delivery systems like lentivectors and AAVs.  
7.2 Thesis hypothesis 
In the context of this study, I aimed at developing an ex vivo system to improve the 
efficiency of gene repair in HSCs in order to correct the Prkdc mutation of the classical 
scid mouse, a model of human PRKDC SCID disorder. The scid mouse suffers from a 
nonsense point mutation in Prkdc which causes a truncation of 83 amino acids at C-
terminus region of DNA-PKcs (Bosma et al., 1983). To achieve this approach, lentiviral 
vectors were recruited to deliver ZFNs which create site-specific DSBs at the mouse 
genome very close to the scid point mutation to enhance cellular HR-mediated gene 
repair machinery. The ex vivo treated HSCs were transplanted back into scid mice 
recipients where they are expected to have a selective advantage to proliferate and 
restore the scid mouse immune system.  
Although the first in vivo gene repair of a mouse model of haemophilia has been done 
successfully (Li et al., 2011b), there is no animal model of haematopoietic disease that 
has been corrected yet by gene repair. The results presented in this work highlight the 
potential of gene repair for future therapy to treat recessive genetic PID disorders. The 
success of this approach to treat a haematological disorder could be applied to cure 
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many other inherited diseases that are potentially amenable to correction by gene repair. 
Nonetheless, a number of challenges had to be addressed before considering a 
therapeutic approach to rescue the scid mouse using combined technology of ZFNs and 
lentiviral vectors: (i) the ZFN cutting specificity with minimal genotoxic / cytotoxic 
adverse effects, (ii) lentiviral vectors as a ZFNs delivery system with maximal 
expression and biosafety, and (iii) selective advantage ability of the corrected cells to 
repopulate and rescue the mouse immune system.  
Previous reports have shown that ZFN technology can efficiently modify human CD34+ 
HSCs (Holt et al., 2010). Moreover, the transplantation techniques nowadays are well-
established to manipulate the haematopoietic cells clinically. Thus, the objective of the 
investigations in this thesis is to explore the use of new ZFNs technology to induce site-
specific DSBs at the scid mouse Prkdc aiming to a significant increase in HR frequency 
which eventually creates permanent repair. The genes coding for ZFNs and donor 
template will be delivered by lentiviral vectors to maximise the opportunity for efficient 
gene expression. The vital aim is to demonstrate proof-of-principle for correction of 
haematopoietic disease which will contribute to the development of clinically applicable 
approach to cure patients suffering from PIDs.  
7.3 ZFN design and delivery platforms 
ZFNs are known to introduce sequence-specific DNA DSBs that can be repaired by 
either NHEJ generating small alterations at targeted genomic sites, or by HR-mediated 
gene repair in the availability of a homologues DNA sequence. Accordingly, ZFN 
technology has emerged rapidly and facilitated highly efficient gene disruption in many 
cell types (Hockemeyer et al., 2009; Santiago et al., 2008), plant engineering (Tzfira 
and White, 2005; Zhang et al., 2010b) animal models (Doyon et al., 2008; Geurts et al., 
2009b) and even mediated the progress of targeted gene therapy in humans (Holt et al., 
2010; Perez et al., 2008). The state-of-the art ZFN technology could be deigned to 
target any of the 64 possible DNA 3-base combinations, making ZFN a custom 
designed molecule for genome surgery (Kohn, 2010). So, theoretically ZFNs could be 
designed to target any site in the genome including those mutated ones of inherited 
disease patients. But, practically not all the genomic regions are accessible because of 
many reasons like compact chromatin structure and DNA modification (Carroll, 2011). 
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As an example, it has been suggested that cleaving of intact recognition sites of homing 
endonucleases is prevented by chromatin structure in S. cerevisiae during mating-type 
switching (Rusche et al., 2003). The ZFN recognition site in mammalian genomes is at 
least 18 bp in length which should occur only once, offering a unique site within the 
genome. 
Despite these achievements, a major challenge related to this technology is their 
imperfect specificity, where unintended DSBs induced at genomic DNA (off-target 
cutting) may lead to genotoxic and cytotoxic effects (Cornu et al., 2008). The binding of 
ZFN domains to DNA sites could be determined by several techniques like ELISA 
assays, microarrays and systematic evolution of ligands by exponential enrichment 
(SELEX) (Zykovich et al., 2009). However; it has been reported that ZFN cytotoxicity 
is mainly ascribed to DNA cleavage rather than domains binding alone (Beumer et al., 
2006). Importantly, Gabriel et al, have shown that ZFN wide spectrum of off-target 
cutting could be determined by deep sequencing and linear amplification-mediated 
(LAM)-PCR (Gabriel et al., 2011). 
ZFNs used in this study were prepared by Sangamo BioScience Inc (California, USA) 
as collaboration. These nucleases were engineered to encompass 5 and 4 zinc-finger 
domains in the right and the left ZFN monomers, respectively (Figure 1.8). In principle, 
at least three ﬁngers in each ZFN monomer are required to offer sufficient afﬁnity for 
efficient and specific cleavage. More ﬁngers could be added to improve ZFN speciﬁcity, 
as well as afﬁnit y, and examples of up to six ﬁngers have been used (Geurts et al., 
2009a; Hockemeyer et al., 2009; Porteus, 2009); however recently it has been 
confirmed that extra fingers of 5 or 6 in each monomer could lead to significant 
decrease in the performance of designed ZFNs (Shimizu et al., 2011). For maximising 
the specificity of ZFN cutting and minimising possible off-target cutting, ZFNs 
designed for this study have included obligatory heterodimeric monomers via mutations 
in the Fok I domain preventing illegal cutting from unwanted homodimers. This 
strategy has been used earlier by others to improve ZFNs specificity (Miller et al., 2007; 
Szczepek et al., 2007). Noteworthy, continuous development in ZFN technology has 
highlighted that highest ZFN performance can be achieved by providing highest DNA-
binding affinity and specificity leading to minimise ZFN off-target related toxicity 
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(Cornu et al., 2008). Therefore, the design of ZFNs used in current study takes into 
account the maximal ZFN features required both for affinity as well as specificity. 
In present thesis, it is expected that the ZFN cutting site could occur anywhere within 
the nucleotide spacer (of 6 nucleotides) between the two recognition sites of ZFN 
monomers (see Figure 1.8). The ZFN recognition (binding) and the ZFN cutting sites 
are located at 20 and 32-38 nucleotides downstream from the Prkdc scid point mutation, 
respectively (see Appendix, Box 1). In the framework of tailoring ZFN recognition site 
to target mouse Prkdc, the point of major importance was to keep the ZFN site as close 
as possible to scid point mutation to ensure that the corrected scid site will be within the 
gene conversion tract, which will be presented during the HR-mediated gene repair. As 
it is observed earlier that in mammalian cells the gene conversion tracts are generally 
short; between 100– 200 bp from the DNA break (Elliott et al., 1998). 
A diagnostic feature of restriction enzyme BsaWI has been introduced via site directed 
mutagenesis at 2 nucleotides upstream from scid point mutation locus in Prkdc-BsaWI 
template creating only a silent mutation (for exact site see Appendix, Box 2). The 
advantage of having this site is to be used as a diagnostic tool to certify that possible 
repaired Prkdc had occurred because of incorporation of corrective Prkdc-BsaWI 
template during HR-mediated gene repair; not by natural spontaneous mutation. Also 
the presence of this site was used successfully to estimate HR repair frequency in the 
targeted cells (in BsaWI assay). Moreover, both corrective Prkdc-BsaWI and Prkdc-neo 
templates used in this work were encoded the ZFN recognition site (see Figure 4.8). The 
idea of incorporation of a mutant ZFN recognition site into the corrective template, to 
prevent template cutting, was excluded as the main purpose for this study is to correct 
scid point mutation. Adding another mutation, even if it is silent, to the homologous 
donor sequence could result in reduction of % identity between supplemented template 
and genomic target, leading to possible significant reduction of HR frequency. Once the 
ZFN two monomers are dimerised, there will be a continuous cycle of cleaving and 
rejoining events in their target sites, until a NHEJ repair process generate a mutated 
ZFN target site (Kandavelou et al., 2009).  
Different applications have used different approaches to deliver ZFNs into the targeted 
cells. In plants, ZFNs have been delivered effectively by direct DNA transformation 
(Cai et al., 2009; Shukla et al., 2009), agrobacterial transformation under the expression 
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of a viral promoter (de Pater et al., 2009; Zhang et al., 2010b), and viral delivery 
(Marton et al., 2010). Direct injection of ZFN mRNA into the embryos of Drosophila 
(Beumer et al., 2008), zebrafish (Foley et al., 2009), frog (Young et al., 2011) rat 
(Geurts et al., 2009a; Mashimo et al., 2010), and mouse (Carbery et al., 2010) have 
been used successfully. Other ZFNs have been introduced into mammalian cells by 
direct DNA transfection via nucleofection or LipofectAMINE (Orlando et al., 2010; 
Perez et al., 2008; Urnov et al., 2005), and viral delivery (Li et al., 2011b; Lombardo et 
al., 2007). Interestingly, it has been demonstrated very recently the possibility of direct 
delivery of purified ZFN proteins into targeted cells (Gaj et al., 2012). 
In current study, the ZFNs are delivered by IDLV platforms while the IPLVs were used 
alongside for comparison and optimisation. A one useful approach to bypass inefficient 
transfection problems (Ellis et al., 2012), ensure transient gene expression, and enhance 
HR therapeutic levels; is to use lentiviral vectors as a delivery strategy. It has been 
shown earlier that lentiviral vectors are able to transduce quiescent human HSCs (Case 
et al., 1999). Thus, using of lentiviral vectors would be beneficial because: firstly, 
lentiviral vectors are able to efficiently transduce quiescent cells, like HSCs, as they 
incorporate NLS which facilitate entry of PIC into nuclei of non dividing cells. 
Secondly, the episomal nature of IDLVs to generate transcriptional functional elements 
rather than integrate into the genome made them safer compared to other lentiviral 
vectors. This is be of particular importance for the purpose of delivering ZFNs to ensure 
transient expression leading ultimately to reduce ZFNs overexpression and minimise 
possible cytotoxic effect because of off-target cutting. And thirdly, the lentiviral vectors 
used in present study to deliver ZFNs are self-inactivating third-generation human 
immunodeficiency virus-1 (HIV-1)-based vectors have been known with their improved 
biosafety (Dull et al., 1998; Yanez-Munoz et al., 2006; Zufferey et al., 1998). 
Three research groups have demonstrated that recruiting of IDLVs to induce site-
specific DSBs can be effective method to achieve high HR-mediated gene repair 
frequency in a range of human and mouse cell types (Cornu and Cathomen, 2007; 
Lombardo et al., 2007; Okada et al., 2009). Additionally, combination of IDLVs and 
ZFNs could result in approaching the threshold that would be therapeutically useful for 
PIDs (Lombardo et al., 2007). Hence, the possibility of therapeutic use of ZFN-
mediated gene repair in mammalian cells has become more hopeful and it seems that 
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some monogenic PIDs could be cured by application of this strategy. Such progress has 
led to anticipate that the first monogenic inherited disease to be cured would be SCID 
disorders (Hatada et al., 2000; Miller et al., 2007).  
The success of ZFN recruitment depends on their abilities to induce site-specific DSBs 
at their targeted loci. Both repair mechanisms of HR and NHEJ are presented in 
essentially all cells and they are likely to be presented in most circumstances. 
Nevertheless; which repair mechanism will be used in DSBs repair depends on many 
factors like (i) cell cycle status (Branzei and Foiani, 2008), (ii) availability of DNA 
repair proteins (Cann and Hicks, 2007), and (iii) availability of homologous donor 
templates (Shrivastav et al., 2008). The alterations that could influence some of HR or 
NHEJ repair components, could lead to swap from one to another pathway. As an 
example, it is known that DNA ligase plays a vital role in the NHEJ repair pathway, but 
in its absence the repair pathway will be diverted mainly toward HR (Carroll, 2011). 
The scid HSC progenitors are the main target cells to be corrected in present study; 
however for convenience and practicality the BALB/c 3T3 scid fibroblasts are used to 
optimise experiments of demonstration of ZFN cutting, gene targeting and gene repair. I 
started the work in this project with a problem of extensive cellular senescence of scid 
fibroblasts. These cells had showed limited life-span and they were dying upon cloning 
before completion of the intended experiment. Therefore, and in order to overcome this 
problem they were immortalised by transduction with retroviral vectors encoding mTert 
and Pac. Telomerase is an RNA-dependent DNA polymerase that catalyzes the addition 
of telomeric repeat sequences to chromosome ends, and telomeres shorten with 
successive cell divisions in the absence of telomerase (Harrington et al., 1997). 
Importantly, the temporal start of senescence is related firmly to telomere length 
(Harley et al., 1990). Cellular senescence has been bypassed by immortalisation with 
retroviral vectors expressing human TERT in human cells (Vaziri and Benchimol, 
1998) or Tert in mouse cells (Kawai et al., 1994). Upon their immortalisation, I noticed 
that mTert scid fibroblasts possessed considerably higher clonal efficiency and that such 
clonal populations were able to grow and expand to complete the required experiments. 
Previous work in current study has begun prior to my arrival by designing of two long 
corrective donor templates both coding for wild type homologous sequences, but they 
differ in their additional markers. The first one carried the neo cassette to be used as a 
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positive selective marker in in vitro system optimisation; this template is referred to as 
Prkdc-neo template. The second encoded a novel site for the enzyme BsaWI 
(introduced via site-directed mutagenesis causing only silent mutation) to be used as a 
diagnostic feature of occurrence of gene repair. Subsequently, the last template was 
replaced with a shorter template coding for the same BsaWI site and called Prkdc-
BsaWI template, which already used for gene repair experiments in vivo and ex vivo. 
The short template was used because of two reasons: the first, it was easier to clone it 
together with ZFN monomers into the same lentiviral backbones, and the second, it was 
more practical to detect gene repair events in targeted cells by PCR amplification using 
external primers to the shorter template (BsaWI assay).   
The long corrective template with BsaWI site (that was replaced afterwards) was 
incorporated into lentiviral backbones to construct pCCLscPrkdcHindBsaWIF and 
pCCLscPrkdcHindBsaWIR. Both constructs were incorporating the same sequence 
(HindIII BsaWI fragment), which is coding for the wild type sequence around the scid 
point mutation in the Prkdc gene and BsaWI site. However, there was only one 
difference between them which is the orientation of inserted Hind BsaWI fragment; one 
construct carried the insert in forward orientation while the other in reverse. These two 
constructs prepared to be used as donor templates in HR-mediated gene repair; but 
eventually I did not use them anywhere as I replaced them by Prkdc-BsaWI template. 
On the other hand, three different strategies (data not shown) were carried out in order 
to clone the Prkdc-neo template into lentiviral backbones to construct 
pCCLscPrkdcHindPmlIneo; but I was not able to get it. This could be attributed to the 
large size of insert and inconsistency between plasmid electronic file and real plasmid 
as sometimes I ended up with fragments which are not expected by vector NTI 
software. The cloning of obligatory heterodimeric ZFNs into lentiviral backbones with 
and without Prkdc-BsaWI template has been carried out successfully.  
I have produced ZFNs, ZFNs/Prkdc-BsaWI template and CMV-eGFP third-generation 
HIV-1 based lentiviral vectors, and SFFV-eGFP second-generation HIV-1-based 
lentiviral vectors by transient transfection of 4 or 3 plasmids, respectively, into HEK-
293T cells using the calcium phosphate coprecipitation method (as explained in section 
2.2.7). HEK-293T cells were used as producer cells because of their high transfect- 
ability to calcium phosphate. All prepared lentiviral vectors were titrated in HeLa cells 
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by real-time quantitative PCR, which is most reliable method to titrate HIV-1 based 
lentiviral vectors as it measure all HIV-1 based lentiviral vectors cDNA varieties (Yoder 
and Fishel, 2008). Those eGFP prepared vectors were additionally titrated by flow 
cytometry analysis. 
As all ZFNs used in current study were FLAG-tagged and in order to detect of ZFN 
expression in scid mTert fibroblasts from original pVAX plasmids, lentiviral plasmids, 
and produced lentiviral vectors, Western blotting assay was used. A successful ZFN 
monomer detection was observed from both second and third version ZFN pVAX 
constructs. Also, ZFN expression was detected from all cloned monomeric ZFN 
lentiviral (pRRL and pCCL) backbones. However, the expression from dimeric ZFN 
constructs was not detectable because of the lack of a N2A self-processing polyprotein 
signal which helps to separate ZFN monomers during transcription. In fact, first ZFN 
version had included this signal, but next versions (second and third) did not includ it. 
Thus, ZFN dimeric constructs were not used in any next experiments. On the other 
hand, I have detected ZFN expression from all produced lentiviral vectors and I also 
have not noticed any difference between ZFN expression under the control of CMV and 
SFFV promoters. However; ZFN expression from IPLVs was stronger than that from 
IDLVs, which can be explained if expression from IPLVs is more efficient than that of 
IDLVs in these highly proliferating cells (Wanisch and Yanez-Munoz, 2009). As an 
attempt to detect ZFN expression in lin- scid HSCs, the transduction with ZFN lentiviral 
vectors was conducted and followed by detection with internal antigen labelling (data 
not shown). This assay is commonly used to check the expression of surface and 
intracellular antigens. Unfortunately, the flow cytometric analysis showed that there 
were no detectable signals above the background which could be attributed to weak 
ZFN signals.  
Three versions of Prkdc ZFNs were received from Sangamo; the first contained a first 
version of the ZF binding domains and non-optimised wild-type Fok I domains which 
allow homodimerisation; the second had optimised ZF domains and wild-type Fok I 
domains; and the third version contained the optimised ZF domains and mutated, 
obligatory heterodimeric Fok I domains. Optimisation of ZF domains by Sangamo was 
on the basis of their binding activity to the cognate sequence. A gene targeting assay 
was conducted in order to select the best Prkdc ZFN version that could induce higher 
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levels of DSB-mediated HR which can be detected by number of G-418r CFUs using 
the three versions of Prkdc ZFNs and Prkdc-neo template (section 4.4). As it was 
expected, the results clearly demonstrated that the combination of optimised ZF 
domains with obligatory heterodimeric monomers (third version ZFNs) produced the 
highest number of G-418r CFUs (10-fold increase) suggesting highest DSB generation. 
This finding has agreed with previous report when similar system was used (Olsen et 
al., 2010). Different approach using same strategy (co-transfection of ZFN monomers 
and donor plasmid) has showed potentially relevant frequencies of ZFN-mediated gene 
targeting in a variety of primary cells of mouse model of a generic recessive genetic 
disease (Connelly et al., 2010). 
Ideally gene targeting/repair events could to be verified easily by Southern blotting 
assay, as this assay can detect the presence of a known DNA fragment within a sample, 
as well as to inspect the integration status of the sequence, by probing DNA digested 
with a restriction enzyme. In this context, two different radioactive probes were 
designed (data not shown) and then used to attempt detection of gene targeting at G-
418r CFUs using Southern blotting. Unfortunately, after few trials with each probe I 
could not observe any signal for gene targeting; a matter that could be attributed to that 
signals from those probes were very poor. Because of that failure, I conducted other 
alternative experiments to demonstrate gene targeting events at targeted locus in G-418r 
fibroblasts by PCR based analysis. By designing targeting construct internal (forward) 
and external (reverse) primers (Figure 4.10), I was able to detect an amplification of a 
1335-bp product in 20 out of 36 examined samples. This is represented a clear evidence 
for ZFN-mediated gene targeting at the mutated Prkdc locus. For further confirmation, I 
carried out an enzymatic digestion using successful amplified samples to double check 
whether the right amplicons had been amplified. All 20 amplicons subjected to 
digestion with BglII showed the presence of fragments of 746 and 589bp suggesting that 
right amplification. Additionally I did one more confirmation step; randomly selected 
sample was subjected to further enzymatic digestion with HindIII and XhoI generating 
right expected fragments. The finding of that 20 out of 36 G418r clones were targeted 
although the increase in their frequency was 10-fold in previous experiment (above 
paragraph) could be explained by that the 36 G418r clones were selected randomly out 
from two separated experiments (18 clones each) allowing the collection of some non-
targeted G418r clones and eventually leading to reduce the targeting frequency. 
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In the light of above gene targeting results, only the third version Prkdc ZFNs 
(optimised obligatory heterodimeric) was cloned into lentiviral-backbones and 
eventually used to produce IPLVs and IDLVs. Additionally lentiviral-backbones 
carrying both a ZFN monomer and the Prkdc-BsaWI template were generated and used 
to produce IDLVs. Therefore; the first and second ZFN versions were not used 
anywhere in next experiments.  
7.4 ZFN cutting specificity 
I was particularly interested in further characterising of ZFN abilities to generate site-
specific cuttings at their genomic target site. ZFN-induced DSBs would be repaired 
usually by NHEJ in absence of homologous donor template leading to the introduction 
of InDels, which can be detected by the Surveyor Cel-I nuclease assay. In scid mTert 
fibroblasts, my results revealed that there was an effective dose- and dimer-dependent 
ZFN-mediated cutting at the target site. Also, correlating with the increased expression 
level from IPLVs noticed in the Western blot, InDel frequencies from IPLVs were 
higher than those from IDLVs for both CMV or SFFV-driven ZFNs, such finding 
would be understandable in these proliferative cells. ZFN expression under CMV or 
SFFV promoters reached similar levels. In lin- scid HSCs, I was only able to observe 
effective dose- and dimer-dependent ZFN-mediated cutting at the target site with ZFN 
IPLVs driven by SFFV promoter, suggesting that in this experiment only this 
configuration and promoter mediated sufficient target cutting.  
Because of limited sensitivity of Surveyor Cel-I nuclease assay (I showed that its 
minimal detectable modification was 5% in section 4.5.1), I was unable to detect ZFN 
site-specific cuttings in ZFN IDLVs controlled by SFFV promoter in lin- scid HSCs. 
Nonetheless, I detected ZFN site-specific cuttings by deep-sequencing technology 
instead. Deep-sequencing results showed that there are effective dose- dependent ZFN-
mediated cutting when SFFV-driven ZFN IDLVs used. Although detected ZFN site-
specific cuttings from IDLV SFFV was not as high as (maximum ~ 0.5 % at high dose) 
that observed in IPLVs, yet still informative to confirm that Prkdc ZFNs are able to 
induce efficient site-specific cuttings at their targeted loci. Noteworthy, the results of 
using IDLVs with SFFV-driven eGFP in HSCs confirmed that expression levels were 
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extremely poor compared to the integrating configuration, confirming the unsuitability 
of this promoter in IDLVs 
Using the Surveyor Cel-I nuclease assay I have also been unable to detect ZFN site-
specific cutting in HSCs using IPLVs or IDLVs driven by the CMV promoter. These 
results could be explained by the fact of CMV is not compatible for robust expression in 
hematopoietic lineages in contrast to its very good compatibility in other cell lines like 
HEK293 and HeLa (Logan et al., 2002). It is worth mentioning that the SFFV promoter 
has been broadly used to regulate transgene expression within retroviral vectors, 
especially due to its high activity in hematopoietic cells (Demaison et al., 2002; Kung et 
al., 2000; Zhang et al., 2010a). 
Interestingly, one of major questions that arose in current work was: how these DNA-
PKcs deficient cells can repair their induced-DSBs by NHEJ mechanism? (as these 
NHEJ-repaired DSBs were observed by Surveyor Cel-I nuclease assay). This repair 
mechanism could be attributed to the assumption of that in the case of absence of one or 
more of NHEJ required factors (like Ku DNA, DNA-PKcs, DNA ligase IV XRCC4, 
and a number of DNA end-processing factors), there is an ‘‘alternative’’ NHEJ pathway 
could take place instead allowing the cells to repair their DSBs even in the absence of 
classical NHEJ (Brunet et al., 2009; Carroll, 2011; Lieber et al., 2003). 
7.5 ZFN-mediated gene repair 
I expanded my research to detect HR events (by BsaWI assay) in targeted scid 
fibroblasts and HSCs using a silent diagnostic restriction site for the enzyme BsaWI, 
previously introduced via site-directed mutagenesis two nucleotides upstream from the 
scid mutation site in the Prkdc-BsaWI template. The successful gene targeting attempt 
could be followed by the detection for cells carrying the new DNA using BsaWI 
diagnostic feature. In scid mTert fibroblasts, the results demonstrated that gene repair 
could be detected in SFFV-driven ZFNs in both IPLVs (maximum 7.7 % at MOI 1000) 
and IDLVs (maximum 4.7 % at MOI 5000), and was vector dose-dependent. Using the 
same assay, no gene repair was observed in the case of CMV-driven ZFNs used in 
either IPLVs or IDLVs. While in lin- scid HSCs, the results showed that gene repair 
could only be detected in SFFV-driven ZFNs in IPLVs (8.3 % at MOI 100). In fact, the 
latter gene repair calculations could be an overestimated result, as the diagnostic band of 
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1068 bp was about to be seen. It is important to state that in both scid fibroblasts and 
HSCs, the calculations of gene repair results were based on a formula with a correction 
factor to obtain more accuracy as the smallest band of 640 bp was hard to be detected 
because the overlapping smear on the gel.  
As deep-sequencing results suggested earlier that ZFN site-specific cuttings would be 
low generally in the case of SFFV-driven ZFNs used in IDLVs, the undetectable gene 
repair in this case might be justifiable. Lack of detection of gene repair in CMV-driven 
ZFNs would not be unexpected because of that CMV promoter is not as good as SFFV 
promoter to control lentiviral vector gene expression in hematopoietic cells. However, 
for the ex vivo gene repair and transplantation experiment I used CMV-driven ZFN 
IDLVs because this configuration has showed the higher eGFP expression levels among 
all vectors and promoters that were tested in HSCs.  
To this end, from above results of Surveyor Cel-I nuclease assay to detect ZFN site-
specific cuttings and BsaWI assay to detect HR events in targeted locus, it can be 
concluded that our third Prkdc ZFN version can cut the target locus and induce gene 
repair to correct scid Prkdc. 
7.6 Restoration of functional Prkdc 
The next important question to be addressed was whether correction of Prkdc gene at 
DNA level had led to restore gene function and produce functional DNA-PK? To 
answer this, two experiments were conducted using gene-repaired scid mTert 
fibroblasts. The first one is concentrated on detection of DNA-PK activity using 
SignaTECT DNA-dependent protein kinase assay. The results demonstrated that there is 
a vector dose-dependent restoration of DNA-PK activity in the case of SFFV-driven 
ZFN IPLVs or IDLVs were used, matching the results of the BsaWI assay. The other 
experiment was carried out to explore the functionality of enzyme DNA-PK through the 
response to DNA damaging agents like melphalan. Melphalan can induce DSB which 
will be repaired by NHEJ and importantly DNA-PK is a determinant in the cellular 
response to this DNA damaging agents (Muller et al., 2000). The results revealed that 
the number of enriched melphalan-resistant CFUs was remarkably vector dose-
dependent. Furthermore, these melphalan-resistant CFUs were subjected to BsaWI 
assay to investigate whether melphalan-mediated enrichment has correlated with gene 
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repair at the DNA level. The results showed that there is (1.5-3) fold increase in gene 
repair frequency detected after enrichment with melphalan, compared to that prior to 
drug treatment. Alternatively, what I could have done is to isolate individual melphalan-
resistant clones to try and identify one that has undergone correction and then show scid 
correction clearly by Southern blotting. Generally, these results have suggested that 
gene-repaired cells had a selective advantage over uncorrected cells in the presence of 
melphalan. Altogether, the results obtained from above two experiments clearly 
confirmed that correction of Prkdc has led to restoration of functional DNA-PK.  
7.7 Ex vivo gene repair and transplantation 
HSC progenitors are stem cells with self-renewal and multipotency abilities; their 
multilineage differentiation generates all hematopoietic cells of the myeloid and 
lymphoid lineages including erythrocytes, platelets, macrophages, T-cells and B-cells. 
They emerge early during embryogenesis and maintain hematopoiesis throughout the 
whole lifetime of the organism (Medvinsky et al., 2011). HSC progenitors are very rare 
cells, for example they can be found in adult human bone marrow at a frequency of only 
one in thousands of cells. While from one mouse, only about a thousand HSC 
progenitors can usually be obtained. Importantly, HSCs are distinguished from other 
cells in myeloid tissue by their lacking of the surface markers found in more mature 
blood cells (lin-) but do express CD117 (c-kit) and stem cell antigen 1 (Sca-1). Their 
isolation from the surrounding cell populations is therefore based on fluorescent or 
magnetic labelling and following removal of lineage-positive cells. However and in 
spite of advanced isolation techniques, the HSCs separated are still heterogeneous 
population. It has been reported that after murine transplantation, only 30 % - 50 % of 
potential HSCs were found to be real HSCs after single cell molecular analysis (Osawa 
et al., 1996; Schroeder, 2010). Furthermore in a landmark paper, it has been 
interestingly shown that a after transplantation of single HSCs into mice, > 25% of stem 
cells are capable of repopulating the hematopoietic system (Dykstra et al., 2007). 
Because HSCT procedure has became an established treatment for different patients 
suffering from various haematological disorders, the frequency of HSCT has increased 
worldwide (Mohty and Apperley, 2010). The source of HSCs used for HSCTs could be 
bone marrow, cord blood, or mobilized peripheral blood (Zibara et al., 2012). In present 
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study, bone marrow lin- HSCs were routinely purified by magnetic cell depletion and 
grown without passaging in serum free comprehensive medium containing a cocktail of 
cytokines for in vitro culture. Cytokines human IL-6 and murine Flt3 have been added 
to promote stem cell proliferation in culture, and the murine SCF was added to promote 
survival rather than cell division (Broudy, 1997). 
As scid lin- HSCs were the main target cells to be corrected here in current study, I have 
particularly concerned to achieve the highest possible transduction efficiency in these 
cells. For that, I have assessed different vectors, configurations and promoters. I carried 
out lin- HSCs transduction with SFFV-driven eGFP IPLVs and IDLVs, CMV-driven 
eGFP IPLVs and IDLVs, control (no external) promoter-driven eGFP IDLVs, GFAP-
driven eGFP IDLVs, PGK-driven eGFP IDLVs, SV40-driven eGFP IDLVs, ASFV 
P11.5-driven eGFP IDLVs, ASFV P54-driven eGFP IDLVs and three derivatives of 
Ad5 CMV-driven eGFP adenoviral vectors. The overall results from these experiments 
suggested that SFFV IPLVs and CMV IDLVs were most efficient; therefore I used 
these optimised conditions for ex vivo transduction.  
In the main experiment of present study “rescue of Prkdc deficiency by ex vivo gene 
repair and transplantation”, the recipient mice were divided into 4 groups of five 
animals each: Wt and eGFP control groups, and ZFN IPLVs and ZFN IDLVs 
experimental groups. The purified scid lin- HSCs in eGFP control group were 
transduced with lentiviral vectors encoding the eGFP. For ZFN IPLVs and ZFN IDLVs 
groups, the purified scid lin- HSCs were transduced with lentiviral vectors encoding the 
Prkdc-BsaWI template and ZFNs. The HSCs transduction was about 16 h then followed 
by treated cells injection into sublethally irradiated recipients. The transduction 
efficiency in eGFP control group 72 h post-transduction was ~ 38 % at MOI 400. 
Following ex vivo gene repair and upon intravenous injection in transplantation 
experiment, the corrected cells will be circulated and finally localised at specific body 
compartments. The injected cells are most likely to be engrafted in bone marrow cavity 
and spleen, which possess the accommodating stromal elements essential for effective 
proliferation and hematopoiesis (Samlowski and Daynes, 1985). 
To address the main question that arose initially: do the gene-repaired cells have the 
ability to rescue the mouse immune system? Firstly, the vast majority of mutated native 
HSCs will be eliminated by sub-lethal irradiation facilitating the expansion and 
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proliferation of corrected cells with their selective advantage. This ambitious aim 
theoretically needs just one corrected HSC to repopulate the entire mouse immune 
system; however the applicability of this fact is quite challenging, taking into 
consideration many limiting factors including: the original rarity of HSCs in the scid 
mice, the purity of lin- scid HSCs after depletion procedure, the transduction efficiency 
of corrective template and ZFN lentiviral vectors, all requirements for HR-mediated 
gene repair mechanism, the efficiency of transplantation and injection procedure, and 
corrected HSCs seeding efficiency. Secondly, as this project based on gene repair 
principle meaning that only low percentage of manipulated cell population will be 
corrected. Subsequently, this has led to face a problem of injection of maximal cell 
number into recipients in order to maximise the opportunity of higher numbers of 
transplanted cells. For that, 1 X 106 cells were injected back into recipients. In 
comparison with previous study to correct other mouse scid model, this cell number is 
considered higher as other study based on gene addition strategy (Huston et al., 2011).   
In order to track the reconstitution of mouse immune system, all animals were bled at 9, 
16, and 24 weeks post-transplantation and PBMCs were stained with different 
antibodies directed against lymphoid (T and B) and myeloid (monocyte/macrophage, 
NK and granulocytes) cell CD surface receptors. The observed gradual increase in T 
cell populations throughout 24 weeks after transplantation in two responder animals 
(one from each group of ZFN IPLV and IPLV) is considered as a dramatic finding 
showing that possible immune system restoration has begun, albeit possibly at different 
speeds. On the other hand, B cells restoration during same period is not observed which 
can be attributed to that B cells restoration is slower and requires higher numbers of 
transplanted cells, at least in the Il2rg model (Huston et al., 2011). The overall 
conclusion that could be made here is that transplanted ZFN-mediated gene-repaired 
cells could lead to slow rescue of the mouse immune system. In this regard, an 
additional experiment could be carried out by probing for Y-chromosome-specific 
markers in non-lymphoid lineages in order to assay for a positive control for 
engraftment. This experiment would be helpful to track the origin (donors or recipients) 
of all non-lymphoid cells in responder animals. 
Altogether, the work presented here showed the feasibility of recruiting ZFN 
technology to mediate gene repair to correct classical scid mouse point mutation. 
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Current work has provided a proof of principle to restore both original Prkdc genotype 
and phenotype. Further experiments would be required to ascertain of both Prkdc 
correction on DNA level and kinase function after ex vivo gene repair transplantation. 
As a closing remark, all the obtained results suggested that scid mouse model is 
possibly rescued representing the first animal model of haematopoietic disease to be 
corrected by gene repair. The highly importance of such achievement could contribute 
to the ongoing efforts to treat monogenic inherited diseases. 
7.8 Conclusions  
The experiments in this Thesis have revealed the following important conclusions: 
 
 Scid fibroblasts transduced with mTert-pac retroviral vectors are resistant to 
puromycin, and can be cloned and expanded, suggesting immortalisation.  
 ZFN monomers are expressed efficiently after transfection or transduction of scid 
fibroblasts, and less so in HSCs. 
 ZFN-mediated gene targeting with a neo-containing construct results in a 
significant increase in G418r CFUs, suggestive of DSB-mediated HR, with a ZF-
optimised, obligatory heterodimer ZFN. Clonal analysis of G418r CFUs by PCR 
indicated that ~ 60 % of the randomly selected samples have undergone gene 
targeting. 
 ZFN site-specific cutting and ZFN-mediated gene repair at the Prkdc locus has 
been demonstrated with IPLVs and IDLVs. In HSCs only the former 
configuration produces detectable gene repair by gel assay. 
 After Prkdc correction, DNA-PK activity is restored and corrected fibroblasts 
show enhanced resistance to the DNA damaging drug melphalan.  
 Preliminary results of the ex vivo gene repair and transplantation experiment 
indicate potential rescue of the T-cell compartment in a fraction of the scid 
transplant recipients. 
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7.9 Future work 
• Second transplantation experiment using animals of first transplantation (one 
animal of each control groups of wt and eGFP, and two responder animals) has 
been conducted already. It is hoped that the corrected HSC progenitors from the 
first transplantation will be able to rescue recipients in the second 
transplantation. Such rescue would be considered a further demonstration of the 
presense of gene-repaired HSCs. The results are still in processing.   
 
• Molecular analysis of gene repair events at the DNA level in cultured scid 
fibroblasts and HSCs, and in PBMCs of responder animals, by deep sequencing. 
This analysis is required to provide a clear evidence of the correction of the scid 
point mutation which will be a formal demonstration of scid genotype repair. 
The samples were prepared and shipped to Dr. Manfred Schmidt / Germany for 
analysis. 
 
• Analysis of restoration of DNA-PK activity in PBMCs of responder animals in 
order to confirm the correlation between scid genotype repair and phenotype 
restoration.   
 
• Analysis of off-target ZFN cutting in cultured scid fibroblasts and HSCs, and in 
PBMCs of responder animals, using PCR amplification and deep sequencing of 
the 10 most likely off-target sites  selected by SELEX protocol. The samples 
were prepared and shipped to Sangamo for analysis. 
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Appendix I 
 
Box 1 
The sequence of Surveyor PCR product of (of 304 bp). Sequence F and R Surveyor 
primers are shown at the 5’ and 3’ end of the amplicon sequence. The ZFN 1 target is 
the recognition site for 17834-FOK EL ZFN domain; whereas ZFN 2 target is the 
recognition site of 17373-FOK KK ZFN domain and in between there is the cleavage 
site where the DSB should take place. The diagnostic BsaWI restriction site is located 
upstream of the scid point mutation which is in turn upstream of the ZFN full 
recognition site. 
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Box 2 
The sequence of Prkdc-BsaWI corrective template (of 1626 bp) amplified by PCR. 
Sequence F and R BsaWI assay primers are shown at the 5’ and 3’ end of the amplicon 
sequence. This template also includes the sequence and features of Surveyor PCR 
product of (304bp) shown in Box 1 above. 
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Box 3 
The sequence of Prkdc probe (1708bp) amplified by PCR. Sequence F and R probe 
primers are shown at the 5’ and 3’ end of the amplicon sequence. The template also 
includes the sequence and features of Prkdc corrective template (1626bp) shown in Box 
2 above.  
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Box 4 
The sequence of gene targeting product (of 1335bp) resulted from co-transfection with 
ZFNs and pPrkdcHindPmlIneoF constructs created by PCR. Sequence F and R probe 
primers are shown at the 5’ and 3’ end of the amplicon sequence. The template also 
included the recognition sites for restriction enzymes BglII, XhoI and HindIII. 
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Box 5 
Table of home made / obtained plasmids that were used throughout current study.  
Plasmid Made by/ obtained from  
pCCLsc ISce-IT Home made by Rafael Yáñez 
pCCLsc_S_W Home made by Rafael Yáñez 
pHR’sc-SEW Obtained from Prof Adrian Thrasher (UCL) 
pPrkdcHindBsaWI Home made by Rafael Yáñez 
pRRLsc_C_W Home made by Rafael Yáñez 
pRRLsc-CEW Obtained from Prof. Luigi Naldini (Milano, Italy) 
pVAX-3FN-17373-FokKK Made by Sangamo Biosciences Inc. (California-USA) 
pVAX- N2A-3FN-17834-
FokEL2 Made by Sangamo Biosciences Inc. (California-USA) 
 
Box 6 
Table of collaborators and their detailed contributions to the currnt study. 
Collaborator Contribution 
Dr. Céline Rocca (RHUL) Doing together some cloning, BsaWI assay, DNA-PK activity assay and melphalan enrichment 
Dr. Manfred Schmidt 
(NCTD, Germany) Deep sequencing of potential samples 
Dr. Maria Alonso-Ferrero 
(ICH-UCL) Setting up of multicolour flow cytometric analysis. 
Dr. Michael Blundell 
(ICH-UCL) Injection and bleeding of transplanted animals. 
Dr. Ramon 
Alemany (IDIBELL, 
Spain) 
Preparation of adenoviral vectors. 
Miss. Sara Oliván 
(RHUL) 
Preparation of some lentivectors (GFP IDLV with different 
promoters). 
Sangamo Biosciences 
(CA, USA) Design and preparation of ZFNs. 
 
